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Summary of the main findings of my PhD research 
 
The overall aims of my PhD research project were to identify which particular 
gamma-amino butyric acid A receptor (GABAAR) subunits are expressed by 
neurochemically defined cell-types of the enteric nervous system (ENS) of 
the mouse colon, and what effect the pharmacological activation of specific 
receptor subtypes had on colonic contractility, as well as assessing whether 
two key determinants of gastrointestinal (GI) plasticity, namely stress and 
ageing, altered such GABAAR expression and functional phenotypes in the 
colon. My main findings were: 
 
1) Using RT-PCR and homogenates of whole mouse colon, I demonstrated 
that the majority of mRNA transcripts for GABAAR subunits are expressed 
within the mouse colon, apart from the GABAAR α6 and ε subunits 
(Chapter 2).  
 
2) Using immunohistochemistry and confocal microscopy on fixed whole-
mount preparations of the mouse colon, I discovered that 
immunoreactivity for the GABAAR alphas (α) 1-5 and gamma (γ) 2 
subunits was divergently localised to ENS neurons in a cell-type (based 
on neurochemical signature), cell-domain (somata; dendrite; axon), 
subunit and ENS plexus (myenteric or submucosal)-specific manner 
(Chapter 2).  
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3) Using organ bath preparations of the isolated, intact mouse colon and 
subunit-preferring GABAAR ligands, I demonstrated that the activation of 
specific GABAAR subtypes had contrasting effects on the force and 
frequency of spontaneous contractions of colonic longitudinal smooth 
muscles as follows: 1) the activation of α1-γ2-GABAARs and α4-
GABAARs increased the force of spontaneous contractions, but not their 
frequency; 2) the activation of α2-γ2-GABAARs increased their frequency, 
but not their force; 3) the activation of α3-γ2-GABAARs decreased their 
force and; 4) an inverse agonist at α5-γ2-GABAARs decreased their force 
(Chapter 3). This suggests that the engagement of various GABAAR 
subtypes within the cellular networks of the ENS cooperate to modulate 
the distinct physiological processes, which underlie coordinated GI 
contractility and thus motility.  
 
4) Using various animal models of stress, either in early life, or in adulthood, 
I discovered that different forms of stress, which generally induce 
changes in CNS function as well as in behaviour, potently engage the 
ENS and the GABAAR system of the mouse colon in a stress- and 
GABAAR subunit-specific manner, by demonstrating the stress-induced 
changes in native colonic contractility, colonic GABAAR subunit 
expression and GABAAR-mediated colonic contractions (Chapter 4).  
 
 
5) Using mouse subjects of varying ages (postnatal days 10; 15; 60 and 18 
months), quantitative RT-PCR (qRT-PCR), organ bath preparations of 
isolated mouse colon and subunit-preferring GABAAR ligands, I 
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discovered that: 1) GABAAR subunit expression varies significantly with 
age, with the highest relative mRNA expression levels occurring at early 
postnatal stages and then decreasing dramatically during adulthood, in a 
subunit-specific manner; 2) the effects of the pharmacologically mediated 
activation of GABAAR subtypes on the force and frequency of longitudinal 
colonic smooth muscles also varies significantly across ages (Chapter 4).  
 
Collectively, these data demonstrate the central role that the GABAAR 
system plays in at least one aspect of GI function, namely motility. 
Furthermore, the profound changes in the expression and functional 
phenotypes of the GABAAR system across the life-time of an individual, 
either in response to emotional challenges, or healthy ageing, appears to 
parallel the functional plasticity of the GI system itself under such diverse 
conditions. This leads me to conclude that the colonic GABAAR system plays 
an integral role in native GI physiology and represents a potential therapeutic 
target for GI disorders arising either due to emotional challenges or the 
ageing process. The data arising from this thesis thus provide the scientific 
rationale for future translational studies targeting selectively the GI GABAAR 
system in various GI disorders using GABAAR subtype-specific ligands which 
do not cross the blood brain barrier and are thus devoid of any unwanted 
CNS effects. 
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1 Chapter 1: General Introduction 
 
The overall aims of my PhD project were to elucidate the cellular, sub-
cellular and region-specific expression patterns of distinct gamma-amino 
butyric acid A type receptor (GABAAR) subunits within the cellular networks 
of the enteric nervous system (ENS) of the mouse colon as well as 
determine their functional impact on one aspect of gastrointestinal (GI) 
function, namely colonic contractility, and how this changes with age or in 
response to stress.  
 
In this introductory chapter to my thesis, I will critically review the anatomy 
and functions of the ENS with special emphasis on its crucial role in the 
regulation of GI functions as well as its role in the pathophysiology of specific 
GI disorders. I will then review the roles of stress and ageing as key factors 
in inducing changes in native ENS and GI functions as well as contributing to 
GI disorders, with a view to hypothesising that stress-induced and age-
specific alterations in GABAARs expression and function might underlie these 
associated GI disorders. In order to provide the scientific justification for the 
need to fully understand the role of the GABAAR system in GI function, I will 
also review the importance of GABAARs to neural function where it will 
become apparent that our knowledge in this field is almost exclusively 
restricted to the domain of the central nervous system (CNS). The intention 
is thus to provide the scientific rationale and importance for investigating 
GABAAR expression and function in the ENS and how these data are likely 
to provide the scientific basis for targeting the GI GABAAR system in specific 
GI disorders.  
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1.1 The Enteric nervous system 
 
1.1.1 The place of the ENS within the body’s nervous system 
 
The body’s nervous system consists of the central (CNS) and the peripheral 
nervous systems (PNS). The brain and the spinal cord form the CNS 
whereas the PNS consists of the somatic nervous system, the autonomic 
nervous system and the ENS. The ENS has been of special interest to 
researchers as it is the only limb of the PNS which has the ability to generate 
activity independent of the CNS and as such it has often been referred to as 
the second brain (Lebouvier et al., 2009). However, the CNS innervates the 
enteric nerve processes via the parasympathetic and sympathetic pathways, 
and thus can modulate ENS activity (Mulak and Bonaz, 2004). It is the 
coordinated bidirectional communication of the CNS and the ENS which 
accounts for the neuronal control of various GI functions (Fig. 1).  
 
Similar to the CNS, the ENS functions through molecularly and functionally 
diverse neurons (Brookes, 2001). These diverse ENS neuronal networks 
innervate the gastrointestinal tract (GIT), thereby providing the intrinsic 
neuronal control and integration of virtually all GI functions. As such, 
dysregulation of the ENS has been shown to be implicated in numerous GI 
disorders (Grundy et al., 2009). Therefore, to therapeutically address the 
ever burgeoning array of ENS-mediated GI disorders, it is absolutely 
essential to understand the native molecules and cells which underpin ENS 
function in the first place. This is a central objective of my PhD research. 
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Figure 1 
Bidirectional communication of the CNS and the ENS  
Within the ENS, sensory neurons, interneurons and motor neurons are 
connected to form neuronal microcircuits. Motor neurons are synaptically 
connected to effector cells and modulate their activity. The ENS control of 
the gut behaviour can, in turn, be modulated via bidirectional communication 
between the ENS and the CNS. Taken from (Wood, 2009). 
 
 
1.1.2 Anatomy of the ENS  
 
The very first anatomical depictions of the ENS were illustrated by Georg 
Meissner in 1857 and Leopold Auerbach in 1862 (Brookes and Costa, 2006). 
In terms of anatomical location, the ENS is a large collection of neurons and 
glial cells positioned within the muscle wall of the GIT. These neurons and 
glia are generally grouped into clusters, known as enteric ganglia, which in 
turn are connected by interganglionic fibres (Goyal and Hirano, 1996, 
Furness, 2008). Whilst the ganglia are relatively small in terms of neuron 
numbers, their multitude accounts for the overall neuronal density of the 
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ENS. The processes of enteric neurons innervate other neurons, as well as 
non-neuronal cell-types which compose the tissue-types of the GIT, such as 
muscle layers, epithelium and blood vessels (Costa et al., 2000).  
 
Enteric ganglia are arranged into two separate but connected plexuses, 
called the myenteric plexus and the submucosal plexus. Neurons of the 
myenteric plexus are located between the outer longitudinal muscles and 
inner circular muscle layer, provide the neural regulation of both the 
longitudinal and circular smooth muscles and are thus primarily involved in 
GI contractility and thus motility (Hall and Duke, 2000, Olsson and Holmgren, 
2001). In contrast, neurons of the submucosal plexus are located on the 
luminal side of the circular muscle layer in the submucosa and innervate 
cells (epithelial cells, secretory glands, blood vessels, inflammatory cells) in 
the epithelial layer and the smooth muscle of the muscularis mucosae, 
thereby providing the neural regulation of mucosal function (Kunze and 
Furness, 1999) (Fig. 2).  
 
The molecularly and functionally distinct neurons and the interconnected 
cellular networks that comprise these plexuses, cooperate to ensure 
coordinated neural activity throughout the ENS and thus the regulation of GI 
functions. However, the morphology of the ENS alters dramatically between 
different species and different regions of the gastrointestinal tract (Furness, 
2006). Thus it is important to consider the molecules and the cells within the 
cellular networks of the ENS of a defined region of the GIT and a particular 
species. Hence, for the purpose of this thesis, I used the ENS of the mouse 
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colon as my model in order to ensure the reproducibility of our data. This is 
done with a view to the future exploitation of the available GABAAR mutant 
mouse models as well as the opportunity to compare my GABAAR-ENS data 
with GABAAR data obtained within the CNS, the majority of which has been 
obtained using mouse models. 
 
 
Figure 2 
 
Anatomy of the enteric nervous system 
Representation of the ENS as seen in (A) whole-mount sections and (B) 
cross sections. Taken from (Furness, 2006). Whole-mount preparations were 
used for immunohistochemical studies in this thesis. 
 
 
1.1.3 Cellular diversity of the ENS 
 
The number of neurons within the ENS of humans reach 500 million cells 
which make it the largest collection of neurons outside of brain (Furness, 
2006). ENS neurons are diverse in terms of their somato-dendritic-axonal 
morphologies, neurochemistry and their biophysical properties. 
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Morphology: within the mammalian ENS, there are two main morphologically 
distinct types of neurons, described by Jan von Dogiel in the 1890s and 
termed Dogiel type I and Dogiel type II neurons. Both types are present 
within the submucosal plexus as well as the myenteric plexus. The cell 
bodies of both types of neurons are flat and placed in a two-dimensional 
plane with multiple processes around the cell bodies. Uniaxonal neurons with 
angular or stellate shaped somata and multiple short dendrites are known as 
Dogiel type I neurons, whereas neurons with very large cells bodies and 
multiple long axons and processes are described as Dogiel type II cells 
(Dong et al., 2013, Brehmer et al., 1999, Song et al., 1996). Intrinsic primary 
afferent neurons of the ENS possess Dogiel type II morphology, whereas the 
Dogiel type I morphology has been associated with motor neurons and 
interneurons (Costa et al., 2000). 
 
Chemical and functional coding of ENS neurons: over thirty functionally 
distinct types of neurons have been discovered which communicate using 
more than 25 different neurotransmitters (Furness, 2000, McConalogue and 
Furness, 1994) including the classical neurotransmitters such as glutamate 
(Liu et al., 1997), GABA (Jessen et al., 1986), acetylcholine (Schemann et 
al., 1993), the mono-amines (NA, 5HT, DA, Histamine) (Li et al., 2010, Li et 
al., 2004), an array of neuropeptide neuromodulators such as corticotrophin 
releasing hormone (CRH) (Liu et al., 2006), vasoactive intestinal peptide 
(VIP) and the gaseous signalling molecule nitric oxide (NO) (Furness et al., 
1994, Alves et al., 2010). This has resulted in immense complexity of 
neuronal networks within the ENS, making it difficult to unequivocally 
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attribute a particular role in GI function to a particular ENS cell-type. 
However, ENS neurons with distinct roles in GI function can be classified as 
1) excitatory and inhibitory motor neurons, 2) interneurons and 3) intrinsic 
primary afferent neurons (IPANs), based on their morphologies, their 
projections, and the primary neurotransmitters they utilise, as summarised in 
Table 1. 
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Table 1  
 
Types of neurons in the enteric nervous system 
This table lists the neuron types that are found in the guinea-pig small 
intestine, some of their defining characteristics, and percentages of 
occurrence in each of the ganglionated plexuses. I have also listed three 
types of motor neuron that are found in other parts of the tubular digestive 
tract, marked by asterisks*. Taken from (Furness, 2000). 
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1.1.4 Non-neuronal cells interacting with ENS neurons 
 
Enteric glia: the ENS also contains a large number of glial cells which 
previously have been described to be similar to the astrocytes of the CNS, 
thereby providing structural and metabolic support for neurons (Boesmans et 
al., 2013). However, this dogma has been discarded in the recent years and 
enteric glia are considered to be active contributors to the ENS and 
ultimately GIT functions (Neunlist et al., 2013, Gulbransen and Sharkey, 
2012, De Giorgio et al., 2012). For example, enteric glia have been shown to 
colonise the intestinal mucosa and are constantly renewed throughout 
development; a process which is regulated by the indigenous gut microbiota 
(Kabouridis et al., 2015). Furthermore, a recent study revealed the existence 
of four morphologically distinct populations of enteric glia which show great 
heterogeneity in terms of their neurochemical content and their response to 
purinergic receptor activation (Boesmans et al., 2015). Therefore, enteric glia 
cells are fast becoming recognised as major players in the ENS function and 
the control of GI homeostasis.   
 
Interstitial cells of Cajal (ICCs): The final type of cells which are expressed in 
close proximity to the ENS and seem to form synapse-like connections with 
enteric neurons are the ICCs. ICCs act as the pace-makers for GIT motility 
by creating slow wave potentials which lead to the contraction of GI smooth 
muscles (Garcia-Lopez et al., 2009). As such, ICCs are hypothesised to be 
the cellular links between ENS neurons and intestinal smooth muscle cells 
(Sanders and Ward, 2006, Huizinga et al., 2009). 
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1.1.5 Physiology of the ENS neurons  
 
Electrophysiological studies using intracellular recordings of myenteric 
neurons of the guinea-pig ileum indicate that there are two physiologically 
distinct enteric neuronal cell-types known as S and AH neurons (Hirst and 
McKirdy, 1974, Nishi and North, 1973). S type neurons have a relatively high 
resistance, are classified as tonically firing and are followed by a fast after-
hyperpolarisation (AHP) (Smith et al., 1999). However, some studies have 
shown evidence of S neurons, including filamentous interneurons, which 
exhibit slow AHP (Lomax et al., 1999, Song et al., 1997). The morphology of 
S type enteric neurons is restricted to Dogiel type I and never Dogiel type II 
morphology (Furness, 2006). In contrast, AH neurons produce very large 
action potentials, ranging in amplitude from 75-110 mV, which are longer 
lasting than those of S neurons, and are followed by a fast and a late slow 
AHP (Brookes et al., 1995). In contrast to S neurons, the majority of AH 
neurons display Dogiel type II morphology (Bornstein et al., 1991). Thus, 
ENS cell-types have been classified according to their morphology, 
physiology and neurochemical content (Furness, 2000).  
 
1.1.6 The ENS as a regulator of gut function in health and disease 
 
The mammalian GIT is the organ which, amongst other functions, provides 
not only the principal nutritional gateway, but also the pathogenic barrier to 
the other internal organs, underlining its importance to lifelong health and 
wellbeing. Therefore, it requires precisely orchestrated systems of control of 
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its muscle activity, defensive mechanisms and fluid secretion. The intrinsic 
control and integration of all these GI functions is dependent upon ENS 
neuronal activity (Furness, 2008, Di Nardo et al., 2008, Lake and 
Heuckeroth, 2013).  
 
Enteric neurons form intricate cellular networks with neuronal and non-
neuronal cell-types and provide the intrinsic neural control of virtually all GI 
functions such as peristalsis (Grider, 1989), secretion (Riegler et al., 2000), 
barrier function (Neunlist et al., 2003, Toumi et al., 2003) and local immune 
function (Goyal and Hirano, 1996, Furness, 2006, Schneider et al., 2001). As 
such, disruption in the ENS and enteric neuronal pathways leads to 
impairments in GI functions and eventually GI disorders as shown in a 
number of studies on motility and secretion deficits (Grundy et al., 2009, Di 
Nardo et al., 2008).  
 
Enteric neuropathies can be categorised as: 1) hereditary or developmental 
disorders; 2) acquired or irregular neuropathies; 3) enteric neuropathies 
developed as a result of another disease state such as mental illnesses and; 
4) drug-induced enteric disorders (De Giorgio and Camilleri, 2004, De 
Giorgio et al., 2004, De Giorgio et al., 2007). In GI disorders such as 
Hirschsprung's disease, where the ENS fails to develop, and Chagas 
disease, where the ENS is severely damaged due to parasitic infection, the 
importance of the ENS is self-evident as the patient will not survive without 
immediate medical interventions (Furness, 2008).  
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The alterations in the ENS which give rise to GI disorders are highly complex 
and could be due to overlapping physiological, neurochemical and 
morphological changes within enteric neuronal pathways and reflexes 
(Geboes and Collins, 1998). In the past 20-30 years, there has been an 
extensive amount of research focusing on the ENS in healthy intestine and 
disease models which has led to a greater appreciation of its importance in 
clinical medicine (Raj K. et al., 1996). Although these studies have shed a 
light on the importance of ENS dysregulation in GI disorders, the specific 
neurons and the neurochemical signalling pathways involved in the 
pathology of such disorders remain unclear.  
 
1.2 Plasticity of the ENS and GIT: the roles of Stress and Age 
in health and GI health and disease 
 
A central requirement for life-long health and wellbeing is a GIT that is able 
to evolve functionally as the individual develops and ages, as well as adapt 
homeostatically to changing external emotional or physical challenges such 
as stressors which directly engage not only the CNS but a host of body 
systems, including the GIT. The importance of GI plasticity, either in terms of 
stress or age, becomes abundantly obvious in light of the strong co-morbidity 
of GI disorders with stress-induced mental illnesses or elderly individuals. I 
therefore believe that it is not only important to characterise the GABAAR 
system within the ENS, but to do so in the context of two key determinants of 
GI plasticity, namely stress and healthy ageing.  
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1.2.1 The stress response and its importance in regulating homeostasis  
 
The body’s stress response is a defence mechanism to contend with threats 
to homeostasis (Selye, 1950, Karatsoreos and McEwen, 2013). Stressors, 
whether real (physical) or perceived (psychological) engage a host of 
physiological events at both the systems and local level. At the systems 
level, the initiator of the body’s stress response is the activation and release 
of the neurohormone CRH from parvocellular hypothalamic neurons in 
response to external stimuli, processed through a variety of brain pathways 
including the amygdala and prefrontal cortex (Hsu et al., 1998). The release 
of CRH (and arginine vasopressin, AVP, from magnocellular hypothalamic 
neurons) stimulates the release of adrenocorticotropic hormone (ACTH) from 
the anterior pituitary into the bloodstream (Smith and Vale, 2006) (Fig. 3). 
ACTH induces the release of glucocorticoids from the adrenal gland, which 
then go on to induce a range of physiological, metabolic and immune 
responses which allow for adaptation to the stressor.  
 
A key process in homeostatic stress responses is the negative feed-back 
loop, via glucocorticoid receptors (GRs) located within the CNS which 
determines the appropriate cessation of the stress response (Tasker et al., 
2005). This occurs in most cases, especially when the stress presents only 
acutely, and serves to allow adaptive responses to future stressors. 
However, exposure to sustained, chronic stressors, or a disassociation 
between the perception of stress and its presentation leads to impairment in 
the GR-mediated feedback loop and thus a sub-optimal cessation of the 
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stress response, which is thought to contribute to the maladaptive biological 
mechanisms which underlie stress-induced disorders (Bonne et al., 2004), 
including various mental illnesses or GI disorders such as irritable bowel 
syndrome (IBS) or inflammatory bowel disease (IBD) (Fichna and Storr, 
2012, Mawdsley and Rampton, 2005). Thus, identifying the biological events 
which determine both the adaptive and maladaptive responses to stressors 
are essential for devising directed therapeutic strategies for the ensuing 
pathologies.  
 
 
Figure 3 
 
The central and peripheral mammalian stress response via bidirectional 
communication of the CNS and peripheral organs. ACHT, 
adrenocorticotropic hormone; CRF, corticotrophin releasing factor. Taken 
from (Mawdsley and Rampton, 2005). 
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1.2.2  Stress response within the GI tract and the ENS 
 
The stress response involved in GI homeostasis is likely to involve a central 
and local response, with CRH signalling being a central mediator of the 
respective responses. CRH, whether it arises from the brain or peripheral 
systems, is generally produced by neurons. Within the ENS, CRH is 
expressed within somata and processes of both myenteric and submucosal 
neurons of the guinea-pig ENS. These neurons also express VIP and 
innervate neighbouring cholinergic neurons that express CRH1 receptor (Liu 
et al., 2006). Since CRH release is so important for the stress response, the 
regulatory mechanisms which govern CRH release, such as the 
neurotransmitters and their receptors located on CRH-expressing neurons 
are likely to be integral to the stress response. Whilst we have made 
considerable progress in dissecting the molecular, cellular and behavioural 
machinery of the stress response at the CNS level (McEwen and Gianaros, 
2010, de Kloet et al., 2005), such correlates at the peripheral level, including 
the ENS, remain relatively poorly described, despite evidence of stress 
directly impacting on GI function (Mayer, 2000). Indeed, CRH signalling 
pathways within the brain and the gut have been implicated in the stress-
evoked GI functional abnormalities including motor and barrier dysfunction 
(Tache et al., 2004, Tache and Perdue, 2004). Furthermore, stress and 
hypothalamic-pituitary axis (HPA) activation have been shown to induce the 
expression of inflammatory cytokines including tumour necrosis factor α 
(TNF-α), interleukin (IL)-1, and IL-6 within the GI tract (Sternberg et al., 1992, 
Perlstein et al., 1993), indicating the direct effect of stress on GI physiology.  
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CRH exerts its effects by acting on two CRH receptor subtypes expressed by 
enteric neurons, namely the CRH1 and CRH2 receptor subtypes 
(Dautzenberg and Hauger, 2002). Current evidence indicates that 
environmental stress directly engages the CRH-CRH receptor system within 
the ENS. For example, subjecting adult rats to crowding stress for 15 days 
has been shown to lead to an increase in the expression of CRH1 receptor 
mRNA but not CRH2 receptor within the small intestine and colon (Vicario et 
al., 2012). Furthermore, exposure of rats to early life stress, in form of 
maternal separation, leads to an increase in CRH1 and CRH2 receptors 
within the colon at protein levels (O'Malley et al., 2010). Importantly, increase 
in CRH1 receptor expression within certain disorders of the GIT such as 
ulcerative colitis has been reported (Tache et al., 2004, Tache and Perdue, 
2004, Yuan et al., 2012). These studies demonstrate that exposure to 
different stressors at different ages result in various changes in the CRH-
CRH receptor system of the GIT. Therefore, to understand the biological 
correlates of both adaptive and maladaptive stress responses at the ENS 
level, it is imperative to employ a range of stress paradigms.  
  
1.2.3 Stress and GI disorders  
 
Stress not only predisposes individuals to mental illnesses such as anxiety 
and depression, but is also a key contributor to the underlying pathology of 
numerous GI disorders (Mayer, 2000). A comprehensive body of research 
indicates that stress plays an important role in the development, onset and 
symptom exacerbation of a number GI disorders such as irritable bowel 
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syndrome (IBS), inflammatory bowel disease (IBD) and gastric ulcers 
(Levenstein et al., 1994, Wood, 2002, Greene et al., 1994, Drossman, 2004). 
In addition, on a functional level, stress leads to the inhibition of gastric 
emptying which is accompanied by an increase in the colonic motility, 
mucosal electrolyte secretion and faecal pellet discharge (Tache et al., 1999, 
Maillot et al., 2000, Martinez et al., 2002). Importantly, similar studies 
suggest that many of the stress-induced functional alterations in the GI tract 
are mediated via peripheral CRH and its release from CRH-containing 
neurons within the myenteric and submucosal plexus of the ENS (Saunders 
et al., 2002a, Saunders et al., 2002b). Since the excitability of these neurons 
is controlled via a repertoire of neurotransmitter receptors, it is important to 
explore the neurotransmitter receptor expression and neurobiology of such 
enteric neurons in order to understand their role in mediating the stress 
response within the GI tract.  
 
1.2.4 Enteric nervous system and ageing  
 
The ENS is believed to develop by the migration of neuronal crest cells 
(NCC) into the foregut and spreading through the entire length of the gut, 
where they give rise to enteric neurons. These ENS crest cells originate from 
two specific regions of the neuraxis namely the vagal and the sacral regions 
(Anderson et al., 2006). Age-dependent changes in ENS and GI function can 
arise as a natural consequence of ageing, or as a result of age-dependent 
medical conditions such as Parkinson’s disease (Wakabayashi and 
Takahashi, 1997, Micieli et al., 2003), Alzheimer’s disease (Van Ginneken et 
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al., 2011) and diabetic neuropathies (Vinik et al., 2003). The changes in the 
ENS which occur as a consequence of natural ageing can be divided into 
cellular, morphological and functional alterations (Saffrey, 2004). At a cellular 
level, a significant reduction in the number of enteric neurons and glial cells 
has been widely reported during the ageing process (Wade and Cowen, 
2004, Phillips et al., 2004). In addition, the enteric neuronal loss has been 
shown to be cell-type specific with cholinergic neurons being the most 
vulnerable and nitrergic neurons being spared (Cowen et al., 2000, Phillips et 
al., 2003). This is intriguing as significant neuronal loss in other divisions of 
the nervous system is only associated with pathological ageing; although 
mild neurodegeneration in certain brain regions such as the locus coeruleus 
occurs through healthy ageing (Turlejski and Djavadian, 2002).  
 
On a morphological level, evidence indicates that there are age-related 
morphological changes in ENS such as increased size of myenteric neurons 
and reduced density of peptide immunoreactive fibres (Phillips et al., 2003, 
Feher and Penzes, 1987). Whilst the precise relationship between age-
related neuronal loss and gastrointestinal dysfunction remains to be fully 
resolved, it is clear that reduced intestinal motility is the main functional 
consequence of the ageing gut with as many as 24% of people over the age 
of 65 suffering from chronic constipation (Saffrey, 2004). In addition to age-
related changes in motility, the absorptive and inflammatory processes within 
the stomach and the intestine are also altered with ageing, presumably due 
to an increase in free radical count and a decrease in neurotrophic factors 
(Cowen et al., 2000).  
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1.2.5 Ageing and GI disorders  
 
It is very difficult to relate the development or existence of a certain GI 
disorder solely to ageing due to the usual co-existence of these disorders 
with other age-related pathologies such as dementia, Parkinson’s disease 
and diabetic neuropathies. However, different parts of the entire length of gut 
go through major changes during ageing. For example, in the stomach, age-
related decreases in mucus production and prostaglandins level are 
suggested to lead to the development of peptic ulcer disease (Feldman et al., 
1996). As mentioned before, constipation is a major problem in older people 
and as we get older bowel movements appear to slow down which suggest 
changes in the intestinal transit time. Indeed a significant number of older 
people suffer from symptoms of IBS which is accompanied by abnormal 
motility, increased sensation and psychosocial disturbances (D'Souza, 
2007). Despite the fact that ageing is accompanied by a range of GI 
disorders, one should also consider the fact that these disorders may be the 
result of some other underlying pathologies or the vulnerability of the immune 
system in older people. Nevertheless, it is particularly important to 
understand the pathways through which these age-related GI disorders are 
developed with a view to finding potential therapeutic targets. 
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1.2.6 Current treatments targeting the ENS in GI disorders  
 
The level of neuronal activity of the ENS is determined by those 
neurotransmitter–receptor systems utilised by enteric neurons (Furness, 
2006). Importantly, whilst altered levels of neuronal activity within the ENS 
are implicated in many GI disorders (Ohman and Simren, 2010, Margolis and 
Gershon, 2009), most treatment is still primarily aimed at alleviating the 
associated GI symptoms (Di Nardo et al., 2008). Nevertheless, most of the 
identified therapeutic targets for the treatment of GI disorders within the ENS 
are neurotransmitter and hormone receptors (Furness, 2008). Some of these 
targets which are located on enteric neurons include 5-HT receptors, 
muscarinic receptors, adrenoreceptors, NK tachykinin receptors, CRH 
receptors, dopamine receptors, motilin receptors, opioid receptors and CCK 
receptors (Camilleri et al., 2006, Pasricha, 2007).  
 
There are currently a number of clinically available drugs which have been 
used to target these receptors. However, most of these drugs have limited 
use or have been withdrawn due to their low frequency and long list of side 
effects (Sanger and Alpers, 2008). For example, cisapride, a 5-HT4 receptor 
agonist used in constipation and treatment of GERD, was withdrawn due to 
activity at the hERG channel which leads to long QT syndrome and 
arrhythmias (Rampe et al., 1997). In addition, other drugs such as NK3 
receptor antagonist which have been useful in animal studies have been 
ineffective in patients (Houghton et al., 2007). Therefore, despite the 
substantial body of research focused on discovery of new potential 
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therapeutic targets within the ENS, there still exists a need to find safer and 
more specific targets for the treatment of GI disorders which is the basis for 
this thesis.  
 
1.2.7 Why consider GABAARs as potential therapeutic targets for GI 
disorders  
 
GABAARs are central to virtually all aspects of the body’s nervous system yet 
all the current focus on GABAAR biology is on the CNS. As a consequence, 
GABAAR biology within the PNS and the ENS in particular, remain relatively 
unexplored and thus untapped therapeutically. The importance of GABAARs 
to health and wellbeing is demonstrated by their pivotal role in regulating 
neurological and mental functions (Dunlop and Davis, 2008, Rudolph and 
Mohler, 2014, Fritschy, 2015), as well as the contributions of GABAAR-
modulating drugs to modern clinical medicine and pharmacology of the CNS 
(Rudolph and Knoflach, 2011).  
 
Importantly, GABAAR subunit mRNA expression has been demonstrated in 
the rat small intestine (Zeiter et al., 1996, Poulter et al., 1999). However, the 
functional contribution of specific GABAAR subtypes to GI contractility is yet 
to be determined. Hence, these receptors have been completely overlooked 
as therapeutic targets for GI disorders. Their neglect as targets of 
investigation in terms of GI disorders is ever more surprising in light of them 
being the targets for a number of clinically useful drugs for the treatment of 
brain disorders which often occur in conjunction with GI disorders such as 
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IBS (Yacob et al., 2013, Fichna and Storr, 2012). Furthermore, drugs 
targeting GABAAR successfully treat diverse CNS conditions such as anxiety 
and depression and provide secondary relief from co-existing GI disorders 
(Chouinard, 2006). This raises the question whether GABAARs could provide 
novel therapeutic targets for specific GI disorders. If so, in order to design 
therapeutics that target these receptors within the ENS, we first need to 
understand the precise expression pattern and functional role of various 
GABAAR subtypes within the GIT which form two of the objectives within this 
thesis.  
 
1.3 The GABA-GABAAR system 
 
GABA is the major inhibitory neurotransmitter within the nervous system and 
is central for modulating neuronal excitability and, thus neural function 
throughout the body (Sieghart and Sperk, 2002, Sieghart, 2006, Pallotto and 
Deprez, 2014). GABA exerts its fast inhibitory effects predominantly through 
GABAARs (Olsen and Sieghart, 2009b). GABAARs are one of the most 
comprehensively studied neurotransmitter receptors within the CNS and are 
targeted by a number of clinically available drugs for the treatment of various 
disorders of neural origin. However, most of what we know about GABAARs 
relates to their expression and function in the CNS and very little in the PNS, 
in particular, the ENS. This represents a potentially missed therapeutic 
opportunity in terms of GI disorders. The focus of my PhD research is to 
investigate the expression and function of GABAARs within the healthy, 
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stress and aged ENS with a view to providing the scientific rationale for 
future translational studies in GI medicine.  
 
1.3.1 The structure of GABAARs  
 
GABAARs belong to a family of ligand-gated ion channels, called Cys-loop 
receptors, which respond to the binding of a ligand or neurotransmitter by 
allowing the passage of ions such as Na+, Ca+, K+ or Cl- through the 
membrane (Sieghart and Sperk, 2002). GABAARs are heteropentameric 
receptors composed of 5 interacting subunits with an integral ion channel 
which is selectively permeable to Cl- ions (Olsen and Sieghart, 2008, Olsen 
and Sieghart, 2009a) (Fig. 4). To date, 19 different mammalian GABAAR 
subunits have been cloned and classified as follows: α1-6, β1-3, γ1-3, δ, ε, θ, 
π and ρ1-3. The heteropentameric assembly of these receptors results in 
immense complexity in their structure and function since it is the subunit 
combinations which determines the function and pharmacology of the 
receptor complex (Barnard et al., 1998).  
 
Most GABAARs within the CNS are made up of two α, two β and a γ subunit 
(Sigel and Steinmann, 2012, Rudolph and Knoflach, 2011). Each subunit 
contains and extracellular domain comprising the N and C-terminus and 
extracellular loop between TM2-TM3, four alpha helical transmembrane 
spanning domains (M1-M4) and two intracellular loops located between 
TM1-TM2 and TM3-TM4 (Miller and Aricescu, 2014). The functional binding 
site for GABA molecules has been shown to be located at the interface of the 
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α and β subunits (Boileau et al., 1999, Miller and Smart, 2010). Although, 
each receptor is equipped with two GABA binding sites, the opening of the 
channel may also occur through occupation of the receptor with a single 
GABA molecule. However, the channel opening has been shown to be 
enhanced by about 60-fold in receptors occupied by two GABA molecules 
(Baumann et al., 2003). The binding of two GABA molecules to the receptor 
induces a conformational change in the pore leading to passage of chloride 
ions across the membrane. The directional flow of chloride ions (into or out of 
the cell), and thus the eventual effect in neuronal excitability 
(hyperpolarisation or depolarisation respectively) is dependent upon the 
chloride concentration gradient across the cell membrane and the membrane 
potential. In adulthood, when neurons have relatively lower levels of 
intracellular chloride, compared to extracellular levels, the gating of 
GABAARs results in the inward movement of the negatively charged chloride 
ions which results in neuronal hyperpolarisation, or inhibition of excitability 
(Rudolph et al., 2001).  
 
In addition, there are distinct binding sites for various pharmacological 
ligands which have affinity for GABAARs. For instance, the binding site for 
benzodiazepines, which are positive allosteric modulators of GABAARs, is 
located between the α and γ subunits (Amin et al., 1997, Teissere and 
Czajkowski, 2001). There are additional binding sites for other GABAARs 
ligands such as picrotoxin which blocks the GABAAR pore, bicuculline which 
is an inverse agonist and gabazine which is a competitive antagonist 
(Wlodarczyk et al., 2013). Thus, the subunit composition and structure of 
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GABAARs is inextricably linked to their function and pharmacology within the 
nervous system. 
 
 
Figure 4 
 
The structure of GABAARs 
(a) Each GABAAR subunit contains four transmembrane spanning domains 
which form the chloride ion conducting pore. (b) The combination of specific 
GABAAR subunits within a particular receptor determines its kinetics and 
pharmacological properties and leads to immense receptor heterogeneity 
(Jacob et al., 2008).  
 
 
1.3.2 Physiology of GABAARs 
 
GABAARs are principally expressed on the postsynaptic domains of neurons 
within the adult CNS (Fritschy and Mohler, 1995). These receptors cluster 
primarily within synapses and thus directly apposed to GABA release sites 
(Nusser et al., 1996). However, significant proportions are also located on 
extrasynaptic cell surfaces of somata, dendrites and axonal regions, some 
distance from the neurotransmitter release site (Kasugai et al., 2010) 
(Kullmann et al., 2005) (Fig. 5). The close proximity of synaptically located 
GABAARs to the released GABA results in this cohort of receptors being 
49 
 
exposed to the highest concentrations of GABA and producing rapid, 
inhibitory postsynaptic currents (IPSCs). However, due to the rapid removal 
of GABA from the synaptic cleft by GABA transporters, as well as receptor 
desensitisation, these IPSCs are of short duration and therefore termed 
phasic IPSCs (Fig. 5B). In contrast extrasynaptic GABAARs, are slower to 
desensitise and use the lower ambient levels of GABA, which are beyond the 
reach of GABA transporters, to mediate slow and persistent IPSCs which are 
termed tonic IPSCs (Fig. 5C) (Hunt et al., 2013, Farrant and Nusser, 2005).  
 
It is this combination of fast phasic and sustained tonic GABAAR-mediated 
IPSCs which allows a neuron to adapt its excitability, thereby contributing to 
the rhythmic network activity within and between brain regions which is 
essential for coordinated brain function and behaviour (Somogyi and 
Klausberger, 2005, Singer, 1996, Jonas et al., 2004). Therefore, determining 
the precise expression patterns of various GABAAR subtypes are important 
in terms of identifying their roles in native neural function or in disease. 
Within the CNS, we have made considerable progress in terms of identifying 
the roles of individual GABAARs subunits in different facets of neural 
regulation, as discussed below. 
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Figure 5 
 
Physiology of synaptic and extrasynaptic GABAARs 
(A) GABAARs can be located adjacent to the GABA release site, i.e. synaptic 
cleft, or away from the GABA release site, extrasynaptic. (B) Phasic IPSCs 
are rapid events and produced by synaptic GABAAR activation. Three 
Individual IPSCs are shown here. (C) Tonic currents which are produced by 
extrasynaptic GABAAR activation and blocked by the GABAAR antagonist 
bicuculline methiodide (BMI; 100 μM). Taken from (Hunt et al., 2013).  
 
 
1.3.3 The expression and function of specific GABAAR subtypes within the 
mammalian CNS 
 
GABAARs are widely expressed within various regions of the brain with an 
immense molecular heterogeneity manifesting in multiple functional GABAAR 
subtypes on different neuronal populations (Rudolph and Knoflach, 2011) 
(Fig. 6). The most widely expressed subunits within the CNS are the 
GABAAR α1 and the γ2 subunits which are consequently the constituent 
subunits of a large number of GABAARs (Nutt, 2006). In contrast, expression 
of specific subunits is restricted to specific regions of the brain. The most 
abundantly expressed GABAAR subtypes within the CNS are purported to 
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contain GABAAR α1β2γ2 subunits. However, α2β3γ2 and α3β3γ2 subunit-
containing GABAAR receptors are also widely expressed throughout the 
brain (Wisden et al., 1992). Some GABAAR subunits are predominantly 
expressed within synapses, such as γ2 subunit-containing receptors, 
whereas others, such as delta-containing receptors, are only expressed on 
extrasynaptic domains (Somogyi et al., 1996). In addition, within distinct 
regions of the brain, different GABAAR subunits are expressed on 
neurochemically distinct populations of neurons. For example, within the 
locus coeruleus, the GABAAR α1 subunit is exclusively located on non-
noradrenergic neurons, whereas the GABAAR α2 and α3 subunits are 
expressed by noradrenergic cells (Corteen et al., 2011). Therefore, the 
expression of diverse GABAARs with distinct subunit compositions within the 
CNS is cellular, sub-cellular and region specific.  
 
Pharmacological and behavioural studies of transgenic mouse models in 
which specific GABAAR subunits have been deleted (knockout mice, KO) 
show that these receptors are involved in a number of functions within the 
CNS such as sedation, myelorelaxation, learning and memory (Low et al., 
2000, Collinson et al., 2002, Jurd et al., 2003). Yet again, the functional 
property of each GABAAR is determined by its subunit composition as 
elaborated in Figure 6 (Mohler et al., 2002, Rudolph and Knoflach, 2011). It 
is important to remember that subunit-specific GABAAR ligands currently do 
not exist. All currently available drugs bind to most GABAAR subtypes, to 
varying degrees. However, the use of specific agents at specific 
concentrations can limit their binding affinity to a subset of GABAAR 
52 
 
subtypes. Nevertheless, not only diverse GABAAR subunits are expressed 
on different neurons within different regions of the brain, but they are also 
associated with specific functions within the CNS (Fig. 6).  
 
As such, an understanding of subunit-specific expression pattern is critical to 
account for the function of GABAARs within the nervous system. The α 
subunit provides GABAARs with their most prominent functional and 
pharmacological signatures. The GABAAR γ2 subunit is also functionally very 
important as it is present in 90% of all GABAARs and is the binding site for 
benzodiazepines. Therefore, in this chapter, I will focus on reviewing our 
knowledge on the expression and function of GABAAR α1-5 subunits and the 
γ2 subunits within the CNS.  
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Figure 6 
 
The expression and function of various GABAARs within the CNS 
α1 subunit is expressed in cortex, thalamus, pallidum and hippocampus. 
α2 is expressed in hippocampus, cortex, striatum, and nucleus accumbens. 
α3 is expressed in the cortex and the reticular nucleus of the thalamus, and 
α5 in the hippocampus and in deep layers of the cortex. The Pie chart 
represents the relative expression and function of diverse GABAAR subunits 
within the mouse brain. Taken from (Rudolph and Knoflach, 2011).  
 
 
1.3.4 The GABAAR alpha1 subunit 
 
The α1 subunit is the most widely expressed GABAAR subunit within the 
CNS with approximately 50% of all GABAARs throughout the brain containing 
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this subunit (Benke et al., 1994). However, certain areas of the brain, such 
as the cerebral and cerebellar cortex, and specific cell types within those 
brain regions, such a interneurons, express the GABAAR α1 subunit to a 
much larger degree than other areas and cell types within the CNS (Fritschy 
and Mohler, 1995, Gao and Fritschy, 1994). The deletion of this subunit does 
not result in an overt phenotype and is not essential for survival (Sur et al., 
2001), although the deletion does result in the prolongation of IPSCs, 
indicating that α1-subunit containing GABAARs (α1-GABAARs) contribute to 
fast phasic IPSCs.  
 
The native function of the GABAAR α1 subunit, as well as the mechanisms of 
action of various GABAAR-modulating drugs has been elucidated by α1 
subunit-KO mice (Rudolph et al., 1999). Indeed, the GABAAR α1 subunit is 
required for the sedative and amnesiac effect of benzodiazepines (Rudolph 
et al., 1999) but not their anxiolytic, myorelaxant and ethanol-potentiating 
effects (McKernan et al., 2000). Furthermore, application of zolpidem, an α1 
subunit preferring atypical benzodiazepine, in WT and α1 subunit-deleted 
mice (α1-KO) has revealed that GABAAR α1 subunit activation results in an 
increase in frequency and prolongation of the miniature IPSC (mIPSC) decay 
time (Goldstein et al., 2002). Importantly, despite the comprehensive body of 
data on this subunit within the CNS, there has been little evidence for the 
expression and function of α1 subunit in the ENS. 
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1.3.5 The GABAAR alpha2 subunit 
 
The GABAAR α2 subunit is also widely expressed throughout the brain but to 
a lesser extent in comparison to the α1 subunit, with the majority of the α2 
subunit being expressed in the hippocampus, cortex, striatum, nucleus 
accumbens and amygdale (Hortnagl et al., 2013). Deletion of the GABAAR 
α2 subunit is not accompanied by any behavioural phenotypes but results in 
a decrease in the mIPSC amplitude and prolongation of their decay, 
indicating that the α2-GABAARs contribute predominantly to fast phasic 
IPSCs (Dixon et al., 2010). Therefore, the α2 subunit seems to endow 
GABAARs with relatively fast kinetics.  
 
In terms of their clinical roles, α2-GABAARs have been linked to the anxiolytic 
(Dixon et al., 2008) and myorelaxant effects (Crestani et al., 2001) of 
benzodiazepines. However, agents used to target such receptors, such as 
benzodiazepines, often lack specificity, and engage α1-GABAARs to a 
certain degree, thereby inducing unwanted sedative side-effects. An 
additional side effect of such agents is the development of dependence in 
long term use which limits their clinical utility. This potential for inducing 
dependence could be coupled to emerging evidence for such receptors 
being involved in other neural mechanisms of substance abuse and alcohol 
dependence (Li et al., 2014). However, recent utilisation of GABAAR α2/3 
subtype-selective modulators in pre-clinical trials which show non-sedative 
anxiolytic effects has been promising (Atack, 2011).  
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1.3.6 The GABAAR alpha3 subunit 
 
Unlike the GABAAR α1 and α2 subunits, expression of the α3 subunit is 
highly restricted to specific brain regions and cell-types, these being mono-
aminergic neurons of the brain stem, basal forebrain cholinergic neurons and 
the reticular nucleus of the thalamus (Hortnagl et al., 2013). Deletion of the 
GABAAR α3 subunit is also not essential for survival but is accompanied by 
changes in the sensorimotor information processing alluding to a role in the 
pathogenesis of schizophrenia (Winsky-Sommerer et al., 2008, Yee et al., 
2005).  
 
Importantly, the GABAAR α3 subunit imparts a physiological signature which 
is distinct to that of the α1 and α2 subunits since α3-GABAARs are 
significantly less sensitive to GABA and possess a much slower decay time 
and activation (Gingrich et al., 1995, Okada et al., 2000). In addition, whilst α 
1 and α2 subunits predominantly mediate fast phasic GABAergic currents, a 
recent study has indicated that the GABAAR α3 subunit is involved in 
mediating the tonic GABAergic currents in the amygdale (Marowsky et al., 
2012). This was a unique finding since tonic inhibitory currents were 
presumed to be mediated primarily by GABAAR α 4, 5, 6 or delta subunits 
(Glykys and Mody, 2007), which, apart from α5-GABAARs, are not modulated 
by benzodiazepines. Thus, α3-GABAARs could contribute to the tonic 
inhibitory currents generated by benzodiazepines, whereas α1/2-GABAARs 
are likely to mediate the phasic inhibitory currents generated by such agents. 
This, together with the diverse expression patterns, might help to explain the 
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myriad of physiological effects induced by these reagents, further 
emphasising the need for subunit-specific GABAAR ligands. 
 
1.3.7 The GABAAR alpha4 subunit 
 
 The GABAAR α4 subunit expression is relatively restricted to distinct regions 
of the brain such as specific layers of the neocortex, the dentate gyrus, 
striatum and the thalamic nuclei (Hortnagl et al., 2013). In contrast to the 
GABAAR α1-3 subunits, GABAARs containing the α4 subunit are 
predominantly expressed on the extrasynaptic cell surfaces (Nusser et al., 
1998, Chandra et al., 2006) and as such are involved in mediating the tonic 
inhibitory currents (Walker and Kullmann, 2012, Richardson et al., 2011).  
 
The α4 subunit endows GABAARs with unique properties such as high 
sensitivity for ethanol and insensitivity for benzodiazepines, high affinity for 
GABA, and slow desensitisation kinetics (Brown et al., 2002, Jia et al., 2005, 
Wallner et al., 2003). In addition, the absence of the α4 subunit reveals a 
central role for this subunit generating basal tonic inhibitory currents as well 
as inhibitory tonic currents potentiated by ethanol (Chandra et al., 2006, 
Liang et al., 2004, Glykys et al., 2007). Emerging evidence further indicates a 
role for α4-GABAARs in drug addiction pathophysiology (Maguire et al., 
2014). Once again, the lack of any specific α4-GABAAR-targetting ligands is 
an immense obstacle to the clinical exploitation of these receptors.  
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1.3.8 The GABAAR alpha5 subunit 
 
The expression of α5 subunit containing GABAARs is somewhat more 
restricted and region specific compared to the α1-4 subunits. This subunit is 
mainly expressed in the hippocampus, olfactory bulb and to a lesser extent in 
the cortex (Hortnagl et al., 2013). This receptor subunit can be located 
synaptically or extrasynaptically. For instance, the GABAAR α5 subunit is 
expressed extrasynaptically in the hippocampus and mediates tonic 
inhibitory currents (Glykys et al., 2008) whereas in the neocortex, this subunit 
is expressed synaptically and mediates inhibitory postsynaptic potentials 
(IPSPs) elicited by dendrite-preferring cells (Ali and Thomson, 2008). In 
addition, the synaptic localisation of the GABAAR α5 subunit has been 
recently shown to be involved in the regulation of dendritic outgrowth and 
spine maturation throughout brain development (Brady and Jacob, 2015). 
 
The high levels of expression of GABAAR α5 subunits in the hippocampus 
suggested that it might be involved in the memory and cognitive performance 
that is associated with this brain region. This was supported by evidence 
obtained using GABAAR α5-KO mice which exhibited superior performance 
to Wild-types (WTs) in terms of learning and memory (Prut et al., 2010, 
Collinson et al., 2002). Thus, α5-GABAARs appear to impair such cognitive 
processes. As such, these subunits enjoy an immense amount of interest as 
targets for cognitive enhancers. Along these lines, promising evidence for the 
therapeutic potential of α5-GABAAR targeting ligands is beginning to emerge, 
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for example, in the treatment of Down’s syndrome (Martinez-Cue et al., 
2013) or schizophrenia (Gill and Grace, 2014).  
 
1.3.9 The GABAAR gamma2 subunit 
 
The GABAAR γ2 subunit is one of the most widely expressed GABAAR 
subunits through the mouse brain with most areas of the brain expressing 
this subunit to some level (Hortnagl et al., 2013). In contrast to α subunits, 
deletion of GABAAR γ2 subunit is essential for survival and homozygous 
GABAAR γ2-KO mice die prenatally which is in part due to the essential role 
of this subunit in clustering of GABAARs within synapses; thereby mediating 
the important role which GABAARs play in development (Essrich et al., 
1998). 
 
The GABAAR γ2 subunit can be co-expressed with any of the α subunits, and 
as such, can be located in synapses or extrasynaptically, thereby mediating 
both phasic or tonic inhibitory currents respectively (Brunig et al., 2002, 
Prenosil et al., 2006). However, GABAAR γ2 subunit appears to endow 
GABAARs with fast deactivation kinetics and reduced desensitisation 
(Benkwitz et al., 2004). This subunit is functionally very important as it is 
essential for mediating the effect of benzodiazepines on GABAARs. Indeed, 
GABAAR γ2 deficient mice are completely unresponsive to the effect of 
benzodiazepines at molecular and behavioural levels (Gunther et al., 1995). 
It is the clinical utility of these drugs which suggests that changes in the 
expression of the γ2 subunit underlies a host of neurological as well as 
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mental disorders (Rudolph and Knoflach, 2011). It remains to be seen what 
role this subunit plays in the PNS. 
 
1.3.10 The GABAAR beta subunits 
 
Although GABAAR β subunits are not a focus of this thesis, these subunits 
are essentially present in majority of GABAAR subtypes and play an 
important role in the function of these receptors. Hence, here, I will give a 
brief overview of their expression and function within the CNS. Three 
different β subunits have been identified within the CNS which including β1-3 
subunits, with β2 subunit being the most widely express of the three 
(Rudolph et al., 2001). The β2 subunit is expressed widely throughout the 
CNS whereas the expression of β1, 3 is more restricted to the cortex, 
cerebellum, hippocampus, hypothalamus and amygdala (Hortnagl et al., 
2013).  
Mutations in β2 and 3 subunits have been shown to result in epilepsy in 
animals suggesting that dysfunction of these subunits participate in the 
pathology of epilepsy (Hirose, 2014). In addition, previous studies have 
shown that β subunits such as β3 subunit are involved in the ion selectivity of 
GABAARs and as such play an important role in the function of the receptor 
as a ligand-gated ion channel (Jensen et al., 2002). The function of individual 
GABAAR β subunits have been relatively less explored in comparison to α 
subunits.  
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1.3.11  Stress-induced plasticity in the GABA-GABAAR system  
 
Since my PhD research focuses on the expression and function of GABAARs 
within the ENS with a view of exploiting their therapeutic potential in age and 
stress-related GI disorders, here I focus on reviewing some of the literature 
on the effects of acute and chronic stress on the GABA-GABAAR system.  
 
Within the CNS, stress leads to alterations in the expression of GABA and 
GABA synthesising enzyme (GAD) throughout the brain (Maguire and Mody, 
2009, Gunn et al., 2011). These stress-induced alterations in the GABAergic 
system are region specific and depend on the severity of stress, i.e. acute or 
chronic stress (Acosta et al., 1993, Bowers et al., 1998). Furthermore, similar 
stress induced alterations in the expression of distinct GABAAR subunits 
within distinct regions of the brain have been reported. Indeed, exposure of 
animals to acute stressors leads to a decrease in the α1 and γ2 subunits and 
an increase in the GABAAR δ subunit within the hippocampus (Maguire and 
Mody, 2007, Zheng et al., 2007). On the other hand, chronic stress has been 
shown to result in an upregulation of GABAAR α5 and β2 subunits and down-
regulation of GABAAR δ subunit within the rat hypothalamic paraventricular 
nucleus (PVN) (Cullinan and Wolfe, 2000, Verkuyl et al., 2004). Importantly, 
a recent study by our group illustrated a repeated restraint stress-induced 
increase in the expression of GABAAR α3 subunit in the dorsal raphe 
nucleus; a region of the CNS implicated in stress-induced mental disorders 
(Corteen et al., 2014). Therefore the impact of stress on the expression of 
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GABAARs within the CNS is subunit specific and depends on the type of 
stress and the region of the brain.  
 
Importantly, the application of stress and the consequent alterations in the 
GABA-GABAAR system underlie a number of brain disorders such as 
anxiety, depression and seizure susceptibility (Maguire, 2014, Shen et al., 
2013). Interestingly, these disorders are often accompanied by GI symptoms 
and disorders such as IBS and IBD (Mayer et al., 2001). In addition, drugs 
targeting GABAAR successfully treat diverse CNS conditions such as anxiety 
and depression and provide secondary relief from co-existing GI disorders 
(Chouinard, 2006). These together raise the question whether GABAAR 
within the ENS are also sensitive to acute and chronic stress and if so, are 
they likely to play a role in the pathophysiology of the stress-induced GI 
disorders which emphasises on the importance of the research carried out in 
this thesis. 
 
1.3.12 GABAAR plasticity in the ageing brain 
 
Most studies investigating the functional plasticity of the GIT in healthy 
ageing have shown that the gut and the ENS are plastic and evolve with the 
age of an individual (Pilotto et al., 2011). Since the function and physiology 
the ENS is regulated through a range of neurotransmitters and 
neurotransmitter receptors, it is important to investigate the expression and 
function of such proteins in ageing. One of these neurotransmitter systems is 
the GABA-GABAAR system. Many studies carried out in humans and 
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primates show changes in the expression of specific GABAAR subunits 
mRNA within specific regions of CNS of aged animals (Hashimoto et al., 
2008, Fillman et al., 2010, Duncan et al., 2010).  
 
Importantly, changes in the expression of distinct GABAAR subunits have 
also been implicated in age related CNS diseases such as Alzheimer’s 
disease (AD). Previous studies have illustrated a reduction in the GABAAR 
α1 subunit and an increase in the GABAAR γ1/3 subunit expression in the 
brain of AD subjects (Mizukami et al., 1998, Iwakiri et al., 2009). Since the 
ENS is also plastic during ageing and evolves with the age of the individual, I 
hypothesis that similar to the CNS, the expression and function of distinct 
GABAARs are dynamic and change in response to healthy ageing. Hence, in 
this thesis I also focused on investigating the plasticity of the expression and 
function of various GABAARs in the aged colon. 
 
1.3.13 The expression and function of GABA-GABAARs within the 
mammalian ENS 
 
Since 1980, a number of studies have reported on the existence of a 
GABAergic system within the ENS and the GIT consisting of GABAergic 
neurons and neuronal fibres (Jessen et al., 1986), GABA synthesising 
enzyme (GAD) (Miki et al., 1983), and GABA reuptake and release 
mechanisms (Jessen et al., 1988). In addition, GABA has been shown to be 
involved in various facets of GI functions such as motility and secretion 
(Bayer et al., 2002, Krantis, 2000). Similar to the brain, the fast effects of 
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GABA within the ENS are mediated through GABAARs (Bertrand and 
Galligan, 1992, Giotti et al., 1983). Furthermore, pan-GABAAR ligands have 
been used to demonstrate the effects of GABAAR modulation on intestinal 
contractility, mainly in guinea pig and rat preparations (Hebeiss and 
Kilbinger, 1999, Roberts et al., 1993, Tonini et al., 1989b, Tonini et al., 1987). 
These data collectively suggest that a functional GABA-GABAAR system 
exists within the ENS which is involved in the control of GI functions such as 
motility. However a caveat to all these studies is the crude investigation of 
the function of GABAARs using agents which activated all GABAARs 
simultaneously regardless of their subunits composition.  
 
As mentioned above, diverse GABAAR subunit assembly combinations 
manifest in functionally (Eyre et al., 2012, Belelli et al., 2009) and 
pharmacologically (Rudolph and Knoflach, 2011) diverse receptor subtypes 
within distinct regions (Hortnagl et al., 2013, Wisden et al., 1992, Fritschy 
and Mohler, 1995) of the CNS, emphasising on the importance of identifying 
which particular GABAAR subunits are expressed on the cellular and 
subcellular domains of which neurons within a particular neural system. 
Despite the recognised importance of GABAARs to neural function and 
clinical medicine of the CNS, relatively less is known about the expression 
and function of distinct GABAARs within the PNS and the ENS in particular. 
Although sparse studies have shown the expression of the GABAAR subunits 
mRNA expression within the rat small intestine (Zeiter et al., 1996, Poulter et 
al., 1999), the expression of particular GABAAR subtypes at the cellular and 
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sub-cellular level of neurochemically-defined cells remains to be fully 
elucidated (Krantis et al., 1995).  
 
This thus elucidates the large gaps in our knowledge of the GABA-GABAAR 
system within the ENS, in comparison to the CNS. Therefore, in this thesis, I 
have provided the first detailed account of cellular, subcellular and region-
specific expression of distinct GABAARs within the ENS of the mouse colon, 
as well as the functional consequences of the activation of specific GABAAR 
subunits in colonic contractility. In addition to this, I have also investigated 
whether, similar to the brain, the GABA-GABAAR system of the ENS is 
dynamic and goes through alterations as a result of ageing and exposure to 
life experiences such as stress.  
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1.4 Aims 
 
The overall aims of my PhD are to determine: 1) which GABAAR subunits are 
expressed within particular cell-types of the ENS of the mouse colon; 2) how 
the pharmacological activation of particular GABAAR subtypes influences 
colonic motility and; 3) how specific life experiences, namely stress and 
ageing, alter colonic GABAAR subunit expression and function. These aims 
will be achieved by pursuing the following objectives: 
 
1.5 Objectives 
 
1.5.1 Objective 1; chapter 2 
 
Determine which particular GABAAR subunits are expressed within the 
mouse colon at the mRNA level and localise the expression patterns of the 
GABAAR α1-5, γ2 subunits at the protein level within the cellular networks of 
the ENS, using RT-PCR together with immunohistochemistry and confocal 
microscopy respectively. 
 
1.5.2 Objective 2; chapter 3 
 
Determine the functional consequences of colonic GABAAR subtype 
activation on colonic contractility in-vitro using isometric tension recordings of 
the mouse colon in an organ bath and GABAAR subunit-preferring ligands. 
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1.5.3  Objective 3; chapter 4 
 
Determine the effects of stress and age on GABAAR subunit expression and 
function in the colon, using animal models of stress, mice of various ages, 
quantitative RT-PCR and isometric tension recordings of the mouse colon in 
an organ bath in the absence or presence of GABAAR-subtype preferring 
ligands.  
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2 Chapter 2: Expression of GABAAR subunits at the 
mRNA and protein level within the ENS of the 
mouse colon 
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2.1 Summary and Importance 
 
Background: The enteric nervous system (ENS) provides the intrinsic neural 
control of the gastrointestinal tract (GIT) and regulates virtually all GI 
functions. Altered neuronal activity within the ENS underlies various GI 
disorders. Thus, elucidating the expression and function of the 
neurotransmitter systems which determine neuronal excitability within the 
ENS, such as the GABA-GABAA receptor (GABAAR) system, could reveal 
novel therapeutic targets for such GI disorders. Molecularly and functionally 
diverse GABAARs modulate rapid GABAergic-mediated regulation of 
neuronal excitability throughout the nervous system. However, the cellular 
and sub-cellular GABAAR subunit expression patterns within 
neurochemically-defined cellular enteric circuits remains to be determined.  
 
Methods: I used RT-PCR performed on homogenates of mouse colon in 
order to investigate the expression of GABAAR α1-6, β1-3, γ1-3, δ and ε 
subunits at the mRNA levels within the mouse colon. I also used 
immunohistochemistry and confocal microscopy in order to map the cellular, 
sub-cellular and region-specific expression patterns of the GABAAR α1-5 and 
γ2 subunit, at the protein levels, in whole-mount preparations of the mouse 
colon. 
 
Results: The RT-PCR studies revealed mRNA expression for 14 out of the 
16 GABAAR subunits investigated. Immunohistochemical analyses revealed 
that enteric neurons and ICCs receive extensive GABAergic innervation 
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through VGAT positive inhibitory terminals. In addition, immunoreactivity for 
the GABAAR gamma (γ) 2 and alphas (α) 1, 2, 3 subunits was located on 
somato-dendritic surfaces of neurochemically distinct myenteric plexus 
neurons, whilst being on axonal compartments of submucosal plexus 
neurons. In contrast, immunoreactivity for the GABAAR α4-5 subunits was 
only detected in myenteric plexus neurons. Furthermore, GABAAR α-γ2 
subunit immunoreactivity was located on non-neuronal ICCs.  
 
Importance: This study provides the first demonstration of the variety of 
GABAAR subtypes expressed within the cellular networks of the mouse 
colon. These diverse expression patterns suggest a series of complex roles 
for the GABAAR system in regulating the excitability of ENS neurons and 
thus GI function. 
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2.2 Methods 
 
All procedures involving experimental animals were approved by the Ethics 
Committee of the University of Portsmouth and were performed by a 
personal licence holder, in accordance with the Animals (Scientific 
Procedures) Act, 1986 (UK) and associated procedures. 
 
2.2.1 Reverse transcription-polymerase chain reaction (RT-PCR) 
 
RT-PCR was used to detect which GABAAR subunits are expressed in the 
mouse colon at the mRNA level with matched brain tissue used as positive 
control. Adult male C57/BL6J mice (Charles River) (N=3) were killed by 
cervical dislocation and the segments of the colon and whole brain removed 
and snap frozen in liquid nitrogen. The frozen tissue was thawed and cut into 
small pieces which were then homogenised in lysis buffer from which RNA 
was extracted using a RNeasyR mini kit (Qiagen) according to the 
manufacturer’s protocol. mRNA was reverse transcribed into complementary 
DNA (cDNA) using SuperScript™ First-Strand Synthesis System for RT-PCR 
kit and oligo (dt) primers (Invitrogen). Equal amounts of cDNA (1 µl) were 
then used for subsequent polymerase chain reaction (PCR) using 12.5 µl of 
GoTaqR green mastermix (Promega), 9.5 µl of PCR grade water and 1 µl of 
each of the forward and reverse primers, in a 25 µl reaction. Exon-exon 
spanning GABAAR subunit specific PCR primers used in the study (Table 1) 
have previously been published (Tan S et al., 2011, Glassmeier G et al., 
1998, Gustincich S et al., 1999). The reactions were heated to 94 Co for 5 
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minutes in order to produce single-stranded DNA. This was followed by 35 
cycles of 94 Co for 30 seconds, 55 Co for 30 seconds and 72 Co for 30 
seconds. Finally the elongation of any remaining DNA strand was ensured by 
heating the reactions to 72 Co for 5 minutes. 20 µl of the RT-PCR transcript 
products for the GABAAR subunits and the positive control β-actin from brain 
and colon tissue were run on a 2% (w/v) agarose gel at 110 mV. The 
agarose gel was made by dissolving 2 grams of agarose in 100 ml of TAE 
buffer and adding 2 µl of SYBR® Safe DNA Gel Stain (Invitrogen). The TAE 
buffer was prepared as 200 ml of 50X stock solution by dissolving 60.5 
grams of Tris base in 100 ml of deionised water followed by addition of 14.27 
ml acetic acid, 25 ml of 0.5 M Ethylenediaminetetraacetic acid (EDTA) and 
the PH was adjusted to 8.2. The DNA was visualised under ultraviolet light 
(280 nm) using a SYBR green-based DNA stain and photos were acquired 
using Gel Doc EZ Imager (Biorad). 
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Table 1: Details of RT-PCR primer sequences used in this chapter 
 
Gene 
 
Primer sequence 
RT-PCR 
Product 
length (bp) 
Reference 
 
 
GABAAR 
α1 
 
CCA AGT CTC CTT CTG GCT CAA CA 
GGG AGG GAA TTT CTG GCA CTG AT 
 
 
111 
 
(Tan S et al., 2011). 
GABAAR 
α2 
TTA CAG TCC AAG CCG AAT GTC CC 
ACT TCT GAG GTT GTG TAA GCG TAG C 
 
 
103 
 
(Tan S et al., 2011). 
GABAAR 
α3 
CAA GAA CCT GGG GAC TTT GTG AA 
AGC CGA TCC AAG ATT CTA GTG AA 
 
 
119 
 
(Tan S et al., 2011). 
GABAAR 
α4 
GAG ACT GGT GGA TTT TCC TAT GG 
GGT CCA GGT GTA GAT CAT CTC ACT 
 
 
94 
 
(Tan S et al., 2011). 
GABAAR 
α5 
CCC TCC TTG TCT TCT GTA TTT CC 
TGA TGT TGT CAT TGG TCT CGT CT 
 
 
99 
 
(Tan S et al., 2011). 
GABAAR 
α6 
TAC AAA GGA AGA TGG GCT ATT 
ACG ATG GGC AAA GTC AGA GAG 
 
 
439 
 
(Glassmeier G et al., 
1998). 
GABAAR 
β1 
GGG GCT TCT CTC TTT TCC CGT GA 
GGT GTC TGG TAC CCA GAG TTG GT 
 
 
334 
 
(Gustincich S et al., 
1999). 
GABAAR 
β2 
CAA CTC TGG GTG CCT GAC ACC TA 
TCC TAA TGC AAC CCG TGC AGC AG 
 
 
495 
 
(Gustincich S et al., 
1999). 
GABAAR 
β3 
GGT TTG CTG CGC TCA GAG CGT AA 
TAC AGC ACT GTC CCA TCA GGG T 
 
 
390 
 
(Gustincich S et al., 
1999). 
GABAAR 
γ1 
CAG TTT GCA TTT GTA GGG TTA CG 
AGA CAC CCA GGA AAG AAC CAC TG 
 
 
165 
 
 
(Gustincich S et al., 
1999). 
GABAAR 
γ2 
GGT GGA GTA TGG CAC CCT GCA TT 
AGG CGG TAG GGA AGA AGA TCC GA 
 
 
322 
 
(Gustincich S et al., 
1999). 
GABAAR 
γ3 
TGC TCG GTC CAG GAG GGT AGA 
CTG ATC AGC TGC CTC AAC TGA ATT TTT 
 
 
592 
 
(Gustincich S et al., 
1999). 
GABAAR 
δ 
GAC TAC GTG GGC TCC AAC CTG GA 
ACT GTG GAG GTG ATG CGG ATG CT 
 
 
398 
 
(Gustincich S et al., 
1999). 
GABAAR 
ε 
CAA TGC GAA GAA CAC TTG GAA GC 
CTG GCA GCA GCA GCT TCT ATC TT 
 
 
225 
 
(Gustincich S et al., 
1999). 
β-actin 
AGG CCA ACC GTG AAA AGA TG 
ACC AGA GGC ATA CAG GGA CAA 
 
 
101 
 
(Gustincich S et al., 
1999). 
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2.2.2 Tissue preparation for immunohistochemistry 
 
Adult male C57/BL6J (Charles River) mice were anaesthetised with 
isoflurane and pentobarbitone (1.25 mg/kg of bodyweight; i.p.). The animals 
were transcardially perfused using a fixative containing 1% w/v 
paraformaldehyde and 15% v/v saturated picric acid in 0.1M phosphate 
buffer (pH 7.4) according to previously described protocols (Corteen et al., 
2011). After perfusion, the brains and colons were removed and post-fixed in 
the same fixative over night at 4oC. The next day, tissue was washed in 0.1M 
phosphate buffer until it was clear of the fixative. Whole-mount preparations 
of the longitudinal muscle-myenteric plexus and circular muscle-submucosal 
plexus were obtained using a dissecting microscope and fine forceps, which 
were then stored in 0.1M phosphate buffer containing 0.05% w/v sodium 
azide.  
 
2.2.3 Immunohistochemistry 
 
The native GABAAR subunit immunoreactivity patterns within the ENS of the 
mouse colon were confirmed in at least 4 animals. Non-specific binding of 
secondary antibodies was blocked by incubating the tissue with 20% v/v 
normal horse serum for 2 hours at room temperature. The tissue was 
incubated with cocktails of primary antibodies (Table 2), diluted in Tris buffer 
saline containing 0.3% w/v Triton X-100 (TBS-Tx) and 20% v/v normal horse 
serum, overnight at 4°C. After washing with TBS-Tx, the tissue was 
incubated in a mixture of appropriate secondary antibodies conjugated with 
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either Alexa Fluor 488 (Invitrogen, Eugene, OR), indocarbocyanine (Cy3; 
Jackson ImmunoResearch), and indodicarbocyanine (Cy5; Jackson 
ImmunoResearch) for 2 hours at room temperature. The tissue was washed 
in TBS-Tx and mounted on glass slides in Mowiol mounting medium 
(Polysciences) and then cover slipped.  
 
2.2.4 Antibody specificity 
 
Although the specificity of all the antisera against the GABAAR subunits used 
in this study have been reported upon extensively in other studies 
concerning the CNS (see Table 2), the specificity of the signal obtained in 
the ENS in this study was confirmed using perfusion-fixed, matched brain-
colon tissue from GABAAR subunit-specific gene deleted mice. Method 
specificity was also tested by omitting the primary antibodies in the 
incubation sequence. To confirm the absence of cross reactivity between 
IgGs in double and triple immunolabelling experiments, some sections were 
processed through the same immunohistochemical sequence, except that 
only an individual primary antibody was applied with the full complement of 
secondary antibodies.  
 
2.2.5 Image acquisition 
 
Sections were examined with a confocal laser-scanning microscope 
(LSM710; Zeiss, Oberkochen, Germany) using either a Plan Apochromatic 
40x DIC oil objective (NA1.3) (pixel size 0.29 μm), a Plan Apochromatic 63x 
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DIC oil objective (NA1.4) (pixel size 0.13 μm) or a Plan Apochromatic 100x 
DIC oil objective (NA1.46) (pixel size 0.08 μm). Z-stacks were used for 
routine evaluation of the labelling. All images presented represent a single 
optical section. These images were acquired using sequential acquisition of 
the different channels to avoid cross-talk between fluorophores, with the 
pinholes adjusted to one airy unit. Images were processed with the software 
Zen2008 Light Edition (Zeiss, Oberkochen, Germany) and exported into 
Adobe Photoshop. Only brightness and contrast were adjusted for the whole 
frame, and no part of a frame was enhanced or modified in any way. 
  
Table 2: Details of primary antibodies used in this chapter 
 
Primary 
antibody 
Host Dilution Source Specificity/Reference 
ChAT Goat 1:100 Millipore (AB144P) 
(Heinze et al., 2007). 
(Härtig et al., 2007). 
c-Kit Rat 1:250 
eBioscience (14-
1172) 
(Sato et al., 1996). 
(Torihashi et al., 
1995). 
CRH 
Guinea- 
pig 
1:1000 
Peninsula Labs (T-
5007) 
(Stanic et al., 2010). 
(Armstrong et al., 
2009). 
 
GABAAR α1 Rabbit 1:5000 
Synaptic systems 
(224203) 
 
(Wisłowska-Stanek et 
al., 2013). No signal in 
knockout mouse, this 
study. 
GABAAR α2 Rabbit 1:1000 
Werner Sieghart, 
antigen sequence 
α2L amino acids 
322-357. R # 28/16 
Bleed # 01/10/2002 
(Pirker et al., 2000). 
No signal in knockout 
mouse, this study. 
GABAAR α3 
Guinea- 
pig 
1:3000 
Jean-Marc Fritschy, 
Antigen sequence 
α3N amino acids 1–
15. 
(Fritschy and Mohler, 
1995). No signal in 
knockout mouse, this 
study. 
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GABAAR α4 Rabbit 1:500 
Werner Sieghart, 
antigen sequence α4 
amino acids 379-
421. R # 25/1 Bleed 
# 19/03/2001. 
(Pirker et al., 2000). 
No signal in knockout 
mouse, this study. 
GABAAR α5 Rabbit 1:1000 
Werner Sieghart, 
antigen sequence α5 
amino acids 337-
388. R # 34/30 
Bleed # 17/12/2007 
(Pirker et al., 2000). 
No signal in knockout 
mouse, this study. 
GABAAR γ2 Rabbit 1:3000 
Synaptic system 
(224003) 
 
(Fish et al., 2013). No 
signal in knockout 
mice, This study. 
Kv2.1 Mouse 1:1000 
Neuromab 
(75-014) 
Western blot; band at 
105-125 kDa. No 
signal in knockout 
mice. (Hermanstyne 
et al., 2010). 
Map-2 Chicken 1:500 
Avēs Labs 
(MAP0607) 
Expression patterns 
as shown in previous 
studies 
Neuroligin2 Rabbit 1:1000 
Synaptic Systems 
(129203) 
(Chih et al., 2005). 
(De Jaco et al., 2006). 
NOS Sheep 1:1000 Millipore (AB1529) 
(Liu et al., 2008). 
(Cauli et al., 2004). 
Serotonin 
transporter 
Guinea- 
pig 
1:250 Chemicon (AB1772) 
(Häring et al., 2007). 
(Collin et al., 2000). 
Somatostatin Rat 1:500 Millipore (MAB354) 
(Tanaka et al., 2011). 
(Dimitrov and Usdin, 
2010). 
VGAT 
Guinea- 
pig 
1:1000 
Synaptic Systems 
(131004) 
(Schock et al., 2012). 
(Geis et al., 2010). 
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2.3 Results 
 
2.3.1 GABAAR subunit mRNA expression in the mouse colon  
 
Currently, up to 19 different GABAAR subunits are known to be expressed 
within the CNS (Sieghart, 2006). Previous studies on GABAAR subunit 
expression in the PNS did not specifically report expression patterns within 
the mouse colon (Akinci and Schofield, 1999, Poulter et al., 1999). Hence, to 
begin the expression studies, I first investigated the mRNA expression of 16 
GABAAR subunits including; α1-6, β1-3, γ1-3, δ and ε subunits. RT-PCR 
performed on RNA extracted from full thickness mouse colon revealed 
mRNA expression for 14 out of the 16 GABAARs investigated (Fig. 1) (N= 3 
animals). No corresponding signal of the similar size was detect for the 
GABAAR α6 and ε subunits in the colon with mouse whole brain 
homogenates and β-actin in a colon sample serving as positive controls (Fig. 
1). A negative control, where nuclease-free water was added to the reaction 
instead of cDNA, was also performed in order to insure no contamination of 
reagents was present.  
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Figure 1 
 
GABAAR subunit mRNA expression in the mouse colon  
Representative gel electrophoresis images of cDNA amplicons for various 
GABAAR subunits using RT-PCR and homogenates from whole mouse brain 
and colon. Corresponding amplicons of the similar size to those obtained 
from brain samples were consistently detected for the GABAAR α1-5, β1-3, 
γ1-3 and δ subunits but not the α6 and ε subunits in colon samples (N = 3 
animals). A negative control was performed with every experiment. 
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2.3.2 Neurochemical and cellular diversity of the mouse ENS  
 
The current study was aimed at characterising the cellular and sub-cellular 
expression patterns of specific GABAAR subunits on neurochemically diverse 
enteric neurons of the mouse colon. However, the neurochemical diversity of 
enteric neurons have mainly been characterised in species such as Guinea-
pig and monkey (Noorian et al., 2011, Furness, 2000, Costa et al., 1996). 
Although these can be similar to that of the ENS of the mouse colon, it was 
sagacious to first, in our hands, look at the neurochemical diversity of the 
ENS of the mouse colon. In order to view the myenteric and submucosal 
plexus neurons and their processes fully, whole-mount preparations of the 
mouse colon were used for all the immunohistochemical analysis in this 
study. Most of the neurochemical markers used in this study seemed to be 
expressed in distinct populations of the submucosal and myenteric plexus 
neurons (Fig. 2A-F). The immunohistochemical studies also revealed the 
presence of three different populations of interstitial cells of Cajal (ICCs) 
which are involved in generation of slow waves of electricity that provide 
pace-maker activity in terms of intestinal contractility (Garcia-Lopez et al., 
2009) (Fig. 2G-I).   
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Figure 2 
 
Neurochemical and cellular diversity of the enteric nervous system of the 
mouse colon 
(A) shows immunoreactivity for microtubule associated protein 2 (Map-2), a 
pan neuronal marker, within a myenteric ganglion. Note that Map-2 
delineated the somato-dendritic domains of all enteric neurons. (B-C) show 
immunoreactivity for nitric oxide synthase (NOS) within the myenteric and 
submucosal plexus respectively. (D-F) Immunoreactivity for choline 
acetyltransferase (ChAT), somatostatin and calcitonin gene-related peptide 
(CGRP) within a myenteric ganglion respecitvely. (G-I) show the 
submucosal, intramuscular and myenteric ICCs within the mouse ENS. Scale 
bars 20 µm. 
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2.3.3 Immunolocalisation of GABAergic synaptic marker proteins in the ENS 
of the mouse colon 
 
Immunoreactivity for putative pre- and postsynaptic GABAergic marker 
proteins was used to determine the distribution of GABAergic innervation 
across neuronal and non-neuronal cell-types in whole mount preparations of 
the mouse colon. Microtubule associated protein 2 (MAP2), a pan-neuronal 
marker protein was used to visualise the somato-dendritic domains of 
neurons located within the myenteric and submucosal plexuses. 
Immunoreactivity for the vesicular GABA transporter (VGAT), a protein which 
within the CNS is selectively expressed in GABAergic axon terminals was 
used to locate presumptive GABAergic input to different sub-cellular 
domains. In addition, immunoreactivity for neuroligin2 (NL2), a protein which 
in the CNS is selectively localised to GABAergic and glycinergic inhibitory 
synapses (Varoqueaux et al., 2004) was used to locate putative inhibitory 
postsynaptic domains with the caveat that ultrastructural studies are required 
to unequivocally demonstrate that, as is the case in the CNS, VGAT and NL2 
are located at inhibitory pre- and postsynaptic junctions. Immunoreactivity for 
the tyrosine-protein kinase Kit (c-Kit) was used to detect the non-neuronal 
interstitial cells of Cajal (ICCs) (Maeda et al., 1992) which provide pace-
maker activity in terms of colonic contractility (Garcia-Lopez et al., 2009). 
 
Immunoreactivity for VGAT was widely distributed amongst MAP2 
immunoreactive somata and dendrites as well as c-Kit immunoreactive 
profiles located within myenteric and submucosal plexuses (Fig. 3A). 
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Immunoreactivity for NL2 presented as individual clusters which were 
concentrated on somatic and dendritic compartments of myenteric and 
submucosal plexus neurons and were closely apposed to VGAT 
immunoreactive puncta (Fig. 3B). VGAT immunoreactive clusters were also 
evident within colonic muscle layers and were distinctly associated with nitric 
oxide synthase (NOS) immunoreactive axon terminals which appeared to 
innervate c-Kit immunoreactive ICCs (Fig. 3C). Thus, the putative sites of 
GABA release and predictive location of GABAergic receptors within the 
ENS of the mouse colon includes the neurons of the myenteric and 
submucosal plexuses as well as the non-neuronal ICCs.  
 
Guided by the patterns of GABAergic innervation and the GABAAR subunit 
mRNA expression patterns, I then used immunohistochemistry and confocal 
microscopy to localise the expression of the GABAAR γ2 and α 1-5 subunits 
within neurochemically defined cell-types of the ENS of the mouse colon.  
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Figure 3 
 
Immunolocalisation of inhibitory synaptic marker proteins in the ENS of the mouse 
colon 
(Ai) immunoreactivity for MAP2 (blue) demonstrates the location of neurons within 
ganglia of the myenteric plexus. Immunoreactivity for the GABAergic presynaptic 
marker protein vesicular GABA transporter (VGAT) (red) shows the widespread 
GABAergic innervation of neurons throughout the ENS. (Aii) shows 
immunoreactivity for the interstitial cells of Cajal (ICCs) marker protein c-Kit (green) 
within the same field of view as (Ai). (Aiii) is an overlay of (Ai and Aii) and 
demonstrates the association of VGAT immunoreactivity with neuronal and non-
neuronal cells of the ENS within the mouse colon. (Bi) shows immunoreactivity for 
the voltage-gated potassium channel 2.1 (Kv2.1) (blue) which delineates somato-
dendritic plasma membranes as well as immunoreactivity for neuroligin2 (NL2), a 
protein located exclusively in inhibitory synapses (green). (Bii) shows 
immunoreactivity for VGAT within the same field of view as (Bi). (Biii) is an overlay 
of (Bi and Bii) demonstrating the close association between presynaptic VGAT and 
postsynaptic NL2 immunoreactive clusters (arrowheads) and the likely locations of 
GABAergic synapses. (Ci) shows nitric oxide synthase (NOS) immunoreactive axon 
terminals (blue) which are also immunopositive for VGAT (red). (Cii) VGAT 
immunoreactive puncta are apposed to cellular profiles immunoreactive for c-Kit 
which are likely to be ICCs. (Ciii) is an overlay of (Ci and Cii) showing the close 
association between GABAergic axon terminals and the profiles of ICCs. The insert 
is a magnified view of the boxed area. Scale bars: (A) 30 µm; (B) 5 µm; (C) 20 µm; 
insert, 2 µm. 
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2.3.4 Immunolocalisation of the GABAAR γ2 subunit in the mouse colon  
 
Immunoreactivity for the GABAAR γ2 subunit was widely distributed across 
both neuronal and non-neuronal cell-types of myenteric (Fig. 4A), and 
submucosal (Fig. 4B) plexuses as well as the intramuscular layer (Fig. 4C). 
Within the myenteric plexus, immunoreactivity for the GABAAR γ2 subunit 
presented as distinct clusters almost exclusively located on the somatic and 
dendritic plasma membranes of nitric oxide synthase (NOS)-, serotonin 
(5HT)-, corticotrophin releasing hormone (CRH)-, somatostatin (SOM) and 
choline acetyl transferase (Chat)-immunoreactive neurons (Fig. 4A). In 
contrast to the membrane-bound location of GABAAR γ2 subunit 
immunoreactivity in myenteric neurons, the location of the signal in NOS-
immunopositive submucosal plexus neurons was predominantly cytoplasmic 
(Fig. 4B). This might be suggestive of a presynaptic locus of expression. 
Thus, the targeting of γ2 subunit–containing GABAARs (γ2-GABAARs) to 
specific sub-cellular domains of ENS neurons is cell-type specific.  
 
Apart from expression in neurons, GABAAR γ2 subunit immunoreactivity was 
also evident on putative ICCs immunopositive for c-Kit located in proximity to 
the submucosal plexus (Fig. 4B) and muscle layers (Fig. 4C). ICCs are 
hypothesised to be the cellular links between ENS neurons and intestinal 
smooth muscle (Sanders and Ward, 2006, Huizinga et al., 2009) and are 
thus predominantly involved in GI contractility. Intestinal smooth muscle cells 
possess spontaneous rhythmic oscillations in their membrane potential, or 
slow waves which are the source of spontaneous contractions (Iino and 
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Horiguchi, 2006). Myenteric and submucosal ICCs are reportedly involved in 
the generation and propagation of these slow waves (Sanders et al., 2004, 
Hirst and Ward, 2003). In addition, the intramuscular ICCs which are 
distributed amongst smooth muscle cells act as mediators of 
neurotransmission from the ENS to intestinal muscle cells (Ward et al., 
2004). Importantly, it has been demonstrated that GABA and the GABAAR 
agonist muscimol can modulate the amplitude of these spontaneous 
contractions in the rat colon (Bayer et al., 2002). The location of GABAAR γ2 
subunit immunoreactivity at the interface between cell-types implicated in 
regulating colon contractility suggests a possible involvement of γ2 subunit 
containing GABAARs (γ2-GABAARs) in such functions. 
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Figure 4 
 
Immunolocalisation of the GABAAR γ2 subunit in the ENS of the mouse 
colon  
(A1) shows immunoreactivity for the γ2 subunit is widely distributed on 
neurons of the myenteric plexus visualised by NOS immunoreactivity (insert). 
Immunoreactivity for the γ2 subunit was located on somato-dendritic 
surfaces of (A2) serotonergic-immunopositive (5HT), (A3) corticotrophin 
releasing hormone (CRH)-immunopositive, (A4) somatostatin-
immunopositive (SOM)- and (A5) choline acetyl transferase (Chat)-
immunopositive myenteric plexus neurons. (B) in contrast to the surface 
location of γ2 subunit immunoreactivity on myenteric plexus neurons (A), the 
signal in submucosal plexus neurons (asterisks) identified by NOS 
immunoreactivity, was located predominantly within the cytoplasm as well as 
in c-Kit immunopositive profiles (arrowheads). The inserts are magnified 
views of the cell identified by the arrow. (C) within the muscle layer, γ2 
subunit immunoreactivity was closely associated with (Ci) NOS-
immunopositive axon terminals and (Cii) c-Kit immunopositive profiles 
(asterisks). Scale bars: (A1) 20 µm; (A2-5) 10 µm; (B, C) 20 µm. 
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2.3.5 Immunolocalisation of the GABAAR α1 subunit in the mouse colon 
 
The specificity of the immunoreactive pattern obtained by the antibody 
against the GABAAR α1 subunit was confirmed in tissue from the brain and 
colon of WT (α1+/+) and α1 subunit-specific gene-deleted mice (α1-/-) (Sur et 
al., 2001) (Fig. 5). Immunoreactivity for the GABAAR α1 subunit was located 
on neurons of both the myenteric and submucosal plexuses (Fig. 6A, B). 
Clustered immunoreactivity for the GABAAR α1 subunit was evident on 
MAP2 immunopositive myenteric plexus neurons closely mirroring the 
expression pattern of the γ2 subunit signal (Fig. 6A1). Immunoreactivity for 
the GABAAR α1 subunit presented as distinct clusters associated with VGAT 
immunoreactive clusters in close proximity to somato-dendritic plasma 
membranes, which were delineated by the voltage-gated potassium channel 
2.1 (Kv2.1), thus implying expression at inhibitory synaptic junctions (Fig. 
6A2). In addition, this clustered somato-dendritic pattern of GABAAR α1 
subunit immunoreactivity was also evident on NOS, 5HT, CRH and Chat-
immunopositive myenteric neurons (Fig. 6A3-6). Furthermore, GABAAR α1 
subunit immunoreactivity was clustered on Chat-immunopositive varicosities 
in the muscle layer (Fig. 6A7). Immunoreactivity for the GABAAR α1 subunit 
within submucosal plexus neurons also closely mirrored the pattern of the γ2 
subunit, appearing wholly cytoplasmic in NOS-immunoreactive neurons, with 
distinct α1 subunit immunoreactive clusters evident on NOS-immunoreactive 
axonal varicosities (Fig. 6B). This immunolocalisation pattern suggests that 
α1-GABAARs are located postsynaptically on myenteric plexus neurons and 
presynaptically on submucosal plexus neurons. 
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Figure 5 
 
Confirmation of the specificity of the GABAAR α1 subunit immunoreactivity 
using tissue from the brain and colon of wild type (α1+/+) and GABAAR α1 
subunit-specific gene-deleted mice (α1-/-) 
(A) shows characteristic immunoreactivity pattern for the α1 subunit in the 
hippocampus and neocortex of WT mouse brain. (B) no specific α1 subunit 
signal was detectable in brain tissue from α1-/- mice. (Ci) a whole-mount 
preparation of the ENS of a WT mouse colon demonstrating myenteric 
plexus neurons identified by NOS immunoreactivity. (Cii) in the 
corresponding field of view, α1 subunit immunoreactivity is strongly 
associated with myenteric plexus neurons. (Di) a whole-mount preparation of 
the ENS of a α1-/- mouse colon demonstrating myenteric plexus neurons 
identified by NOS immunoreactivity. (Dii) in the corresponding field of view, 
no specific α1 subunit signal was detectable. Scale bars: (A, B) 200 µm; (C, 
D) 40 µm. 
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Figure 6 
 
Immunolocalisation of the GABAAR α1 subunit in the ENS of the mouse 
colon  
(A1) shows clustered α1 subunit immunoreactivity (red) widely distributed on 
the somato-dendritic surfaces of MAP2-immunopositive myenteric plexus 
neurons (blue). (A2i) shows that α1 subunit immunoreactivity (red) on 
plasma-membrane surfaces, identified by Kv2.1 immunoreactivity (blue) is 
closely apposed to (A2ii, iii) VGAT immunoreactive puncta (green) and thus 
likely GABAergic synaptic junctions. Immunoreactivity for the α1 subunit was 
located on somato-dendritic surfaces of (A3) NOS-immunopositive, (A4) 
Chat-immunopositive, (A5) 5HT-immunopositive and (A6) CRH-
immunopositive myenteric plexus neurons as well as (A7) Chat-
immunopositive axon terminals in the muscle layer. (B) shows that α1 
subunit immunoreactivity within neurons of the submucosal plexus was 
located on cytoplasmic and axonal compartments. (Bii) is a magnified view of 
the boxed area in (Bi). Scale bars: (A) 10 µm; (A7 insert) 2 µm; (B) 10 µm. 
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2.3.6 Immunolocalisation of the GABAARs α2, 3 subunits in the mouse 
colon 
 
The specificity of the immunoreactive patterns obtained by the antibodies 
against the GABAAR α2 and α3 subunits were confirmed in tissue from the 
brain and colon of WT and subunit-specific gene-deleted mice (α2-/-, α3-/-) 
(Dixon et al., 2008, Yee et al., 2005) (Figures. 7, 8 respectively). 
Immunoreactivity for the GABAAR α2 subunit was more restricted compared 
to other subunits investigated and was localised preferentially on MAP2-
immunopositive neurons of the myenteric plexus (Fig. 9A). In addition, within 
this region, GABAAR α2 subunit immunoreactive clusters also decorated c-
Kit immunopositive profiles, the putative ICCs (Fig. 9A). There was a 
noticeable gradient in the comparative levels of GABAAR α2 subunit 
immunoreactivity in NOS-immunopositive neurons of the myenteric and 
submucosal plexuses with the latter exhibiting strikingly higher levels of 
signal, which, in a similar manner to other GABAAR subunits, was located 
cytoplasmically (Fig. 9B, C). Finally, somatostatin immunoreactive 
varicosities were closely apposed to GABAAR α2 subunit immunoreactive 
clusters within the myenteric plexus (Fig. 9D) suggesting that GABA released 
from somatostatin-expressing neurons may signal via α2-GABAARs. Indeed, 
somatostatin is a neurochemical signature of GABAergic interneurons within 
the ENS (Furness, 2006).  
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Immunoreactivity for the GABAAR α3 subunit was restricted to the somatic 
and dendritic domains of somatostatin-immunopositive neurons (Fig. 9E) as 
well as neurons contacted by Chat-immunopositive varicosities (Fig. 9F) 
within the myenteric plexus. Furthermore GABAAR α3 subunit 
immunoreactivity clusters were evident within the muscle layer and distinctly 
associated with NOS-immunopositive varicosities and c-Kit Immunopositive 
ICCs (Fig. 9G). 
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Figure 7 
 
Confirmation of the specificity of the GABAAR α2 subunit immunoreactivity 
using tissue from the brain and colon of wild type (α2+/+) and GABAAR α2 
subunit-specific gene-deleted mice (α2-/-) 
(A) shows characteristic immunoreactivity pattern for the α2 subunit in the 
hippocampus and neocortex of WT mouse brain. (B) no specific α2 subunit 
signal was detectable in brain tissue from α2-/- mice. (Ci) shows a whole-
mount preparation of the ENS of a WT mouse colon demonstrating 
myenteric plexus neurons identified by NOS immunoreactivity. (Cii) in the 
corresponding field of view, α2 subunit immunoreactivity is strongly 
associated with myenteric plexus neurons. (Di) a whole-mount preparation of 
the ENS of an α2-/- mouse colon demonstrating myenteric plexus neurons 
identified by NOS immunoreactivity. (Dii) in the corresponding field of view, 
no specific α2 subunit signal was detectable. Scale bars: (A, B) 200 µm; (C, 
D) 40 µm. 
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Figure 8 
 
Confirmation of the specificity of the GABAAR α3 subunit immunoreactivity 
using tissue from the brain and colon of wild type (α3+/+) and GABAAR α3 
subunit-specific gene-deleted mice (α3-/-)  
(Ai) in brain tissue from a WT mouse, parvalbumin (PV) immunoreactivity 
was used to delineate the reticular nucleus of the thalamus (nRT), a brain 
region enriched in α3 subunit expression. (Aii) in the corresponding field of 
view, strong specific α3 subunit immunoreactivity is evident in the nRT as 
well as in another α3 subunit-rich brain region, the amygdala complex. (Bi) 
shows PV immunoreactivity in brain tissue from an α3-/- mouse. (Bii) in the 
corresponding field of view, no specific α3 subunit immunoreactivity was 
detectable. (Ci) shows a whole-mount preparation of the ENS of a WT 
mouse colon demonstrating myenteric plexus neurons identified by NOS 
immunoreactivity. (Cii) in the corresponding field of view, α3 subunit 
immunoreactivity is strongly associated with myenteric plexus neurons. (Di) a 
whole-mount preparation of the ENS of an α3-/- mouse colon demonstrating 
myenteric plexus neurons identified by NOS immunoreactivity. (Dii) in the 
corresponding field of view, no specific α3 subunit signal was detectable. 
Scale bars: (A, B) 500 µm; (C, D) 40 µm. 
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Figure 9 
 
Immunolocalisation of the GABAAR α2 and 3 subunits in the ENS of the 
mouse colon  
(A) shows the association of α2 subunit immunoreactivity with neuronal and 
non-neuronal cellular profiles in ENS of the mouse colon. (Ai) is an overlay of 
immunoreactivity patterns for MAP2 (blue) a marker of neurons, c-Kit (green) 
a marker of ICCs and the α2 subunit (red). (Aii) is a magnified view of the 
boxed area in (Ai) showing the significant association between α2 subunit 
immunoreactive clusters with MAP2-immunopositive somata and dendrites. 
(Aiii) in the corresponding field of view numerous α2 subunit immunoreactive 
clusters are located on c-Kit immunopositive profiles (arrowheads). (B) 
shows α2 subunit immunoreactivity on the somato-dendritic surfaces of 
NOS-immunopositive myenteric plexus neurons. (C) shows the comparative 
cytoplasmic immunoreactivity pattern for the α2 subunit in NOS-
immunopositive submucosal plexus neurons. (D) shows α2 subunit 
immunoreactivity clusters closely apposed to SOM-immunopositive puncta 
within the myenteric plexus. The insert is a magnified view of the area 
highlighted by the asterisk. (E) shows α3 subunit immunoreactive clusters on 
the cell body of a SOM-immunopositive myenteric plexus neuron. (F) shows 
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α3 subunit immunoreactive clusters closely associated with Chat-
immunopositive varicosities. (Gi) shows α3 subunit immunoreactive clusters 
decorating NOS-immunopositive axon terminals in the muscle layer. (Gii) in 
the corresponding field of view, α3 subunit immunoreactive clusters are 
located in close proximity to c-Kit-immunopositive profiles. The inserts on the 
left of (Gi and Gii) are magnified views of the boxed area. The insert on the 
right of (Gii) is a magnified merged image of all three channels 
demonstrating the juxtaposition of α3 subunit immunoreactive clusters 
between NOS-immunopositive axon terminals and c-Kit immunopositive 
profiles which are likely to be ICCs. Scale bars: (Ai) 20 µm; (Aii, iii) 10 µm; 
(B-D) 10 µm; (E, F) 5 µm; (G) 50 µm. 
 
 
2.3.7 Expression of the GABAAR α4 subunit in the mouse colon 
  
The specificity of the immunoreactive pattern obtained by the antibody 
against the GABAAR α4 subunit was confirmed in tissue from the brain and 
colon of WT (α4+/+) and α4 subunit-specific gene-deleted mice (α4-/-) 
(Chandra et al., 2006) (Fig. 10). In contrast to that of the GABAAR α1-3 and 
γ2 subunits, α4 subunit immunoreactivity was restricted to the neurons and 
ICCs of the myenteric plexus and was not detectable within the submucosal 
plexus (Fig. 11A). The sub-cellular expression of this subunit was localised to 
the somato-dendritic domains of myenteric neurons. Clusters 
immunoreactive for the α4 subunit were located on somato-dendritic domains 
of NOS, Chat, 5HT and CRH immunopositive neurons (Fig. 11A, B). In 
addition, immunoreactivity for the GABAAR α4 subunit decorated the cell 
bodies and processes of myenteric ICCs but not the submucosal ICCs. Thus, 
within the ENS of the mouse colon, GABAAR subunit expression varies not 
only according to cell-type and sub-cellular domain but also according to 
distinct regions of the ENS delineated by the myenteric and submucosal 
plexuses. 
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Figure 10 
 
Confirmation of the specificity of the GABAAR α4 subunit immunoreactivity 
using tissue from the brain and colon of wild type (α4+/+) and GABAAR α4 
subunit-specific gene-deleted mice (α4-/-) 
(A) shows the characteristic immunoreactivity pattern for the α4 subunit in 
the dentate gyrus and thalamic nuclei in tissue from WT mouse brain. (B) no 
specific α4 subunit signal was detectable in brain tissue from α4-/- mice. (Ci) a 
whole-mount preparation of the ENS of a WT mouse colon demonstrating 
myenteric plexus neurons identified by NOS immunoreactivity. (Cii) in the 
corresponding field of view, α4 subunit immunoreactivity is strongly 
associated with myenteric plexus neurons. (Di) a whole-mount preparation of 
the ENS of an α4-/- mouse colon demonstrating myenteric plexus neurons 
identified by NOS immunoreactivity. (Dii) in the corresponding field of view, 
no specific α4 subunit signal was detectable. Scale bars: (A, B) 200 µm; (C, 
D) 40 µm. 
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Figure 11 
 
Immunolocalisation of the GABAAR α4 subunit in the ENS of the mouse 
colon  
(Ai) shows the association of α4 subunit immunoreactive clusters (red) with 
NOS-immunopositive neurons (blue) of the myenteric plexus. (Aii) shows the 
association of α4 subunit immunoreactive clusters (red) with c-Kit 
immunopositive profiles (green) in the same field of view. (Aiii) is a magnified 
view of the boxed areas in (Ai, ii) demonstrating that α4 subunit 
immunoreactive clusters decorate the surfaces of NOS-immunopositive 
somata and dendrites as well as c-Kit immunopositive processes. (B1) 
shows that α4 subunit immunoreactive clusters are located in the close 
vicinity of Chat-immunopositive varicosities in the myenteric plexus. 
Immunoreactivity for the α4 subunit was also detectable on the somato-
dendritic domains of (B2) 5HT- and (B3) CRH-immunopositive myenteric 
plexus neurons. Scale bars: (Ai, ii) 50 µm; (Aiii3) 10 µm; (B) 10 µm. 
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2.3.8 Expression of the GABAAR α5 subunit in the mouse colon  
 
The specificity of the immunoreactive pattern obtained by the antibody 
against the GABAAR α5 subunit was confirmed in tissue from the brain and 
colon of WT (α5+/+) and α5 subunit-specific gene-deleted mice (α5-/-) 
(Collinson et al., 2002) (Fig. 12). In a similar pattern to GABAAR α4 subunit 
immunoreactivity, signal for the α5 subunit was restricted to neurons and 
putative ICCs of the myenteric plexus with no α5 subunit immunoreactivity 
detectable in the submucosal plexus (Fig. 13A). Within the myenteric plexus, 
immunoreactivity for the GABAAR α5 subunit was located on the somato-
dendritic domains of CRH and 5HT immunopositive neurons as well as 
apposed to Chat immunoreactive varicosities (Fig. 13B). In addition, 
GABAAR α5 immunoreactive clusters decorated the cell bodies and 
processes of the putative myenteric ICCs but not the submucosal plexus 
(Fig. 13Aii). This serves as further evidence that the expression of GABAAR 
subunits within the ENS of the mouse colon is region specific as well as 
cellular and sub-cellular specific.  
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Figure 12 
 
Confirmation of the specificity of the GABAAR α5 subunit immunoreactivity 
using tissue from the brain and colon of wild type (α5+/+) and GABAAR α5 
subunit-specific gene-deleted mice (α5-/-) 
(A) shows the characteristic enrichment of α5 immunoreactivity within the 
dendritic layers of the hippocampus and weaker signal within the neocortex 
in tissue from WT mouse brain. (B) no specific α5 subunit signal was 
detectable in brain tissue from α5-/- mice. (Ci) a whole-mount preparation of 
the ENS of a WT mouse colon demonstrating myenteric plexus neurons 
identified by NOS immunoreactivity. (Cii) in the corresponding field of view, 
α5 subunit immunoreactivity is strongly associated with myenteric plexus 
neurons. (Di) a whole-mount preparation of the ENS of an α5-/- mouse colon 
demonstrating myenteric plexus neurons identified by NOS immunoreactivity. 
(Dii) in the corresponding field of view, no specific α5 subunit signal was 
detectable. Scale bars: (A, B) 200 µm; (C, D) 40 µm. 
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Figure 13 
 
Immunolocalisation of the GABAAR α5 subunit in the ENS of the mouse 
colon  
(Ai) shows the association of α5 subunit immunoreactive clusters (red) with 
NOS-immunopositive neurons (blue) of the myenteric plexus. Note the 
significant number of α5 subunit immunoreactive clusters located towards the 
centre of the field of view which are not associated with neuronal profiles. 
(Aii) shows the strong association of α5 subunit immunoreactive clusters 
(red) with c-Kit immunopositive profiles in the same field of view. (Aiii) is an 
overlay of (Ai and ii). (B1) shows that α5 subunit immunoreactive clusters are 
located in the close vicinity of Chat-immunopositive varicosities in the 
myenteric plexus. Immunoreactivity for the α5 subunit was also detectable on 
the somato-dendritic domains of (B2) CRH- and (B3) 5HT-immunopositive 
myenteric plexus neurons. Scale bars: (A) 20 µm; (B) 10 µm. 
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2.4 Discussion 
 
The study shows that immunoreactivity for the GABAAR α1 and γ2 subunits 
was the most widespread compared to the other subunits investigated, being 
located on chemically diverse neurons of both myenteric and submucosal 
plexuses. This preponderance of GABAAR α1-γ2 subunit immunoreactivity 
within the ENS mirrors GABAAR expression patterns within the CNS where 
α1-γ2-GABAARs are thought to be the major subtypes (Wisden et al., 1992). 
While immunoreactivity for the GABAAR α2 and 3 subunits was also evident 
in myenteric and submucosal plexuses, their signals were restricted to 
smaller sub-sets of neurochemically defined enteric neurons. In stark 
contrast, immunoreactivity for the GABAAR α4-5 subunits was only 
detectable in myenteric plexus neurons. In addition, GABAAR subunit 
immunoreactivity was also located on non-neuronal cells which are likely to 
be the ICCs that act as pace-makers of the GIT and are involved in the 
creation of slow wave potentials which leads to the contraction of smooth 
muscle (Garcia-Lopez et al., 2009).  
 
2.4.1 Implications of GABAAR subunit expression patterns for colonic 
functions such as motility 
 
The ENS is capable of providing complete neural control of GI functions 
independent of input from the CNS (Furness, 2006). Within the mammalian 
ENS, over thirty functionally distinct types of neurons have been discovered 
which communicate using more than 25 different neurotransmitters 
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(McConalogue and Furness, 1994, Furness, 2000), including GABA (Jessen 
et al., 1986). At the organ level, GABA, released predominantly from 
interneurons and endocrine cells (Krantis, 2000, Furness, 2006), influences 
various GI functions including motility (Cherubini and North, 1984), secretion 
(Luzzi et al., 1987) and mucosal function (Hardcastle et al., 1991, 
MacNaughton et al., 1996). The rapid effects of GABA within the ENS are 
mediated via GABAARs (Cherubini and North, 1985). However, the precise 
effects of various GABAAR subtypes on the excitability of the functionally and 
neurochemically diverse ENS neurons remain to be revealed, necessitating a 
detailed description of their expression patterns in the first instance.  
 
The incredible heterogeneity of the GABAAR family has been well 
documented in the CNS where aggregation of distinct GABAAR subunits to 
specific brain regions and cell types results in an enormous versatility in the 
overall impact of activation of these receptors on neural functions of the brain 
(Nutt, 2006, Benarroch, 2007, Fritschy and Panzanelli, 2014). While only five 
subunits are required to form a functional GABAAR receptor, up to nineteen 
molecularly distinct GABAAR subunits (α1-6; β1-3; γ1-3; δ; ε; ρ) have been 
identified within the CNS (Waldvogel and Faull, 2015). Similar to the brain, 
my expression studies show that such heterogeneity in the expression of 
various GABAAR subunits also exists within the mouse colon. The RT-PCR 
performed on homogenates of mouse colon revealed mRNA expression for 
14 of the 16 GABAAR subunits investigated. This is particularly important 
since, the co-assembly of various GABAAR subunits within the ENS can 
104 
 
potentially give rise to a large number of functionally distinct GABAAR 
subtypes and a considerable diversity in GABAergic transmission. 
 
In conclusion, within the CNS, the positioning of distinct GABAAR within 
specific regions of the brain provides a significant evolutionary advantage 
which is essential for survival. In parallel to this, an important feature of my 
immunohistochemical data was the plexus-dependent location of the distinct 
GABAAR subunit. Indeed, while the expression of GABAAR α1, 2, 3 and γ2 
subunits was apparent in the myenteric as well as the submucosal plexus, 
the immunoreactivity for the GABAAR α 4 and 5 were restricted to the 
myenteric plexus. Since different plexuses of the ENS are involved in the 
control of different GI functions, one cannot resist the temptation to speculate 
that, similar to the brain, various GABAAR subunits are involved in the control 
of distinct facets of GI functions. However, the complexity of the expression 
patterns precludes an unequivocal attribution of specific GABAAR subtypes 
to specific intestinal functions. 
 
A striking feature of the GABAAR subunit immunoreactivity patterns revealed 
by this study was the sub-cellular domain and plexus-dependent location of 
specific subunits. GABAAR subunit immunoreactivity in myenteric plexus 
neurons was always located on somato-dendritic cell surfaces, irrespective 
of the neurochemical content of the cell. This clustering on postsynaptic 
domains is the conventional GABAAR subunit expression pattern of the CNS 
(Somogyi et al., 1996, Nusser et al., 1996, Fritschy and Mohler, 1995) and 
serves to regulate the neuron which is postsynaptic to the GABA release site 
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(Farrant and Nusser, 2005). In contrast, GABAAR subunit immunoreactivity in 
submucosal neurons was invariably located cytoplasmically and on axonal 
varicosities. This suggests a presynaptic locus of expression for GABAARs in 
submucosal neurons which is likely to result in an auto-regulatory function 
that could influence the further release of co-expressed neurotransmitters 
(Kullmann et al., 2005). It is difficult to speculate what eventual net effect 
GABAAR activation will have on, for example, myenteric plexus output such 
as colonic contractility given the fact that non-overlapping populations of 
NOS-, somatostatin- or encephalin-immunopositive GABAergic interneurons 
innervate both excitatory as well as inhibitory neurons (Krantis, 2000). An 
added layer of complexity was the association of GABAAR subunit 
immunoreactivity with non-neuronal cells, which, based on their 
immunoreactivity, are likely to be the ICCs.  
 
In conclusions, the cell-type specific targeting of GABAARs to either 
presynaptic or postsynaptic compartments of submucosal and myenteric 
plexuses respectively is likely to result in contrasting effects on the 
excitability of the neurons, the ensuing overall output of the plexuses as a 
whole, and thus GI function, following the application of GABA or the 
ingestion of GABAAR ligands. 
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3 Chapter 3: The functional contribution of distinct 
GABAAR subunits to colonic contractility  
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3.1 Summary and Importance 
 
Background: GI motility or peristalsis relies on the coordinated contraction 
and activity of both the circular and longitudinal smooth muscles, which are 
under the influence of neural inputs from the ENS. Thus, the molecules 
which regulate ENS neuronal excitability have a direct effect on GI 
contractility. In the previous chapter, I demonstrated that a rich repertoire of 
GABAAR subunits is divergently expressed within the neuronal networks of 
the ENS, suggesting a role for the GABAAR system in ENS-mediated GI 
function. With a view to understanding the role of GABAAR system in GI 
function, I exploited various GABAAR subtype preferring ligands to 
investigate the potential role of these receptors in one aspect of GI function, 
namely the colonic contractility. 
 
Methods: Organ bath preparations, segments of the distal colon and 
GABAAR subtype preferring ligands were used in order to investigate the 
effect of pharmacological activation of GABAAR α1-5 and γ2 on the force and 
frequency of longitudinal smooth muscle spontaneous contractions of the 
mouse colon as well as the basal tone of the tissue.  
 
Results: The activation of specific GABAAR subtypes had contrasting effects 
on the force and frequency of spontaneous contractions of colonic 
longitudinal smooth muscles as follows: 1) the activation of α1-γ2-GABAARs 
and α4-GABAARs increased the force of spontaneous contractions, but not 
their frequency; 2) the activation of α2-γ2-GABAARs increased their 
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frequency, but not their force; 3) the activation of α3-γ2-GABAARs decreased 
their force and; 4) an inverse agonist at α5-α2-GABAARs decreased their 
force. Furthermore, while the inhibitory impact of GABAARs on colonic 
contractility was diminished by the inhibition of NO pathways, the excitatory 
effect of GABAARs was removed by blockade of cholinergic pathways.  
 
Importance: The data suggest that the engagement of various GABAAR 
subtypes within distinct cellular networks of the ENS cooperate to modulate 
the distinct physiological processes, which underlie coordinated contractility.  
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3.2 Methods 
 
3.2.1 Isometric tension recordings of the effects of GABAAR subunit-
preferring ligands on colonic longitudinal muscle contractions from 
isolated mouse colon segments 
 
The pharmacological activation of GABAARs within the colon was explored 
with a view to understanding their potential roles in one aspect of colon 
physiology, namely colonic smooth muscle contractility. Intestinal motility or 
peristalsis arises from the coordinated contraction and relaxation of circular 
and longitudinal smooth muscles (Smith and Robertson, 1998). The effect of 
the GABA-GABAAR system on the contractility of intestinal circular smooth 
muscles has been widely explored (Tonini et al., 1989b, Tonini et al., 1989a, 
Bayer et al., 2002, Bayer et al., 2003). Therefore, I focused on the effect of 
ENS GABAAR activation on longitudinal smooth muscle contraction by 
measuring the changes in the force and frequency of spontaneous 
contractions in vitro. The activity of the interstitial cells of Cajal (ICC) is 
thought to underlie such intestinal spontaneous contractions (Sanders and 
Ward, 2006).  
 
Six to eight weeks old male mice were killed by cervical dislocation and the 
distal colon was removed and immediately placed in physiological solution 
containing (mM): NaCl 140, NaHCO3 11.9, D+ glucose 5.6, KCl 2.7, 
MgCl2.6H2O 1.05, NaH2PO4.2H2O 0.5, CaCl2 1.8 (PH 7.4), warmed to 32°C. 
The intraluminal contents were removed by gently flushing the colon with the 
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physiological solution. Approximately 2 cm-long segments were mounted in a 
Harvard organ bath (10 ml chamber) filled with the physiological solution 
(32oC) and bubbled with gas containing 95% O2 and 5% CO2. Contractile 
activity for each colon tissue strip was recorded using an isometric force 
transducer (range 0-25 g) connected to a bridge amplifier, which was in turn 
connected to a dedicated data acquisition system (Power Lab 2.20 AD 
Instruments). The sampling frequency was set to 40 Hz and the sensitivity of 
recording was set to 500 mV. The apparatus was then calibrated using a one 
gram weight in order to express the changes in the amplitude detected by 
the transducer into grams of force. At this stage, in order to assess the noise 
produced by the electrical equipment and as an experimental control, a long 
piece of cotton was tied to the tissue hook placed in an aerated organ bath at 
one end and the other end was passed through the transducer which picked 
up any movement in the piece of cotton due to noise. This was represented 
on the computer as a trace with peaks up to maximum of 0.02 grams of 
tension. Therefore in any subsequent analysis of contractile activities 
produced by pieces of colon, any peak less than 0.02 grams of force was 
disregarded in order to produce accurate account for the force and frequency 
of spontaneous contractions. The tissue was then placed under 1 gram of 
resting tension and allowed to equilibrate for 30 minutes. The AD instrument 
lab chart 7 program installed on a PC was used to monitor, record and 
analyse the activity. After a stable baseline was established, the drugs were 
added to the bath and the tissue was allowed to reach maximum response. 
Ten minute epochs before and after the drug additions were used for manual 
quantification of the drug-induced changes in the force and frequency of 
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colonic spontaneous contractions. One piece of tissue was used per animal. 
The frequency and amplitude of individual spontaneous contractions was 
manually counted before and after the drug and the average for that animal 
determined. A mean value for the individual averages was obtained for a 
particular drug. An N value thus represents one animal and the data are 
presented as the mean ± SD.  
 
In a subset of experiments, we investigated the effects of alprazolam on the 
contractile responses evoked by transmural nerve stimulation (10 Hz, 60 V 
and 0.2 ms duration) (Bayer et al., 2003). The electric pulses were delivered 
for 10 seconds and a single contraction was observed as a result. The tissue 
was then washed several times with the physiological solution and allowed to 
stabilise for 15 minutes. Alprazolam or TTX were then individually added to 
the bath for 10 minutes after which the electrical stimulation was repeated. 
 
3.2.2 Drugs  
 
The following drugs were used in this study: zolpidem (Tocris Biosciences), 
alprazolam (Sigma Aldrich), TP003 (Tocris Biosciences), THIP hydrochloride 
(Tocris Biosciences), L-655, 708 (Tocris Biosciences), tetrodotoxin (Tocris 
Biosciences), atropine (Sigma) and L-NAME (Sigma). Apart from THIP 
hydrochlorid, atropine and L-NAME which were dissolved in distilled water, 
all other drugs were dissolved in DMSO. DMSO at maximum bath 
concentrations used (0.1%) had no effect on the amplitude or frequency of 
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colonic spontaneous contractions in agreement with previous evidence 
(Bayer et al., 2002).  
 
3.2.3 Statistical analysis 
 
All data are presented as the arithmetic mean ± SD unless stated otherwise. 
Statistical comparisons were made using either Student’s t test (paired or 
unpaired where appropriate) or repeated-measures ANOVA (one-way), 
followed by the Tukey’s post hoc test.    
 
3.3 Results 
 
3.3.1 The role of the GABAAR γ2 subunit in the regulation of longitudinal 
smooth muscle spontaneous contractions 
 
In order to investigate whether the activation of γ2-GABAARs influences 
colonic contraction, I applied the benzodiazepine alprazolam to isolated 
mouse colon segments and measured the changes in the force and 
frequency of spontaneous contractions as well as the basal tone of the 
tissue. Benzodiazepines as a class act as positive allosteric modulators at 
α1/2/3/5-β-γ2-GABAARs and therefore enhance the endogenous effects of 
GABA (Rudolph and Knoflach, 2011) with alprazolam in particular being a 
high potency benzodiazepine widely prescribed for the treatment of 
generalized anxiety, panic attacks and depression. Alprazolam at a bath 
concentration of 10 µM induced a significant decrease in the basal tone of 
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the tissue (from - 0.42 ± 0.09 grams to, - 0.52 ± 0.1 grams, N = 4 animals; P 
= 0.003, paired Student’s t test). Alprazolam also significantly decreased the 
force of spontaneous contractions (from 0.19 ± 0.06 grams to 0.08 ± 0.04 
grams, N = 4 animals; P = 0.007, paired Student’s t test) and increased their 
frequency (from 0.054 ± 0.003 Hz to 0.071 ± 0.009 Hz, P = 0.0244, paired 
Student’s t test) (Fig. 1A). Thus, the activation of γ2-GABAARs (i.e., 
GABAARs containing - amongst others - the γ2 subunit) has a direct effect on 
the amplitude and frequency of spontaneous colonic longitudinal muscle 
contractions as well as the basal tone of the colon. 
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Figure 1 
 
The pharmacological effect of activating γ2-GABAARs on spontaneous 
colonic longitudinal smooth muscle contractions 
(A1) representative trace demonstrating the effect of the benzodiazepine 
alprazolam 10 µM on the spontaneous contractions in a piece of isolated 
mouse colon. Note the decrease in the basal tone of the tissue. 
Quantification of the effects of alprazolam 10 µM on (A2) the force and (A3) 
the frequency of spontaneous colonic contractions. Bars represent means 
and the lines represent the SD. N = 4 animals, * P< 0.05. Scale bars: vertical 
0.5 grams, horizontal 5 minutes. 
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The intricate expression patterns of the GABAAR γ2 subunit within the 
neurochemically diverse cell networks of the ENS raises the question 
whether the effects of alprazolam on colonic contractility occur directly or via 
secondary mediators. Two key neurochemical mediators of colonic 
contractility are acetylcholine which, within the intestine, signals primarily via 
cholinergic muscarinic receptors to cause intestinal contraction (Furness, 
2006) and nitric oxide (NO) which acts via various intra- and inter-cellular 
pathways to cause intestinal relaxation (Shah et al., 2004). To explore this 
further, I investigated the effects of alprazolam on the basal tone of the colon 
as well as the force and frequency of spontaneous colonic contractions in the 
presence of either atropine a cholinergic muscarinic receptor antagonist or L-
NAME, an inhibitor of the NO synthesising enzyme nitric oxide synthase.  
 
Alprazolam significantly [F (4, 12) 16.93, P < 0.0001; Repeated measures 
ANOVA, RMA] reduced the basal tone of the colon both alone (P < 0.05, 
RMA) as well as in the presence of atropine (P < 0.05, RMA; N = 5 animals) 
(Fig. 2A1). Furthermore, alprazolam significantly [F (4, 12) 52, P < 0.0001; 
RMA] decreased the force of spontaneous colonic contractions on its own (P 
< 0.05, RMA) as well as in the presence of atropine (P < 0.05, RMA; N = 5 
animals) (Fig. 2A1, 2). In contrast, while alprazolam significantly [F (4, 12) 4.22, 
P = 0.02; RMA] increased the frequency of colonic contractions on its own (P 
< 0.05, RMA), this effect was blocked in the presence of atropine (P > 0.05, 
RMA; N = 5 animals) (Fig. 2A3). Thus, the muscarinic cholinergic system is 
required for the effect of alprazolam on the frequency but not the force of 
colonic contractions.  
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Whilst alprazolam significantly [F (6, 18) 11, P = 0.0064; RMA] reduced the 
basal tone of the colon on its own (P < 0.05, RMA; N = 7 animals), this effect 
was abolished in the presence of L-NAME (P > 0.05, RMA). In contrast to 
atropine, the alprazolam-induced [F (6, 18) 5.78, P = 0.0017; RMA] decrease in 
the force of colonic contraction (P < 0.05, RMA) was blocked in the presence 
of L-NAME (P > 0.05, RMA; N = 7 animals) (Fig. 2B1, 2). However, the 
significant [F (6, 18) 6.45, P = 0.0001; RMA] alprazolam-induced increase in 
the frequency of colonic contraction (P < 0.05, RMA) still persisted in the 
presence of L-NAME (P < 0.05, RMA; N = 7 animals) (Fig. 2B3). Thus, the 
nitric oxide system is engaged in mediating the effects of alprazolam on the 
basal tone as well as the force of colonic contractions. Although the effect of 
alprazolam is likely to be mediated via the GABAARs, it is important to bear 
in mind that alprazolam can also bind to and modulate the activity of 
benzodiazepine receptors. Previous studies have shown that 
benzodiazepine are also expressed in the periphery and specially within the 
colon (Bribes et al., 2004) and that the activation peripheral benzodiazepine 
receptors has an inhibitory effect on electrical field stimulated contractions of 
the intestine, similar to the effect of alprazolam (Bolger et al., 1989). 
Therefore, one cannot dismiss the notion that the effect of alprazolam may 
also to some extent be mediated via peripheral benzodiazepine receptors.     
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Figure 2 
 
The effect of blockading muscarinic cholinergic receptors and nitric oxide synthesis 
on the alprazolam-induced changes in the force and the frequency of spontaneous 
colonic contractions 
(A1) representative trace demonstrating the effect of the benzodiazepine alprazolam 
10 µM on spontaneous contractions in a piece of isolated mouse colon in the 
absence and presence of the muscarinic cholinergic receptor antagonist atropine 1 
µM. Quantification of the effects of alprazolam 10 µM, before and after the co-
application of atropine on (A2) the force and (A3) the frequency of spontaneous 
colonic contractions. (B1) representative trace demonstrating the effect of 
alprazolam 10 µM on spontaneous contractions in a piece of isolated mouse colon 
in the absence and presence of the nitric oxide synthase inhibitor L-NAME 10 µM. 
Quantification of the effects of alprazolam 10 µM, before and after the co-application 
of L-NAME on (B2) the force and (B3) the frequency of spontaneous colonic 
contractions. Bars represent means and the lines represent the SD. N = 7 animals, * 
P < 0.05, repeated measures ANOVA with posthoc Tukey’s test. Scale bars: vertical 
0.25 grams, horizontal 2 minutes. 
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Whilst the direct readout of the preparation used is smooth muscle 
contraction, it would be informative to confirm the involvement of the ENS in 
such effects. We therefore directly engaged neural elements by transmurally 
stimulating the colon segments using electrical field stimulation and 
measured the evoked contractile response (Fig. 3A, B). The application of 2 
µM tetrodotoxin (TTX), a blocker of voltage-gated sodium channels, which in 
this preparation, are expressed by neuronal elements, significantly reduced 
the amplitude of the evoked response (P = 0.003, paired Student’s t test) 
(Fig. 3B) confirming that neural activity underlies the evoked response. The 
application of alprazolam mimicked the effect of TTX by significantly reducing 
the amplitude of the evoked response (P = 0.01, paired Student’s t test). 
There was no significant difference between the evoked responses produced 
by TTX and alprazolam (P = 0.07, unpaired Student’s t test). This suggests 
that alprazolam directly engages the ENS and dampens overall neuronal 
excitability. Dedicated microelectrode studies are required to dissect the 
effects of GABAAR subtype function at the single cell or cellular network 
which manifest in regulating ENS out as a whole.  
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Figure 3 
 
Effect of 10 µM alprazolam on electrically evoked contractile responses of 
colon longitudinal smooth muscles 
(A) shows representative records of the contractile responses of a colon 
segment following electrical field transmural stimulation either alone or in the 
presence of 2 µM TTX, which blocks neural activity, or alprazolam. Note that 
both TTX and alprazolam attenuate the evoked response largely to the same 
degree. (B) Quantification of the effects of TTX and alprazolam on the 
evoked contractile responses. Error bars represent the mean percentage of 
the maximal response and the lines represent the SD; N_4 animals, *p_0.05, 
paired Student’s t test. Scale bars: (A) vertical 0.1 g, horizontal 30 s. 
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3.3.2 The role of GABAAR α1 subunit in the regulation of longitudinal 
smooth muscle spontaneous contractions 
 
In order to investigate whether the activation of α1-GABAARs influences 
colonic contraction, I applied the GABAAR subunit-selective imidazopyridine 
zolpidem to isolated mouse colon segments and measured the changes in 
the force and frequency of spontaneous contractions. Within the CNS, 
zolpidem at a concentration of 100 nM is a selective positive allosteric 
modulator (PAM) of α1-γ2-GABAARs, whereas a concentration of 1µM 
zolpidem has affinity not only for α1-γ2, but additionally α2/3-γ2-GABAARs 
(Peden et al., 2008, Langer et al., 1990, Crestani et al., 2000). Zolpidem at a 
bath concentration of 100 nM significantly increased the force of 
spontaneous contractions (mean ± SD; baseline, 0.07 ± 0.03 grams versus 
zolpidem, 0.10 ± 0.04 grams, N = 4 animals; P = 0.0246, paired Student’s t 
test) (Fig. 4A1, 2). However, zolpidem at this concentration had no significant 
effect on the frequency of spontaneous contractions (mean ± SD; baseline, 
0.07 ± 0.007 Hz versus zolpidem, 0.07 ± 0.012 Hz, N = 4 animals; P = 
0.4228, paired Student’s t test) (Fig. 4A1, 3).  
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Figure 4  
 
The pharmacological effect of activating α1-GABAARs on spontaneous 
colonic longitudinal smooth muscle contractions 
 (A1) representative trace demonstrating the effects of the sequential 
application of zolpidem first at a concentration of 100nM (α1-GABAAR 
selective agonist) and then 1 µM (α1, 2, 3-GABAAR selective agonist) on the 
spontaneous contractions in a piece of isolated colon. Quantification of the 
effects of zolpidem 100nM on (A2) the force and (A3) the frequency of 
spontaneous colonic contractions. Bars represent means and the lines 
represent the SD. N= 4 animals. * P < 0.05 paired Student’s T test. Scale 
bars: vertical 0.5 grams, horizontal 5 minutes. 
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3.3.3 The role of GABAAR α2/3 subunit in the regulation of longitudinal 
smooth muscle spontaneous contractions 
 
In order to investigate the potential functional roles of α2/3-GABAARs in 
colonic contractility, I applied zolpidem 1 µM to isolated mouse colon and 
measured the changes in the force and frequency of spontaneous 
contractions. At this concentration, zolpidem is expected to enhance the 
function of α2/3-γ2 in addition to α1-γ2-GABAARs (Peden et al., 2008). 
Zolpidem at a bath concentration of 1 µM significantly decreased the force of 
spontaneous contractions (mean ± SD; baseline, 0.12 ± 0.02 grams versus 
zolpidem, 0.08 ± 0.03 grams, N = 4 animals; P = 0.0133, paired Student’s t 
test) (Fig. 5B1). In addition, zolpidem at this concentration significantly 
increased the frequency of spontaneous contractions (mean ± SD; baseline, 
0.07 ± 0.007 Hz versus zolpidem, 0.10 ± 0.019 Hz, N= 4 animals; P = 
0.0237, paired Student’s t test) (Fig. 5B2).  
 
To dissect the potential contrasting roles of α2- and α3-GABAARs on the 
force and frequency of spontaneous colonic contractions, we utilised the 
GABAAR ligand TP003 which in recombinant systems is a selective PAM of 
α3-γ2-GABAARs (Dias et al., 2005). A caveat is that TP003 may lack this 
GABAAR α3 subunit selectively in native GABAAR expression systems 
(Peden et al., 2008). TP003 at a bath concentration of 100 µM significantly 
decreased the force of spontaneous contractions (mean ± SD; baseline, 0.16 
± 0.05 grams versus TP003, 0.07 ± 0.01 grams, N = 4 animals; P = 0.024, 
paired Student’s t test) (Fig. 5A1, 2). However, TP003 had no significant 
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effect on the frequency of colonic spontaneous contractions (mean ± SD; 
baseline, 0.066 ± 0.004 Hz versus TP003, 0.069 ± 0.007 Hz, N = 4 animals; 
P = 0.294, paired Student’s t test) (Fig. 5A1, 3). Collectively, the effects of 
zolpidem 1 µM and TP003 suggest that the activation of α2-GABAARs 
influences the frequency of spontaneous colonic contractions whereas the 
activation of α3-GABAARs influences the force of spontaneous colonic 
contractions. I was unable to fully reverse the effects of both zolpidem and 
TP003 by washout and thus not able to use atropine or L-NAME to evaluate 
the potential roles of muscarinic cholinergic receptors and nitric oxide 
pathways in mediating the effects of these drugs. 
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Figure 5 
 
The pharmacological effect of activating α2/3-GABAARs on spontaneous 
colonic longitudinal smooth muscle contractions 
(B) quantification of the effects of zolpidem 1 µM on (B1) the force and (B2) 
the frequency of spontaneous colonic contractions (N = 4 animals). (A1) 
representative trace demonstrating the effect of the α3-GABAAR agonist 
TP003 100 µM on the spontaneous contractions in a piece of isolated mouse 
colon. (A) quantification of the effects of TP003 100 µM on (A2) the force and 
(A3) the frequency of spontaneous colonic contractions (N = 4 animals). Bars 
represent means and the lines represent the SD. * P < 0.05, paired Student’s 
T test. Scale bars: vertical 0.25 grams, horizontal 5 minutes. 
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3.3.4 The role of GABAAR α4 subunit in the regulation of longitudinal 
smooth muscle spontaneous contractions 
 
The lack of availability of a selective α4-GABAAR ligand precluded the 
unequivocal determination of the contribution of α4-GABAAR activation to 
colonic contractility. I therefore utilised the GABAAR agonist THIP which will 
be selective for those α4-GABAARs which are co-assembled with δ subunits 
(Storustovu and Ebert, 2006, Brown et al., 2002) with the caveat that 
GABAARs not composed of γ or δ subunits (i.e. α-β pentamers) might also 
be engaged. THIP, at a bath concentration of 10 µM significantly increased 
the force of spontaneous contractions (mean ± SD; baseline, 0.11 ± 0.04 
grams versus THIP, 0.19 ± 0.09 grams, N = 5 animals; P = 0.0299, paired 
Student’s t test) (Fig. 6A1, 2). However, THIP did not significantly alter the 
frequency of contractions (mean ± SD; baseline, 0.052 ± 0.005 Hz versus 
THIP, 0.051 ± 0.009 Hz, N = 5 animals; P = 0.5583, paired Student’s t test) 
(Fig. 6A3).  
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Figure 6 
 
The pharmacological effect of activating α4-GABAARs on spontaneous 
colonic longitudinal smooth muscle contractions 
(A1) representative trace demonstrating the effect of the GABAAR agonist 
THIP 10 µM on the spontaneous contractions in a piece of isolated mouse 
colon. Quantification of the effects of THIP 10 µM on (A2) the force and (A3) 
the frequency of spontaneous colonic contractions (N = 5 animals). Bars 
represent means and the lines represent the SD. * P < 0.05, paired Student’s 
T test. Scale bars: vertical 0.5 grams, horizontal 5 minutes. 
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I then evaluated the effects of THIP in the presence of atropine and L-NAME. 
Whilst THIP significantly increased the force of colonic contractions (mean ± 
SD; baseline, 0.07 ± 0.02 grams versus THIP, 0.14 ± 0.04 grams, N = 5 
animals; P < 0.05, RMA and Tukey's posthoc test), this effect was abolished 
in the presence of atropine (mean ± SD; atropine alone, 0.09 ± 0.02 grams 
versus atropine plus THIP, 0.1 ± 0.03 grams, N = 5 animals; P > 0.05, RMA 
and Tukey's posthoc test) (Fig. 7A1, 2). In accordance with above (Fig. 6C3), 
THIP had no significant effect on the frequency of spontaneous contractions 
either alone (mean ± SD; baseline, 0.062 ± 0.005 Hz versus THIP, 0.063 ± 
0.004 Hz, N = 5 animals; P > 0.05, RMA and Tukey's posthoc test) or in the 
presence of atropine (mean ± SD; atropine alone, 0.063 ± 0.07 Hz versus 
atropine plus THIP, 0.061 ± 0.03 Hz, P > 0.05, RMA and Tukey's posthoc 
test) (Fig. 7A3). 
 
In contrast to atropine, the significant [F (2, 6) 13.6; P = 0.0059. RMA) THIP-
induced increase in the force of colonic contractions (mean ± SD; baseline, 
0.09 ± 0.03 grams versus THIP, 0.15 ± 0.03 grams, N = 3 animals; P < 0.05, 
RMA and Tukey’s posthoc test) persisted in the presence of L-NAME (mean 
± SD; L-NAME alone, 0.14 ± 0.09 grams versus L-NAME plus THIP, 0.19 ± 
0.09 grams, N = 3 animals; P < 0.05, RMA and Tukey’s posthoc test) (Fig. 
7B1, 2). Once again, THIP had no significant effect on the frequency of 
spontaneous contractions either alone (mean ± SD; baseline, 0.060 ± 0.003 
Hz versus THIP, 0.066 ± 0.004 Hz, N = 3 animals; P > 0.05, RMA and 
Tukey's posthoc test) or in the presence of L-NAME (mean ± SD; L-NAME 
alone, 0.060 ± 0.07 Hz versus L-NAME plus THIP, 0.064 ± 0.08 Hz, P > 
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0.05, RMA and Tukey's posthoc test) (Fig. 7B3). Thus, the muscarinic 
cholinergic system but not the nitric oxide system appears to be involved in 
mediating the effects of THIP on the force of colonic contractions.  
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Figure 7 
 
The effect of blockading muscarinic cholinergic receptors and nitric oxide synthesis 
on the THIP-induced changes in the force and the frequency of spontaneous colonic 
contractions  
(A1) representative trace demonstrating the effect of THIP 10 µM on spontaneous 
contractions in a piece of isolated mouse colon in the absence and presence of the 
muscarinic cholinergic receptor antagonist atropine 1 µM. Quantification of the 
effects of THIP, before and after the co-application of atropine on (A2) the force and 
(A3) the frequency of spontaneous colonic contractions. (B1) representative trace 
demonstrating the effect of THIP 10 µM on spontaneous contractions in a piece of 
isolated mouse colon in the absence and presence of the nitric oxide synthase 
inhibitor L-NAME 10 µM. Quantification of the effects of THIP, before and after the 
co-application of L-NAME on (B2) the force and (B3) the frequency of spontaneous 
colonic contractions. Bars represent means and the lines represent the SD. N = 5 
animals, * P < 0.05, repeated measures ANOVA with post-hoc Tukey’s test. Scale 
bars: vertical 0.25 grams, horizontal 2 minutes. 
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3.3.5 The role of GABAAR α5 subunit in the regulation of longitudinal 
smooth muscle spontaneous contractions 
 
L-655,708, an inverse agonist selective for the benzodiazepine site at α5-γ2-
GABAARs (Quirk et al., 1996), was used to investigate the functional 
implications of α5-GABAARs activity on the force and frequency of 
spontaneous contractions of the mouse colon. L-655,708 at a bath 
concentration of 10 µM induced a profound reduction in the basal tone of the 
tissue (Fig. 8A1, double arrow) (mean ± SD; baseline, -0.28 ± 0.16 grams 
versus L-655,708, -0.58 ± 0.18 grams, N = 8 animals; P < 0.0001, paired 
Student’s t test). Furthermore, L-655,708 10 µM significantly decreased the 
force of spontaneous contractions (mean ± SD; baseline, 0.13 ± 0.05 grams 
versus L-655,708, 0.10 ± 0.02 grams, N= 8 animals; P = 0.0316, paired 
Student’s t test) (Fig. 8A1, 2). However, L-655,708 did not significantly alter 
the frequency of contractions (mean ± SD; baseline, 0.058 ± 0.010 Hz versus 
L-655,708, 0.058 ± 0.011 Hz, N = 8 animals; P = 0.8398, paired Student’s t 
test) (Fig. 8A3). Notably, out of all the GABAAR ligands tested L-655,708 
produced the most robust reduction in the basal tone of the tissue with only 
alprazolam mimicking such an effect, although to a much lesser degree. This 
suggests a central role for α5-GABAARs in setting the muscle tone of the 
mouse colon.  
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Figure 8  
 
The pharmacological effect of activating α4-GABAARs on spontaneous 
colonic longitudinal smooth muscle contractions 
(A1) representative trace demonstrating the effect of the α5-GABAAR inverse 
agonist L-655, 708 10 µM on the spontaneous contractions in a piece of 
isolated mouse colon. Note the significant decrease in the basal tone of the 
tissue (double arrow). Quantification of the effects of L-655, 708 on (A2) the 
force and (A3) the frequency of spontaneous colonic contractions (N = 8 
animals). Bars represent means and the lines represent the SD. * P < 0.05, 
paired Student’s T test. Scale bars: vertical 0.25 grams, horizontal 5 minutes. 
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I then evaluated the effects of L-655,708 in the presence of atropine and L-
NAME. L-655,708 significantly [F (5, 15) 3.23; P = 0.03, RMA] reduced the 
basal tone of the colon both on its own (mean ± SD; baseline, -0.17 ± 0.08 
grams versus L-655,708, -0.34 ± 0.08 grams, N = 6 animals; P < 0.05, RMA 
and Tukey’s posthoc test) and in the presence of atropine (mean ± SD; 
atropine alone, -0.12 ± 0.04 grams versus atropine plus L-655,708, -0.28 ± 
0.09 grams, N = 6 animals; P < 0.05, RMA and Tukey’s posthoc test). The 
effect of L-655,708 in significantly [F (5, 15) 4.79; P = 0.0081, RMA] reducing 
the force of colonic contractions (mean ± SD; baseline, 0.12 ± 0.03 grams 
versus L-655,708, 0.06 ± 0.02 grams, N = 6 animals; P < 0.05, RMA and 
Tukey’s posthoc test) persisted in the presence of atropine (mean ± SD; 
atropine alone, 0.09 ± 0.02 grams versus atropine plus L-655,708, 0.04 ± 
0.01 grams, N = 6 animals; P < 0.05, RMA and Tukey’s posthoc test) (Fig. 
9A1, 2). In accordance with above (Fig. 8A1, 3), L-655,708 had no significant 
effect on the frequency of spontaneous contractions either alone (mean ± 
SD; baseline, 0.060 ± 0.006 Hz versus L-655,708, 0.063 ± 0.006 Hz, N = 6 
animals; P > 0.05, RMA) or in the presence of atropine (mean ± SD; atropine 
alone, 0.063 ± 0.08 Hz versus atropine plus L-655,708, 0.063 ± 0.06 Hz, P > 
0.05, RMA) (Fig. 9A3). The data suggest that the muscarinic cholinergic 
system is not associated with the effect of L-655,708 on the basal tone or 
force of colonic contractions.  
 
Whilst L-655,708 significantly [F (5, 15) 5.8; P = 0.003, RMA] reduced the basal 
tone of the colon on its own (mean ± SD; baseline, -0.37 ± 0.26 grams 
versus L-655,708, -0.58 ± 0.28 grams, N = 6 animals; P < 0.05, RMA), this 
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effect was abolished in the presence of L-NAME (mean ± SD; L-NAME 
alone, -0.37 ± 0.08 grams versus L-NAME plus L-655,708, -0.45 ± 0.13 
grams, N = 6 animals; P > 0.05, RMA and Tukey’s posthoc test). In contrast 
to atropine, the L-655,708-induced significant [F (5, 15) 4.9; P = 0.007, RMA] 
decrease in the force of colonic contractions (mean ± SD; baseline, 0.16 ± 
0.05 grams versus L-655,708, 0.08 ± 0.03 grams, N = 6 animals; P < 0.05, 
RMA and Tukey’s posthoc test) was abolished in the presence of L-NAME 
(mean ± SD; L-NAME alone, 0.18 ± 0.07 grams versus L-NAME plus L-
655,708, 0.16 ± 0.08 grams, N = 6 animals; P > 0.05, RMA) (Fig. 9B1, 2). 
Once again, L-655,708 had no significant effect on the frequency of 
spontaneous contractions either alone (mean ± SD; baseline, 0.060 ± 0.006 
Hz versus L-655,708, 0.063 ± 0.006 Hz, N = 6 animals; P > 0.05, RMA) or in 
the presence of L-NAME (mean ± SD; L-NAME alone, 0.063 ± 0.08 Hz 
versus L-NAME plus L-655,708, 0.063 ± 0.06 Hz, P > 0.05, RMA) (Fig. 9B3). 
Thus, the nitric oxide system is involved in mediating the effects of L-655,708 
on both basal tone and the force of colonic contractions.  
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Figure 9 
 
The effect of blockading muscarinic cholinergic receptors and nitric oxide synthesis 
on the L-655,708-induced changes in the force and the frequency of spontaneous 
colonic contractions  
(A1) representative trace demonstrating the effect of L-655,708 10 µM on 
spontaneous contractions in a piece of isolated mouse colon in the absence and 
presence of the muscarinic cholinergic receptor antagonist atropine 1 µM. 
Quantification of the effects of L-655,708, before and after the co-application of 
atropine on (A2) the force and (A3) the frequency of spontaneous colonic 
contractions. (B1) representative trace demonstrating the effect of L-655,708 on 
spontaneous contractions in a piece of isolated mouse colon in the absence and 
presence of the nitric oxide synthase inhibitor L-NAME 10 µM. Quantification of the 
effects of L-655,708, before and after the co-application of L-NAME on (B2) the 
force and (B3) the frequency of spontaneous colonic contractions. Bars represent 
means and the lines represent the SD. N = 5 animals, * P < 0.05, repeated 
measures ANOVA with post-hoc Tukey’s test. Scale bars: vertical 0.25 grams, 
horizontal 2 minutes. 
135 
 
3.4 Discussion 
 
The expression of specific GABAAR subunits on distinct cell types of the 
mouse colon involved in the generation (ICCs) and regulation (enteric 
neurons) of colonic motility, suggested a role for distinct GABAAR subtype in 
modulating intestinal motility (Chapter 2). Evidence contained in this chapter 
appears to verify this hypothesis by demonstrating that the application of a 
variety of GABAAR subunit preferring ligands induced contrasting effects on 
the force and frequency of spontaneous contraction of the colon in vitro. The 
implications are that various GABAAR subtypes play different roles in the 
regulation of colonic contractions and thus colonic motility.   
 
3.4.1 Various GABAAR subtypes have contrasting effects on the colonic 
spontaneous contractions 
 
GABAARs are composed of many different subunits and the expression of 
these receptors within the CNS is region and cell type specific. In addition, 
distinct GABAAR subunits are linked to distinct neuronal circuits and 
consequently serve distinct functions within the CNS (Rudolph and Mohler, 
2006). Importantly, the novel pharmacological profiles of various GABAAR 
subunits in the brain were drawn through studies utilising the use of GABAAR 
subtype-preferring drugs. However, this has never been explored within the 
ENS and the GI tract. Since I demonstrated in the previous chapter that the 
expression of GABAAR subunits was located at the interface of cells involved 
in the control of colonic motility, I therefore examined the likely functional 
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consequences of such expression patterns by exploiting various subtype 
preferring ligands to investigate the potential role of these receptors in 
colonic motility.  
 
In order to gain a perspective on the potential contributions of various 
GABAAR subtypes to GI function, I concentrated on the myenteric plexus in 
light of its readily measurable physiological output, namely colonic 
spontaneous contractility. Despite the widespread expression of various 
GABAAR subunits throughout the ENS, it is notable that the GABAAR 
subunit-preferring ligands had such distinctly opposing effects on contractile 
function. Indeed, the pharmacological activation of α1-γ2-GABAARs and α4-
GABAARs increased the force of spontaneous contractions, α2-γ2-GABAARs 
increased their frequency, α3-γ2-GABAARs decreased their force and an 
inverse agonist at α5-γ2-GABAARs decreased their force. This suggests that 
the engagement of various GABAAR subtypes within the cellular networks of 
the ENS cooperate to modulate the distinct physiological processes which 
underlie coordinated contractility. It would be beneficial to understand which 
particular GABAAR-cellular pathway modulates distinct facets of the 
contractile process such as amplitude or frequency.  
 
3.4.2 Potential mechanisms underlying GABAAR-mediated alterations in 
spontaneous colonic contractility  
 
Multiple and distinct mechanisms are likely in place to modulate the 
GABAAR-mediated changes in the spontaneous colonic contractions. Firstly, 
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GABAAR ligands may be acting directly on the colonic smooth muscle to 
change the amplitude of these contractions. The direct link between the GI 
nervous system, GABAARs and GI contractility, was demonstrated by my 
electrical field stimulation data (Fig. 3) which showed that GABAAR 
activation, using alprazolam, a ligand which is likely to engage α1/2/3/5-β-γ2-
GABAARs collectively (although it is thought to be mainly α2/3-β-γ2 
preferring), dampens ENS-mediated colonic contractions. This supported my 
expression studies which showed that within GI muscle layer, GABAARs are 
only localised to enteric neurons and ICCs. To dissect the likely cellular 
signalling pathways which mediate these effects, I employed 
pharmacological combinatorial studies using GABAAR ligands in the 
presence and absence of various neuronal pathway blockers. While the 
expression studies (Chapter 2) suggests the overlap of multiple GABAAR 
subtypes on neurochemically diverse cell-types, such as those expressing 
NOS and Chat, these combinatorial pharmacological analyses allow us to 
draw cautious conclusions on the neurochemical and cellular pathways 
mediating the GABAAR-subtype dependent effects on the force and 
frequency of colonic contractions.  
 
Alprazolam, which is likely to preferentially engage α2-3-GABAARs, 
appeared to induce a decrease in the force of contractions via NO pathways. 
In accordance, α2/3-GABAAR immunoreactivity was associated with 
somatostatin-immunopositive neurons, the activation of which via GABAARs 
is linked to the release of nitric oxide and vasoactive intestinal peptide (VIP) 
from inhibitory motor neurons (Krantis, 2000) and a consequent decrease in 
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intestinal motility; this thus tallies with the effect manifested by the 
pharmacological activation of α2/3-γ2-GABAARs in my studies. In addition, 
α4-GABAARs appeared to induce an increase in the force of colonic 
contractions via cholinergic pathways, This is important since, other studies 
have shown that that endogenous and exogenous GABA within the ENS 
enhances the cholinergic pathway and promotes Ach release from myenteric 
neurons (Parkman et al., 1993, Reis et al., 2006). The obvious caveat is that 
the pharmacology of the GABAAR subunit-preferring ligands has been 
demonstrated predominantly in either recombinant systems or CNS 
preparations. Therefore, the future characterisation of these ligands in GI 
tissue from GABAAR subunit-specific mutant mouse models will be 
instrumental in confirming their pharmacological profiles in colon tissue and, 
thus their potential to reverse any of the symptoms of GI disorders arising 
from such ENS mechanism. Since the data presented in this thesis is 
focused on the impact of distinct GABAAR subunits on motility at the organ 
level, electrophysiological recordings such as patch-clamp electrophysiology 
using GABAAR subunit-preferring ligands can also be critical in revealing 
how individual GABAAR subunits behave at the cellular level.  
 
Taken together, the data presented in this chapter and findings from various 
other studies illustrate a fully functional GABAergic system within the ENS of 
the intestine which exerts both excitatory and inhibitory effects on the output 
of ENS as well as intestinal motility by activating different GABAAR subunits.  
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4 Chapter 4: Expression and functional plasticity of 
GABAARs in the mouse colon; the influence of 
ageing and stress 
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4.1 Summary and Importance 
 
Background: In the second and third chapters of this thesis, I demonstrated 
that a variety of GABAAR subunits are expressed within the cellular networks 
of the ENS of the mouse colon and that their pharmacological activation had 
contrasting effects on colonic contractility suggesting a significant role for the 
GABAAR system in regulating colonic motility. However, the functioning of 
the GI system is highly dynamic. For example, GI function evolves during 
development and the healthy ageing process, but is also heavily influenced 
by specific life experiences such as exposure to stressors. Furthermore, 
numerous GI disorders arise as a direct result of either exposure to stressors 
or the ageing process.  
 
The question thus arises whether the GI GABAAR expression and functional 
phenotypes demonstrated in the previous chapters are static, or evolve in 
concert with the stress or age-related changes which occur in the GI; thus 
alluding to potential homeostatic or maladaptive roles for these receptors in 
GI health and disease. Therefore, the overall aims of the experiments 
undertaken for this chapter were to determine the changes in native colonic 
contractility, as well as colonic GABAAR subunit expression and function in 
response to stressors or healthy ageing. 
 
Methods: Animal models of stress, early life stress (ELS), as well as acute 
or repeated stress in adulthood, mice of various ages (P10, P15, P60, 18 
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months), quantitative RT-PCR, organ bath preparations as well as GABAAR 
subunit-preferring ligands were used in a series of experiments. 
 
Results: While acute stress resulted in hyper-contractility of the colon, 
repeated stress induced a significant decrease in the force of colonic 
spontaneous contraction. Interestingly, this acute stress induced hyper-
contractility of the colon was reversed to normal levels by the application of 
10 µM alprazolam. In addition, chronic stress also led to an increase in the 
mRNA expression of the GABAAR γ2 subunit. In contrast, exposure to ELS 
induced a decrease in the mRNA expression of the GABAAR α2 subunit with 
no significant changes in the mRNA expression levels of the GABAAR γ2 
subunit. Furthermore, the impact of 10 µM alprazolam on colonic 
contractions was altered in all types of stress. Apart from the impact of stress 
on expression and function of colonic GABAARs being age specific, the 
healthy ageing studies revealed that the force and frequency of spontaneous 
colonic contractions changes with ageing and that the effect of alprazolam on 
colonic contractions was significantly altered across ages. In addition, qPCR 
studies revealed a trend towards changes in the mRNA expression levels of 
GABAARs at different ages.  
 
Importance: These studies thus show that the colonic GABAAR system is 
highly dynamic in terms of life experience and evolves with the age of an 
individual. This suggests that the age and stress-induced plasticity in the 
GABAAR system could potentially underlie the adaptive mechanisms for GI 
health, or maladaptive mechanisms underpinning GI disorders. Taken 
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together, this study illustrates that the GABAAR system plays an integral role 
in native GI physiology and represents a viable therapeutic target for GI 
disorders arising either due to emotional challenges or the ageing process 
 
4.2 Methods 
 
All procedures involving experimental animals were performed in accordance 
with the Animal (Scientific Procedures) Act, 1986 (UK) and associated 
procedures.  
 
4.2.1 Animal stress models 
 
It is well established that different forms of stress, either during development 
or in adulthood, have vastly different physiological responses (Buynitsky and 
Mostofsky, 2009). Furthermore, exposure to acute stress is generally 
believed to manifest in adaptive behavioural responses to future stressors, 
whereas exposure to chronic stressors induces maladaptive responses 
which underlie such stress-induced disorders (de Kloet et al., 2005). I 
therefore used a variety of stress models with a view to determining the 
potential roles of specific GABAAR subtypes in stress-induced alterations in 
GI contractility.  
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4.2.2 Acute stress in adulthood: 1 hour restraint stress  
 
I have chosen the paradigm of restraint stress since its effects are highly 
reproducible due to all the restrainers used being essentially identical 
(Buynitsky and Mostofsky, 2009). Furthermore, this stress model does not 
result in physical trauma and abuse which might lead to physical wounds. 
One week prior to the commencement of the stress protocol, the animals 
were divided into control and stress experimental groups which allowed 
adaptation to the new cage. Mice aged postnatal day 60 (P60) were inserted 
tail first into a Broome rodent restrainer (Harvard Apparatus # 52-0407) for 1 
hour. The mice were restrained within the tube but not completely 
immobilised. They thus were able to move slightly backwards and forwards 
in the tube. During restraint stress, mice were kept in individual cages 
containing a thin layer of corn cob. After the period of stress, the control and 
stress animals were killed by cervical dislocation, segments of the colon 
removed and placed in a warm aerated physiological solution for organ bath 
studies (N = 7). Thus, functional analysis was undertaken on all subjects 
used for the study. 
 
4.2.3 Repeated restraint stress in adulthood: 20 days of 1 hour restraint 
stress 
 
To assess whether repeated exposure to restraint stress alters GI 
contractility, GABAAR subunit mRNA expression and the effect of GABAAR 
activation on colonic contractility, animals were exposed to 1 hour of restraint 
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stress per day as detailed above, but repeated for 20 days. The stress was 
delivered at a set time during the day for the consecutive 20 days. A day 
after the last stress exposure, animals from both control and stress group 
were killed, segments of the colon removed, either snap frozen for RNA 
extraction and qRT-PCR studies or placed in a warm aerated physiological 
solution for organ bath studies (N = 9).  
 
4.2.4 Early life stress (ELS) 
 
To determine whether stress during development impacts on GI contractility 
as well as the expression and function of the GABAAR system in adulthood, 
we employed a model of early life stress (ELS), adopted from (Rice et al., 
2008, Gunn et al., 2013) (see Fig. 1).  
 
 
 
 
Figure 1  
Photographs demonstrating 
the setup of a control cage 
in comparison with the ELS 
cage. Taken from (Rice et 
al., 2008) 
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Specifically, pregnant dams were housed together with male partners and 
monitored every 12 h for the birth of pups. The day of birth was termed 
postnatal day 0 (P0) and both the control and ELS dams were left 
undisturbed until P2. On P2, litters were adjusted to a maximum of eight 
pups of both sexes, although only male offspring were used for analyses to 
prevent any sex confounds being introduced. Control dams were housed in 
standard sawdust bedding and provided with sufficient nesting material (1 
square; NestletsR, Ancare). In the ELS cages, dams were provided with 
reduced bedding (2/32) placed upon a raised, fine-gauge (5 mm) steel mesh 
platform. The cage floor was covered with a small amount of sawdust to 
prevent ammonia build-up. All litters were left undisturbed between P2 and 
P9. On P9, both control and ELS pups were returned with the dams to cages 
with standard bedding and nesting material. Offspring remained with the 
dams until weaning at P24. This ELS paradigm has been shown to cause the 
dam to frequently leave the nest in search of additional nesting material. 
Whilst this does not alter the total amount of time she spends with the pups, 
it does manifest in a fragmented dam-pup relationship which impoverishes 
the quality of maternal care (Gunn et al., 2013, Rice et al., 2008). Such 
impaired maternal care has been shown to impart a stress hyper-responsive 
phenotype which endures into adulthood, as evidenced by elevated basal 
levels of circulating cortisone (Ivy et al., 2008). Importantly, while the effects 
of this stress paradigm have been evaluated on CNS function and behaviour, 
its impact on GI function has yet to be determined. Notably, ELS offspring 
have significantly lower body weights (Gunn et al., 2013) which might involve 
alterations GI function.  
146 
 
4.2.5 GABAAR subunit expression and function at different ages 
 
Changes in the expression and function of GABAAR subunits were 
investigated at 4 different ages as follows; P10, P15, P60 and 18 months (N 
= 4 for each age category). Male C57BL/6J mice in the P10, P15 and P60 
age category were bred in-house in a temperature and humidity controlled 
environment under a 12-HR light/dark cycle, with free access to standard 
chow and water. Eighteen month-old mice were purchased from a 
commercial vendor. Upon arrival, the animals were allowed to habituate to 
the University of Portsmouth’s Bioresource facility for two weeks prior to use. 
The animals were sacrificed by cervical dislocation and pieces of distal colon 
where dissected for organ bath and qRT-PCR analysis. 
 
4.2.6 Real-time quantitative reverse transcription polymerase chain reaction 
(qRT-PCR) 
 
Adult animals were killed by cervical dislocation and small segments of distal 
colon were removed and snap frozen in liquid nitrogen. The frozen tissue 
was thawed and cut into small pieces which were then homogenised in lysis 
buffer from which RNA was extracted using a RNeasyR mini kit (Qiagen) 
according to the manufacturer’s protocol. mRNA was reverse transcribed into 
complementary DNA (cDNA) using SuperScript™ First-Strand Synthesis 
System for RT-PCR kit (Invitrogen) and oligo (dT) primers. Multiplex qRT-
PCR was then used to simultaneously analyse the expression of both the 
housekeeping gene (Gapdh) and genes of interest which included GABAAR 
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α1-5 (Gabra1-5) and GABAAR γ2 (Gabrg2) subunits. Genes investigated in 
the study are shown in table 1. A primer/probe-based system was used for 
real time detection of PCR amplification (Taqman, Applied Biosystems). For 
each sample, 5 μl of cDNA was mixed with 3 µl of nuclease-free water, 10 µl 
of qRT-PCR master mix 2X (Roche Applied Science), 1 µl of each of the 
primers and probes for Gapdh and genes of interest labelled with VIC (primer 
limited) and FAM, respectively, in a 20 μl reaction. The reactions were 
loaded in a PCR 96 well plate and qRT-PCR was performed under the 
following cycling conditions: 95°C for 10 mins and 40 cycles of 95°C for 15 
sec and 60°C for 60 sec (LightCycler® 96 System, Roche). Every reaction for 
a specific gene of interest was loaded as duplicates, 10 µl in each well, and 
the mean of each duplicate value was then used in subsequent analysis and 
calculations.  
 
4.2.6.1 Choice of analytic methods for RNA expression data 
 
The relative standard curve method and the comparative threshold method 
(2-ΔΔCt method) were used for the ageing and stress studies, respectively, in 
order to quantify the amount of gene of interest in relation to the amount of 
housekeeping gene (Gapdh) (Arya et al., 2005). The relative standard curve 
method was used in ageing studies since the absolute quantification of the 
amount of gene expression at each developmental stage (P10, P15, P60 and 
17 months) was necessary in order to map the expression of these genes 
throughout life. However, in the stress studies, we were only interested in 
any stress-induced significant changes in the expression of genes of interest 
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in compare to our control samples. Therefore, control samples were 
assumed as reference control or calibrator and any relative changes in the 
gene expression within stress samples were calculated using 2-ΔΔCt method.  
 
4.2.6.2 Analysis of qRT-PCR data 
 
Standard curves were generated for Gabra1-5 and Gabrg2 using serial 
dilutions of a known amount of cDNA from mouse distal colon. Each 
measurement was performed in duplicate and each Ct value was then 
converted into ng RNA using linear regression analysis of the standard curve 
(Microsoft Excel). Each ng RNA value was then normalised against the ng 
housekeeping gene level within the same sample and the mean ng RNA 
levels for every sample was finally calculated and compared across all 
experimental groups. In contrast, the 2-ΔΔCt method eliminates the need for 
the standard curve and mathematical equations are used to quantify the 
relative expression levels of a target gene to a reference control. Therefore 
the amounts of Gabra1-5 and Gabrg2 genes in stress samples normalised to 
Gapdh and relative to the control samples were then calculated as 2-ΔΔCt, 
where ΔΔCt = ΔCt (stress) – ΔCt (control), and ΔCt is the Ct of the target 
gene subtracted from the Ct of the housekeeping gene (Gapdh). For 
example, for the Gabra2 subunit which was decreased in ELS animals, the 
following analysis was performed in a control and ELS sample:  
 Control ELS 
Gapdh Ct 17.34 18.53 
Gabra2 Ct 31.71 33.6 
149 
 
ΔCt 14.37 15.07 
ΔΔCt 0.7 
2-ΔΔCt 0.61 
 
 
This was repeated for all the control and treated samples and the final 2-ΔΔCt 
values were averaged to generate the figures. Repeated measure one-way 
ANOVA test, followed by Tukey’s post hoc analysis, and student’s unpaired 
t-test was used for statistical analysis of the ageing and stress data 
respectively.  
 
4.2.7 Organ bath studies  
 
In order to investigate whether the response of colonic spontaneous 
contractions were altered as a function of stress or age, as well as in 
response to the application the benzodiazepine alprazolam, organ bath 
experiments were performed according to the protocol described in chapter 
3. For stress studies, segments of the distal colon from acute stress (N = 7), 
chronic stress (N = 5) and early life stress mice (N = 10) as well as paired 
control colons were used in each experiment. For the ageing studies, 4 
cohort of animals were used which were aged P10, P15, P60 and 17 months 
old. Each cohort contained 4 mice and the organ bath experiments were 
performed in parallel and at the same time each day in order to minimise 
variations in motility patterns. Two-way ANOVA and student’s unpaired T-
test were used for statistical analysis. 
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4.3 Results 
 
In Chapters 2 and 3, I showed that distinct GABAAR subtypes were 
expressed on neurochemically defined enteric neurons and that the 
activation of different subtypes had contrasting effects on one aspect of GI 
function, namely the motility. Therefore, this study was focused on 
determining whether different forms of stress and healthy ageing influence 
the expression and function of diverse GABAAR subunits within the mouse 
colon.  
 
4.3.1 Acute restraint stress increases colonic contractility and alters the 
effect of GABAAR activation on colonic contractility 
 
Psychosocial stress is a key contributor to the underlying pathology of a 
number of GI disorders (Konturek et al., 2011), including IBD and IBS (Tache 
and Perdue, 2004, Mawdsley and Rampton, 2005, Fichna and Storr, 2012). 
However, these conditions remain poorly treated due to the scarcity of 
disease-specific therapeutic agents. Therefore, with a view to elucidating a 
potential role for GABAAR ligands in influencing stress-induced alterations in 
colonic contractions, I compared the effects of one such agent that is 
currently widely used clinically, namely alprazolam, in tissue from control 
animals and animals exposed to 1 hour of restraint stress in organ bath 
preparations. Although alprazolam at a bath concentration of 10 μM 
predictably (See Chapter 3, Fig. 1) reduced the basal tone of tissue from 
control animals (Fig. 2A1, double arrow), this effect was negligible in tissue 
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from stress animals (Fig. 2A2; control, -0.17 ± 0.07 g vs stress, -0.06 ± 0.01 
g, N = 8 animals; p = 0.0021, unpaired Student’s t test).  
 
Acute stress induced a state of hyper-contractility in the isolated mouse 
colon due to an increase in the force of colonic spontaneous contractions 
(Fig. 2A2). The force of baseline spontaneous contractions were significantly 
larger in tissue from stress animals compared with control (control, 0.11 ± 
0.01 g vs stress, 0.19 ± 0.01 g, N = 7, p = 0.001, RMA) with large rhythmic 
contractions superimposed on smaller contractions evident in tissue from 
stress animals (Fig. 2A2, arrows). Alprazolam significantly decreased (F (2.401, 
14.40) = 44.48, p = 0.0001, RMA) the force of spontaneous colonic 
contractions in both control (N = 7 animals; p = 0.001, RMA) and stress 
tissue (p = 0.001, RMA; N = 7 animals). Although the same concentration of 
alprazolam induced a greater percentage reduction in the force of 
spontaneous colonic contractions in tissue from stress animals compared 
with control tissue (mean ± SD percentage reduction; control, 39.76 ± 11.4% 
vs stress, 53.26 ± 14.5%), the effect did not reach statistical significance (p = 
0.07, unpaired Student’s t test). However, it is notable that alprazolam 
reduced the force of spontaneous contractions in tissue from stress animals 
to the levels exhibited at baseline for control tissue (Fig. 2B1).  
 
Stress did not significantly alter the frequency of spontaneous contractions (p 
= 0.05, RMA; N = 7). While alprazolam predictably significantly increased the 
frequency of spontaneous colonic contractions in tissue from control mice (p 
= 0.001, RMA), this effect was not evident in tissue from stress animals (p = 
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0.05, RMA). Collectively, these data suggest that drugs targeting γ2-
GABAAR have the potential to reverse some of the changes in the force of 
colonic contractions arising from exposure to stressors. 
 
Figure 2  
 
The effects of GABAAR activation on the stress induced alterations in the 
force and frequency of colonic spontaneous contractions 
 (A) Representative traces of the effects of alprazolam 10 μM on the 
contractile responses of colon tissue obtained from (A1) control and (A2) 
stress animals. Note in A2, the stress-induced large amplitude rhythmic 
baseline contractions (arrows) and the absence of the alprazolam-induced 
reduction in basal tone of the tissue which is evident in the trace from control 
tissue (A1, double arrow). (B) Quantification of the comparative effects of 
alprazolam 10 μM on the (B1) force and (B2) frequency of spontaneous 
contractions in tissue from control and stress animals. Error bars represent 
means and the lines represent the SD; N = 7 animals. P = 0.05, RMA with 
post hoc Tukey’s post hoc test. Scale bars: A, vertical 0.3 g, horizontal 2.5 
min. 
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4.3.2 Repeated restraint stress decreases colonic contractility and alters the 
effect of GABAAR activation on colonic contractility 
 
In healthy individuals, exposure to stressors elicits rapid adaptive responses 
which are quickly turned on and off in order to limit the exposure of the 
organism to the harmful effects of the stress response (Mayer, 2000). 
However, repeated exposure to stressors and the ensuing physiological 
responses can be maladaptive and contribute to the pathophysiology which 
underlies disorders such as IBD (Mawdsley and Rampton, 2005). Therefore, 
with a view to determining the involvement of the GABAAR system in such 
long-term stress induced GI changes, I compared the effects of alprazolam in 
tissue from control animals and animals exposed to 20 days of 1 hour 
restraint stress in organ bath preparations.  
 
In stark contrast to the effect of acute stress on colonic contractility, repeated 
stress led to a significant decrease in the force of spontaneous contractions 
in comparison to control animals (control, 0.09 ± 0.01 g vs stress, 0.05 ± 0.01 
g, N = 5, p > 0.002, RMA). However, repeated stress did not significantly 
alter the frequency of spontaneous colonic contraction (p > 0.05, N = 5, 
RMA). Although alprazolam significantly decreased the force of spontaneous 
colonic contractions in tissue from control mice (p < 0.001, RMA), this effect 
was negligible in tissue from stress animals (p > 0.05, RMA) (Fig. 3B1). 
Furthermore, while alprazolam significantly increased the frequency of 
spontaneous colonic contractions in control tissue (p < 0.001, RMA), this 
effect was not evident in tissue from stress animals (p > 0.05, RMA) (Fig 
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3B2). Alprazolam at 10 µM bath concentration significantly reduced the basal 
tone of the tissue from control (mean ± SD percentage reduction; control, 
35.17 ± 3.02%, N = 5, p < 0.0001, student’s paired t test) and stress animals 
(stress, 20.28 ± 3.02%, N = 5, p = 0.003, student’s paired t test). However, 
the same concentration of alprazolam induced a significantly greater 
reduction in the basal tone of the tissue from control animals in comparison 
with stress animals (control, 35.17 ± 3.02 % vs stress, 20.28 ± 3.02%, N = 5, 
p = 0.001, student’s unpaired t test). Collectively, these data suggest that 
repeated stress has an immense impact on the gut contractility as well as the 
GABAAR-mediated GI contractility.  
 
The question arises whether the stress-induced changes are due to 
alterations in the expression of specific GI GABAAR subunits, or whether the 
stress-induced changes might be due to the functional plasticity of the 
colonic GABAAR system. To begin to unravel the likely mechanisms, I 
explored the former, by determining whether repeated stress induced any 
changes in the GABAAR subunit mRNA expression levels within the colon 
with the caveat that changes in expression levels could also occur at the 
protein level.  
155 
 
 
 
Figure 3 
 
The effects of repeated stress on the colonic contractility and GABAAR-
mediated alterations in the force and frequency of colonic spontaneous 
contractions  
(A) Representative traces of the effects of alprazolam 10 μM on the 
contractile responses of colon tissue obtained from (A1) control and (A2) 
stress animals. Note in A2, the stress-induced decrease in the amplitude of 
spontaneous colonic contraction in comparison with control tissue. (B) 
Quantification of the comparative effects of alprazolam 10 μM on the (B1) 
force and (B2) frequency of spontaneous contractions in tissue from control 
and stress animals. Error bars represent means and the lines represent the 
SD; N = 5 animals. P = 0.05, RMA with post hoc Tukey’s post hoc test. Scale 
bars: A, vertical 0.2 g, horizontal 5 min. 
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4.3.3 Repeated restraint stress selectively alters the expression of the 
GABAAR γ2 subunit at the mRNA level  
 
The qRT-PCR technique was used to investigate the influence of repeated 
restraint stress on the expression of distinct GABAAR subunits (α1-5 and γ2 
subunits) at the transcript level in the mouse colon (Fig. 4). Repeated 
restraint stress did not significantly alter the expression of the GABAAR α1 (p 
= 0.824), α2 (p = 0.555), α3 (p = 0.789), α4 (p = 0.895) and α5 (p = 0.573) 
subunits. However, chronic stress significantly increased the level of 
expression of the mRNA encoding for the GABAAR γ2 subunit by 0.36 fold (p 
= 0.037, unpaired student’s t  test) in comparison to the control tissue (Fig. 
4). Taken together, these data demonstrate that repeated restraint stress 
leads to alterations in the expression of distinct GABAAR subunit at the 
mRNA level within the mouse colon.  
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Figure 4 
  
The effect of repeated restraint stress on the levels of GABAAR subunit 
mRNA expression within the mouse colon  
The bars represent the mean ± SEM fold change in the expression of 
GABAAR α1-5 (Gabra1-5) and γ2 (Gabrg2) subunits within the mouse colon 
of stress animals in comparison to control mice. Note that the horizontal line 
intercepting the Y axis at 1.0 represents the expression of each gene in 
control samples. The effect of stress was subunit specific with only the γ2 
subunit encoding mRNA levels significantly increased compared to control 
levels (0.36 fold increase, p = 0.037). N = 9 animals per control or stress 
group.  
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4.3.4 Early life stress (ELS) selectively alters the expression of the GABAAR 
α2 subunit at the mRNA level 
 
Since repeated stress during adulthood resulted in altered GABAAR gene 
expression within the mouse colon, I hypothesised that GABAAR subunit 
expression within colon is also sensitive to stress during early stages of life. 
Therefore, I used qRT-PCR in order to investigate the impact of ELS on the 
expression of GABAARs at the transcript level in adulthood. ELS did not 
significantly alter the mRNA expression of the GABAAR α1 (p = 0.966), α3 (p 
= 0.340), α4 (p = 0.611), α5 (p = 0.943) and γ2 (p = 0.137) subunits. 
However, ELS significantly decreased the expression level of mRNA 
encoding for the GABAAR α2 subunit (mean ± SEM fold change; 0.66 ± 0.1, 
N = 9 animals; p = 0.04, unpaired student’s t test) in comparison to the 
control tissue (Fig. 5). These data demonstrate that, similar to the repeated 
restraint stress, ELS also leads to alterations in the expression of a specific 
GABAAR subunit at the mRNA level within the mouse colon, although a 
different subunit appears to be implicated.  
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Figure 5  
 
The effect of ELS on GABAAR subunit mRNA expression levels within the 
mouse colon in adulthood 
The bars represent the mean ± SEM fold change in the expression of 
GABAAR α1-5 (Gabra1-5) and γ2 (Gabrg2) subunits within the mouse colon 
of stress animals in comparison to control mice. The influence of stress on 
the mRNA expression of GABAARs was subunit specific, with only the alpha2 
subunit encoding mRNA levels being significantly decreased below control 
levels (0.66 fold decrease, p = 0.037). N = 9 animals per control or stress 
group.  
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4.3.5 Early life stress increases the force of colonic contractions and alters 
the effect of GABAARs activation on colonic contractility 
 
Following on from my ELS-induced changes in expression studies, I 
investigated whether ELS also influences the effects of GABAAR-mediated 
GI contractility. Therefore, I compared the effects of 10 µM alprazolam on 
tissue from control and ELS animals in organ bath preparations. Although 
alprazolam at a bath concentration of 10 μM reduced the basal tone of tissue 
from both control and ELS animals (Fig. 6A), this effect was significantly 
larger in tissue from stress animals (Fig. 6A2; control, 0.113 ± 0.009 g vs 
stress, 0.143 ± 0.008 g, N = 10 animals; p = 0.031, unpaired Student’s t test).  
 
Importantly, ELS induced a hyper-contractility pattern in the colon in 
adulthood. Indeed, the force of baseline spontaneous contractions was 
significantly larger in tissue from stress animals compared with control 
(control, 0.076 ± 0.012 g vs stress g, 0.121 ± 0.012, N = 10, p = 0.0002, 
RMA) with large rhythmic contractions superimposed on smaller contractions 
evident in tissue from stress animals (Fig. 6A2, arrows). Alprazolam 
predictably significantly decreased the force of spontaneous colonic 
contractions in tissue from control mice (baseline, 0.076 ± 0.012 g vs 
alprazolam, 0.035 ± 0.012 g, N = 10, p = 0.0001, RMA). Although the same 
concentration of alprazolam also induced a reduction in the force of 
spontaneous contractions in tissue from ELS animals, the effect did not 
reach statistical significance (p < 0.05, RMA) (Fig. 6B1). ELS did not 
significantly alter the frequency of spontaneous colonic contractions (p = 
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0.05, RMA). While alprazolam predictably significantly increased the 
frequency of spontaneous colonic contractions in tissue from control mice (p 
= 0.0002, RMA), this effect was not evident in tissue from stress animals (p = 
0.05, RMA) (Fig. 6B2). These data indicate that stress, at different ages, 
directly impacts not only on GI function but also on the expression and 
function of the GABAAR system within the GIT. We therefore explored below 
whether age itself has a role to play in GABAAR-mediated GI function.  
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Figure 6  
 
The effects of ELS on colonic contractility and GABAAR-mediated functions 
on the force and frequency of colonic spontaneous contractions 
(A) Representative traces of the effects of alprazolam 10 μM on the 
contractile responses of colon tissue obtained from (A1) control and (A2) 
ELS animals. Note in A2, the stress-induced large amplitude rhythmic 
baseline contractions (arrows). (B) Quantification of the comparative effects 
of alprazolam 10 μM on the (B1) force and (B2) frequency of spontaneous 
contractions in tissue from control and ELS animals. Error bars represent 
means and the lines represent the SD; N = 10 animals. P = 0.05, RMA with 
Tukey’s post hoc test. Scale bars: A, vertical 0.2 g, horizontal 2.5 min. 
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4.3.6 GABAAR subunit mRNA expression changes dynamically with age  
 
Since the impact of stress on the GI GABAAR system appears to be not only 
stress but also age specific, this suggested an interaction for age in 
influencing the expression and the function of the GABAARs within this 
region of the body. I therefore, determined firstly the relative expression 
levels of various GABAAR subunits, at the mRNA level, in mice across the 
ageing spectrum.  
 
My qRT-PCR analyses revealed that the highest relative amounts of 
GABAAR subunit mRNA expression occurred at the early postnatal stages of 
P10-15 and decrease appreciably in adulthood, but in a subunit-specific 
manner (Fig. 7). Indeed, the highest levels of the GABAAR α1 subunit mRNA 
expression occurred at P10-15 and decreased significantly at P60 and 18 
months of age. Although the mRNA expression levels of the GABAAR α2, 5 
and γ2 GABAAR subunits were also highest at P10, the transcript levels for 
these subunits decreased significantly from P15 onwards unlike the GABAAR 
α1 subunit (p < 0.05, RMA). In addition, the GABAAR α1 subunit continued to 
decrease after P60 whereas the GABAAR α2, 5 and γ2 subunits mRNA 
expression levels seemed to stay on the same levels or increase in tissue 
from 18 months mice in compare to the P60 animals. However these data 
did not reach significant levels (p > 0.05, RMA). In contrast to the GABAAR 
α1, 2, 5 and γ2 subunits, there were no significant differences in the mRNA 
expression levels of the GABAAR α3, 4 subunits across all ages, although 
there was a trend towards higher levels of expression at 18 months 
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compared to P60 (p > 0.05, RMA). These age-related changes in colonic 
GABAAR subunit mRNA expression suggest that the GABAARs expression 
within the mouse colon is age and subunit specific. In light of the significant 
changes in the mRNA expression levels of the various GABAAR subunits 
across various ages, the question arose whether such age-related 
expression changes are reflected at the functional level. 
 
 
 
Figure 7  
 
GABAAR subunit mRNA expression levels relative to the housekeeping gene 
gapdh and at different ages within the mouse colon  
The bars represents the mean ± SEM as a percentage, mRNA expression 
levels of the GABAAR α1-5 (α1-5) and α2 (γ2) subunits within the mouse 
colon of P10, P15, P60 and 18 months old animals. All the expression levels 
are relative to the house keeping gene (gapdh). The asterisks denote 
statistically significant differences (P < 0.05, repeated measure ANOVA; 
RMA with Tukey’s post hoc). N =4 at each age. P = postnatal day. 
165 
 
4.3.7 The pattern of GABAAR–mediated spontaneous colonic contractility 
changes with age  
 
 With a view to elucidating any potential age-related changes in the 
functional consequences of GABAAR activation on colonic spontaneous 
contractions, we compared the effects of alprazolam in tissue from P10, P15, 
P60 and 18 months old animals in organ bath preparations. Firstly, we 
detected significant differences in the force of spontaneous colonic 
contractions across all ages (Fig. 8B1). The amplitude of spontaneous 
contractions decreased from P10 to P15 (mean ± SEM; P10, 0.133 ± 0.013 
vs P15, 0.077 ± 0.013, p <0.05, two-way ANOVA) return to a similar level at 
P60 and continued increasing from P60 to 18 months (P15, 0.077 ± 0.013 vs 
18 months, 0.142 ± 0.013, p <0.05, two-way ANOVA). Whilst 10 µM 
alprazolam significantly decreased the force of spontaneous contractions at 
P10 and P60 (Fig. 2B1; P10, 0.056 ± 0.013; P60, 0.053 ± 0.013, p < 0.05, 
two-way ANOVA), this effect did not reach statistical significance in tissue 
from mice aged P15 and 18 months (P15, 0.021 ± 0.013; 18 months, 0.031 ± 
0.013, p > 0.05, two-way ANOVA).  
 
The frequency of spontaneous contractions increased significantly as a 
function of age (Fig. 8B2). The frequency of spontaneous contractions 
significantly increased as animals aged from P10 to 18 months (P10, 0.015 ± 
0.003 vs P15, 0.045 ± 0.003, vs P60, 0.065 ± 0.003, vs 18 months, 0.071 ± 
0.003, p <0.05, two-way ANOVA). Whilst 10 µM alprazolam significantly 
increased the frequency of spontaneous contractions at P60 (baseline, 0.065 
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± 0.003 vs alprazolam, 0.086 ± 0.003, p <0.05, two-way ANOVA), this effect 
was not evident in tissue from early postnatal ages (P10-15) and aged mice 
(18 months).  
 
Finally, as we previously reported, alprazolam caused overall relaxation of 
the colon by significantly decreasing the basal tone of the tissue from adult 
(P60) and 18 months old mice (Fig. 8B3; P60, 0.193 ± 0.015; 18 months, 
0.216 ± 0.008, p = 0.001, RMA). However, this effect was minimal in tissue 
from P10 and P15 mice (P10, 0.043 ± 0.002; P15, 0.055 ± 0.003). These 
age-related changes in colonic GABAAR subunit mRNA expression and 
function suggest a GABAAR system which evolves dynamically with age and 
imparts contrasting functional roles at particular ages, which in turn may 
contribute to the age-related plasticity of the GIT. 
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Figure 8 
 
The pharmacological effect of activating GABAARs on spontaneous colonic 
longitudinal smooth muscle contractions in mice of different ages 
(A) representative traces demonstrating the effects of the application of the 
benzodiazepine alprazolam 10 µM on the spontaneous contractions in a 
piece of isolated colon. (B) Quantification of the effects of alprazolam 10 µM 
on (B1) the force and (B2) the frequency of spontaneous colonic contractions 
as well as on (B3) the basal colonic tone. Bars represent means and the 
lines represent the SD. N = 4 animals, * P < 0.05, repeated measures 
ANOVA with posthoc Tukey’s test. Scale bars: (A) vertical 0.5 grams, 
horizontal 5 minutes. 
 
 
 
 
 
168 
 
4.4 Discussion 
 
The current chapter demonstrates that GABAAR expression and function 
within the mouse colon changes dynamically with age and that specific life 
experiences, such as traumatic stressful events at various stages of life, 
have the potential to influence the trajectory of the age-dependent GI 
GABAAR expression-function phenotypes. While most previous studies have 
investigated, in isolation, the effects of age or stress on GI function, I have 
sought to integrate the impact of these two key determinants of GI health. 
The implication is that plasticity of the GI GABAAR system is central to the 
evolving functions of the GIT across age, and that GABAAR dysfunction 
could contribute to the molecular mechanisms which underlie stress-induced 
GI disorders, thus offering specific molecular therapeutic targets for such 
debilitating conditions.  
 
4.4.1 The importance of the healthy ageing GIT to wellbeing over the life-
course  
 
The profound changes in nutritional requirements which occur as one 
develops from a neonate, through to old age, necessitates that the GIT is 
constantly evolving functionally with the rest of the body. So too, the 
changing requirements for barrier defence mechanisms via this organ. As a 
result of this functional plasticity of the GIT, most stages of life are devoid of 
any overt or defining GI deficits, apart from old age. As a result, age related 
disorders of the GIT, such as gastro-oesophageal reflux disease (Moore et 
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al., 2012), constipation (Rao and Go, 2010) and faecal incontinence 
(AlAmeel et al., 2010) are a significant contribution to overall morbidity in the 
elderly. As such, uncovering the biological mechanisms which underpin 
healthy GI function at all ages is central to providing life-long GI healthcare. 
Whilst most studies investigating the functional plasticity of the GIT in healthy 
ageing have shown that the GI and ENS function evolve with the age of an 
individual (Pilotto et al., 2011), such neuronal plasticity becomes less optimal 
in the elderly. In turn, many of the age-related GI dysfunctions have been 
linked to alterations in the ENS (Wade, 2002, Wade and Cowen, 2004). 
Thus, the importance of my data arises from the discovery that a molecular 
system that is principally involved in regulating neuronal excitability, namely 
the GABAAR system, changes dynamically with age, and is thus likely to be 
central to healthy GI ageing.  
 
Ageing has been associated with the loss of enteric neurons, enteric glia and 
impairment of ICC function, cellular elements which are all involved in the 
generation and control of intestinal spontaneous contractions and motility 
(Wiskur and Greenwood-Van Meerveld, 2010, Al-Sajee and Huizinga, 2012, 
Bitar et al., 2011). Whilst I did not investigate these particular parameters in 
my studies, I was able to demonstrate age-related changes in the 
contractility of the mouse colon. These manifested in age-related changes in 
the force and frequency of the spontaneous longitudinal muscle contractions. 
Coordinated contraction between these and the circular muscles bring about 
colonic motility which is altered during life and evolve with the age of the 
animals. Since GABAAR subtypes appear to directly impact on colonic 
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contractility, the question arises whether these age-related changes in 
contractile function are due to the changing landscape of the GABAAR 
system within the GIT.  
 
Numerous studies have shown age-induced alteration in the expression and 
function of GABAARs within the CNS which are sub-type, region and disease 
specific (Rissman and Mobley, 2011, Vela et al., 2003, Limon et al., 2012). 
However, this has been entirely unexplored within the GIT and the ENS. I 
now demonstrate that, the highest relative expression levels of most of the 
GABAAR subunits occurred at P10-15 and then decrease precipitously soon 
after to reach adult levels. This ontogenetic profile of GABAAR subunit 
expression is intriguing, and raises the importance of the time-window 
around P10-15 in terms of GI development. Developmentally, this period 
coincides with important stages of motor development in rodents. At 
approximately P10, rodents are first able to stand on all quarters, but exhibit 
uncoordinated, or immature gait patterns (Geisler et al., 1993). However, and 
remarkably, from P15 onwards, motor coordination has progressed to the 
extent that individuals exhibit the adult walking pattern (Westerga and 
Gramsbergen, 1993). In cage-reared rodents such as the ones used in this 
study, the offspring are generally weaned at P24. Therefore, they only 
encounter solid foods after this date. However, the maturation of the adult 
locomotor phenotype at P15 suggests that offspring in the wild are capable 
of leaving the nest if need be. If so, then their GI systems would need to 
have been sufficiently developed to allow for the digestion of food other than 
their mother’s milk. While it is entirely speculative at this point, the coinciding 
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of the peak period of GI GABAAR expression with the potential stage of 
independence for rodents may be an evolutionary conserved mechanism to 
ensure optimal development of the GIT at this stage and thus promote 
survival under various conditions. Future studies using GABAAR subunit 
specific KO mice and investigating GI function at these early stages will allow 
me to explore this hypothesis.  
 
4.4.2 The impact of stress on the GI and colonic GABAAR system 
 
Exposure to negative life experiences throughout one’s life directly or 
indirectly alters the molecular and functional mechanisms which underpin 
ENS function, such as neurotransmitter receptor systems or neuropeptides, 
thereby leading to altered GI functions (Lowette et al., 2014). These stress-
induced and ENS-mediated alterations in GI functions are thought to 
contribute to a range of GI disorders such as irritable bowel syndrome (IBS) 
and inflammatory bowel disease (IBD), (Larauche et al., 2009, Konturek et 
al., 2011). My data demonstrate that, similar to the CNS, the impact of stress 
on colonic motility is directly associated with the duration of exposure to the 
stressor and the age at which the animals experience the stress. This implies 
that a complex array of biological mechanisms underlies these stressor and 
age-dependent changes in GI contractility. The GABAAR system may be a 
role-player in such stress-induced alterations of GI function, given its well 
established role in being engaged by the stressors within the CNS. 
Numerous studies have shown that acute, chronic and early life bouts of 
stress all induce various alterations in the expression and function of 
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GABAARs within the CNS which are subtype and region specific (Lamy and 
Beck, 2010, Crawford et al., 2013, Liu et al., 2014, Martisova et al., 2012, 
Caldji et al., 2003). Despite our wealth of knowledge within the CNS, the 
plasticity of GABAARs within the ENS and the mouse colon has received 
literally no attention, despite the widespread expression on these receptors 
within the mouse colon. Since we showed earlier, in Chapters 2 and 3, that 
various GABAAR are expressed within the ENS of the mouse colon and have 
contrasting effects on the colonic contractility, it was intriguing that, similar to 
the CNS, the GABA-GABAAR system within the mouse colon was also highly 
dynamic.  
 
Acute stress appeared to dampen the effect of alprazolam on the basal tone 
of the tissue as well as the frequency of spontaneous contractions. However, 
it was promising that alprazolam in this study was able to reverse the stress-
induced increase in the force of colonic contractions since, stressors have 
been shown to cause an increase in distal colonic motility and acceleration of 
intestinal transit (Mayer, 2000). In contrast to the effect of acute stress, 
repeated stress led to a decrease in the force of colonic contractions which 
may be due to the maladaptive response of the colon to repeated stress. In 
addition, this decrease in the force of contractions occurred in tandem with 
an increase in the expression of mRNA encoding for the GABAAR γ2 subunit 
in the mouse colon. Whilst this does not necessarily confer a cause-effect 
relationship between the force of colonic contractions and the expression 
levels of colonic γ2-GABAARs, alprazolam, which activates γ2-GABAARs, did 
decrease the force of colonic spontaneous contractions. It is thus tempting to 
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speculate that the increase in GABAAR γ2 subunit expression in stress 
animals could underlie the decrease in colonic contractility evident in animals 
repeated exposed to stressors. Therefore, ligands which modulate such 
receptors may be beneficial in modulating the alterations in motility in 
patients experiencing chronic stress.  
 
The qRT-PCR analysis revealed that ELS significantly decreases the 
expression of mRNA encoding for the GABAAR α2 subunit. Interestingly, in 
our ongoing collaborations with the Universities of Dundee and Sussex, we 
have discovered that ELS also significantly decreases the expression of the 
GABAAR α2 subunit in the CNS (Swinny, Lambert, Stephens, personal 
communications). Importantly, the GABAAR α2 subunit has been shown to 
be involved in the anxiolytic effects of benzodiazepines used to treat anxiety 
which often occur in conjunction with GI disorders (Dixon et al., 2008, 
Wisłowska-Stanek et al., 2013). For instance, chlordiazepoxide, which is a 
benzodiazepine usually used for the treatment of anxiety is also routinely 
prescribed in clinics for the treatment of IBS as it also blocks the acid 
secretion of the gastrointestinal tract and reduces colonic motility (Narducci 
et al., 1985). Therefore, one may speculate that the GABAAR α2 subunit 
could be involved in mediating the impact of ELS on the CNS as well as the 
peripheral effects such as colonic motility. Taken together, the data shows 
that changes in the expression and function of the colonic GABAAR system 
occur in tandem with the stress-induced changes in colonic contractility 
provides support for future studies investigating, whether such stress-
induced changes in GI function can be ameliorated by GABAAR ligands.  
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5 General discussion: the importance of these 
findings 
 
At the outset of my PhD project, my intention was to uncover the expression 
patterns of the various GABAAR subunits within the mouse colon and its local 
nervous system as well as the likely functional implications of this 
neurotransmitter receptor system in one aspect of colonic function, namely 
motility. A further ambition was to assess how malleable these expression-
function relationships were in terms of life experiences, such as healthy 
ageing and emotional stress.  
 
I believe that I have adequately addressed the stated aims and significantly 
contributed to our knowledge in this area of science. Within each Results 
chapter, I have chosen to discuss the implications or importance of the 
findings in the context of the Chapter objectives. For this chapter, I will 
attempt to marry the individual segments of my PhD research and 
extrapolate their functional implications to the wider field of 
neurogastroenterology.  
 
To accomplish these results, it was essential that I utilise a range of 
techniques. Therefore, before I critically discuss my findings and the future 
questions in this area of science, I think it would be prudent for me to discuss 
briefly some of methodological issues which need to be borne in mind when 
drawing conclusions from my data. 
 
175 
 
5.1 Technical considerations: 
 
1. GABAAR subunits expression at the mRNA level:  
At the outset, I used RT-PCR to gain an appreciation of the likely 
GABAAR subunits to be expressed in my target tissue, with a view to 
guiding future questions. This technique, whilst extremely useful in 
terms of indicating the presence or absence of particular mRNA 
transcripts, is not quantitative. One can therefore not draw any firm 
conclusions of the extent of expression, which could be influential in 
terms of the eventual functional significance of the protein encoded by 
the transcript. To achieve this, I would have had to undertake 
quantitative RT-PCR and compare the relative levels of all the 
GABAAR subunits within colonic samples and those of a tissue type in 
which expression-function levels have been extensively characterised, 
such as the CNS. This would have been an exhaustive task, given the 
variations in the expression levels of various GABAAR subunits in 
different brain regions. In addition, since it is the protein which brings 
about the function of the gene, one needs to be cautious when 
attributing functional significance to mRNA expression patterns since 
one assumes consistent translation into protein, and this is not 
necessarily the case for GABAAR subunit expression; see (Hortnagl et 
al., 2013).  
 
A further shortcoming was the way I needed to prepare my samples. I 
used homogenates of complete colon, thus, neuronal and non-
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neuronal tissue elements of the colon. I therefore am not able to 
inform which particular cell-types, either neuronal or non-neuronal 
express the mRNA for the GABAAR subunits. This is particularly 
important in further characterising the GI-GABAAR system and will 
likely require fluorescence in situ hybridisation studies to localise the 
particular transcripts to particular tissue/cell-types. 
 
2.  Immunohistochemistry using confocal microscopy: 
Guided by the mRNA data, I chose to focus my efforts firstly on the 
GABAAR subunits which have been most well characterised (α1-5; γ2) 
and their localisation with neuronal elements of the ENS. For these 
analyses, a key question was, whether similar to CNS neurons, ENS 
neurons target GABAAR subunits to particular sub-domains of 
particular cell-types. Thus, it was essential to use tissue preparations 
in which the orientation of ENS neurons allowed the visualisation of 
their somato-dendritic surfaces in continuity; thus whole-mount 
preparations, rather than cross-sections of the GIT. This thus 
restricted the microscopical inspection to the muscle layers of the GI, 
precluding the localisation of GABAAR subunits in mucosal elements. 
Therefore, I cannot exclude the expression, and thus the functional 
role of GABAARs in mucosal or epithelial cell-types. It is for this 
reason that I restricted our functional analyses to readout of muscle 
activity, namely colonic contractility.  
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While confocal microscopy is immensely valuable in visualising 
GABAAR subunit immunoreactive clusters, it does not allow for 
investigating the location of individual GABAAR subtypes. This is 
important to determine since it is the assembled receptor subtypes, 
not the individual subunits which determine the effect of GABA. To 
overcome this shortcoming in the technique, generally, the convention 
is to extrapolate from the degree of colocalisation between 
immunoreactivity for distinct GABAAR subunits, with the obvious 
caveat that colocalisation does not infer co-assembly. However, such 
colocalisation analyses were not possible since most of our antibodies 
against the various GABAAR subunits were raised in the same 
species.  
 
3. Organ bath configuration: 
GI motility is a manifestation of coordinated activity between GI 
longitudinal and circular muscles. However, in our preparation, we 
essentially measured only longitudinal muscle activity. This was 
simply due to the availability of recording equipment. Thus, my 
functional readout is restricted to one determinant of GI motility 
namely colonic longitudinal smooth muscle activity.  
   
4. GABAAR pharmacology and its limitations: 
I exploited a range of available GABAAR ligands to gain an 
appreciation of the potential functional impact of GABAAR expression 
on colonic contractility. The limitations of these ligands lie in their lack 
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of specificity for individual GABAAR subtypes. Currently, it is accepted 
that these agents have greater affinity for individual GABAAR 
subtypes, but all, at particular concentrations, will activate most 
GABAARs (Rudolph and Knoflach, 2011). This is particularly true for 
the benzodiazepine compounds. The only option is to use them at 
particular concentrations to limit their range of activity.  
 
A further caveat is that their pharmacological profiles have been 
characterised in the CNS. Thus, for my PhD studies, I have had to 
assume that their ENS profiles are aligned with those of the CNS. 
However, this needs to be verified and I hope the publication of these 
data will serve not only as the rationale but also the stimulus for such 
studies. These data will also hopefully invigorate drug development 
scientist in investing further in the discovery of subtype-specific 
GABAAR ligands. Hopefully, the recent, first description of a crystal 
structure of a GABAAR subtype is likely to fuel a new era in GABAAR 
drug discovery (Miller and Aricescu, 2014).  
 
Nevertheless, against these caveats, I would like to discuss the implications 
of the data, as well as the further questions which they provide. 
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5.2 Making functional sense of the bewildering localisation patterns of 
GABAAR subunits in ENS circuits 
 
At the outset, guided by the relatively formulaic patterns of the positioning of 
GABAAR subunits adjacent to GABA release sites within the CNS, my 
expectation was that I would be able to construct similar expression maps for 
various cell-types within the networks of ENS neurons, thereby elucidating 
the roles of individual GABAAR subunits in communication between defined 
ENS cellular networks; and in the future, how this changes in disease. For 
example, in the cerebral cortex, the positioning of different cell-types, such 
as principal cells and interneurons is highly organised into specific layers 
(Thomson and Bannister, 2003). Furthermore, the release of specific 
neurotransmitters onto specific domains of individual cell-types is faithfully 
aligned with the expression of appropriate neurotransmitter receptors on the 
sub-cellular domains of these cells adjacent to the neurotransmitter release 
site (Thomson and Lamy, 2007, Klausberger et al., 2002). In addition, in the 
CNS, we know that the expression of certain GABAAR subunits is restricted 
to certain cell-types with defined roles in nervous system function, such as 
the GABAAR α3 subunit in mono-aminergic neurons, rather than cortical 
principal cells (Fritschy et al., 1992, Corteen et al., 2011). Collectively, this 
contributes to an immense degree of organisation in terms of the flow of 
information and the molecules which are utilised to facilitate that information 
transfer, and thus coordinated neuronal activity (Klausberger and Somogyi, 
2008).  
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However, based on my immunolocalisation patterns within the ENS, such 
highly organised expression patterns are not immediately apparent. Instead, 
a picture emerges of individual GABAAR subunits being located not only 
across a range of neurochemically diverse and thus likely functionally diverse 
cell-types, but also on both pre- and postsynaptic domains. Therefore, the 
construction of theoretical models of the activation of various GABAAR 
subtypes, on excitatory or inhibitory ENS neurons, will need to include 
multiple permutations, for example, classical inhibition, feed-back inhibition 
and feed-forward inhibition cell circuits, amongst others. This creates a 
degree of difficulty in attempting to construct a set of “rules” for GABAARs in 
terms of their functional contribution to network activity within the functionally 
distinct cell-types of the ENS; similar to what has emerged in the CNS. 
 
Further pressing questions are the source, or release sites of GABA within 
the GIT or ENS, as well as the actual effects of GABA on specific ENS cell-
types, that is, does it have an excitatory or inhibitory effect, and is this effect 
consistent across functionally distinct ENS neurons? The release sites for 
GABA which gates GABAARs, within the CNS are generally considered to be 
presynaptic terminals of other neurons. Thus, the use of GABA as a 
signalling molecule within this region of the nervous system, is highly 
localised and essentially a neurotransmitter. However, within the GIT, GABA 
is produced by mucosal endocrine-like cells and thus predicted to serve an 
endocrine role and therefore function as a hormone (Davanger et al., 1994), 
in addition to its role as a classical, localised neurotransmitter. Therefore, if 
GABA acts as a classical hormone which can induce effects, some distance 
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from its origin, it becomes extremely difficult to determine which effects of 
GABA are mediated by particular sets of GABAARs. This is particularly 
important if, like me, one intends to determine the changes in the GABA-
GABAAR system which underlies specific GI disorders.  
 
Finally, unlike the adult CNS, the current dogma is that the effect of GABA is 
depolarising, and thus excitatory in adult ENS neurons (Cherubini and North, 
1984, Krantis, 2000), due to the lack of the potassium-chloride co-
transporter2 (KCC2) and the presence of Na+-K+-2Cl- co-transporters 
(NKCC2), which accumulates Cl- ions inside the cells and results in high 
intracellular concentration of Cl- (Xue et al., 2009, Gameiro et al., 2005). 
However, it is currently unclear if this holds true for ALL ENS neurons, or 
only a sub-population within specific networks. Thus, the possibility arises 
that individual GABAAR subtypes might have directly opposite effects on the 
excitability of different neurons, depending on the expression of 
KCC2/NKCC2 and thus the effect of GABA. Therefore, what is required 
within the ENS is the high degree of molecular-anatomic-functional 
correlative studies which are routine in the CNS (Buhl et al., 1994). 
Hopefully, my data will serve as the scientific rationale for undertaking such 
detailed analyses.  
 
Nevertheless, my stated intention was to inform on the functional 
contributions of specific GABAAR subtypes to ENS-mediated GI function. On 
the basis of the combination of the immunolocalisation and organ bath 
pharmacology, I can conservatively conclude that since α4/5-GABAARs are 
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exclusively expressed by myenteric neurons, these receptor subtypes are 
likely to be principally involved in the contractile functions of ENS neurons 
(Figure 1). However, for α1/2/3-GABAARs which are expressed across 
different cell-types of myenteric and submucosal plexuses, I suggest that the 
use of a range of neurobiological techniques will be essential to disentangle 
their individual functional contributions to GI function. Firstly, I believe that 
cell-specific and subunit-specific KO mice will need to be employed, using 
Cre-LoxP technology (Kos, 2004). This will probably need to be combined 
with optogenetic tools (Deisseroth, 2011, Roux et al., 2014). In vitro, this will 
allow one to selectively activate a particular cell-type and record the activity 
of connected cells which lack individual GABAAR subunits. However, using 
such models in vivo or in an organ bath preparation, changes in certain 
aspects of GI function as well as the functional roles of these subunits in 
defined ENS cell-types can be assessed in certain aspects of GI function, 
such as contractility, simply by applying light of various wavelengths to 
optogenetically modulate ENS function. Based on the immunohistochemical 
and functional data, I have put forward a hypothetical scheme for the 
expression of various GABAAR subunits within distinct neuronal populations 
and pathways within the ENS of the mouse colon. However this scheme 
relies mostly on immunohistochemical data as there are functional data such 
as neuronal pathways involved in the impact of α5 subunit activation on the 
force and frequency of spontaneous colonic contractions.  
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Figure 1 
 
Hypothetical schematic representation of the putative functional 
consequences of the activation of different GABAAR subtypes within the 
principal cellular networks of the ENS. 
GABAergic interneurons (green) have been shown to innervate both 
excitatory and inhibitory neurons of the ENS. Based on the combination of 
the immunoreactivity, organ bath studies and the assumption that GABA is 
excitatory, I postulate that: 
1) GABA, released from interneurons which innervate cholinergic motor 
neurons, gates α1/4/5-GABAARs, causing colonic contractility. 
2) GABA, released from interneurons which innervate NOS-immunoreactive 
neurons, gates α2/3-GABAARs, causing colonic relaxation. 
 
 
Thus, whilst my current data pose more questions than provide answers, 
they will be essential for the judicious construction of future animal models to 
take this research to the next level. 
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5.3 Ageing, stress and GABAAR expression and function: dissecting 
cause and effect 
  
My results from Chapter 4 indicate that GABAAR expression and function 
changes dynamically in response to stress and with age. These data are 
purely observational, or phenomenological. I am therefore not able to 
determine whether changes in the expression patterns of GABAAR subunits 
causes the age-related changes in GI function or vice versa. The same is 
true for the changes in the expression patterns of GABAAR subunits after 
exposure to stress. To determine a cause-effect relationship, I will need to, 
for example, repeat these experiments using GABAAR subunit KO mice. 
Nevertheless, the functional significance of these dynamic changes intrigues 
me as follows:  
 
Ageing:  
During development, the pattern of neurotransmitter-receptor expression is 
tightly controlled, with cells generally expressing the appropriate receptors in 
response to released neurotransmitter (Lujan et al., 2005). Thus, changes in 
the expression of neurotransmitter receptors are generally in response to 
alterations in the pattern or amount of the appropriate neurotransmitter (Balia 
et al., 2015). Thus, simplistically, the age or stress-induced changes in 
GABAAR subunit expression are due to changes in GABA release. Changes 
in GABA release during ageing or in response to stress are not 
unprecedented within the central nervous system (Stanley et al., 2012, 
Maguire, 2014).  
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During early CNS development, GABA is mostly excitatory, and it plays a 
number of key roles in establishing brain function by regulating a number of 
processes including migration, morphological maturation and differentiation 
of neurons (Deidda et al., 2014). Importantly, these effects of GABA are 
mediated by GABAARs, rather than GABABRs (Cellot and Cherubini, 2013). 
However, considerably less is known about the developmental role of GABA 
in the ENS (Gilon et al., 1987). Thus, the dynamic age-related changes in the 
expression patterns of specific GABAAR subunits which I demonstrate here 
could provide the impetus for a new programme of work investigating the 
contributions of individual subunits to healthy GI development and ageing.  
 
This could be important to human health and wellbeing on two fronts:  
1) EARLY DEVELOPMENT; Impaired GI development has a devastating 
consequence on the quality life, as is evident when the ENS fails to develop 
in Hirschsprung’s disease (McKeown et al., 2013). If GABAAR subtypes are 
found to have a direct role in GI development, then early diagnoses and 
therapy with specific GABAAR ligands are likely to offer clinical benefits.  
2) AGEING; our rapidly ageing population, due to improved living conditions 
and healthcare, presents with a range of newer diseases, such as age-
related GI disorders. My data which suggest significant changes in the 
expression of GABAAR subunits at late adulthood provides the scientific 
justification for exploring whether such changes contribute to such age-
related GI pathologies. Thus, these series of data have the potential to 
impact on the lives of diverse patient populations. 
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Stress: 
 Within the CNS, various types of stress including acute stress, chronic and 
early-life stress have been shown to impart contrasting effects on the 
expression and functions of GABAARs in the brain. For instance, while acute 
stress resulted in an increase in the inhibitory synaptic input onto 
serotonergic neurons (Lamy and Beck, 2010, Crawford et al., 2013), chronic 
stress has been shown to lead to loss of GABAergic tonic currents in the 
amygdala of rats (Liu et al., 2014). In addition, ELS imparts long lasting 
effects on GABAAR subtype expression in noradrenergic brain regions (Caldji 
et al., 2004) as well as the GABAergic circuitry by impairing GABA release 
within the rat hippocampus (Martisova et al., 2012). However, such plasticity 
in GABA-GABAAR system within the ENS remains unclear.  
 
Now, I demonstrate that such emotional challenges engage the ENS 
GABAAR system as well. Whether the stress-specific alterations in the 
expression of specific GABAAR subunits (the α2 subunit in ELS; the γ2 
subunit in adult stress) are compensatory or pathological remain unclear. 
Nevertheless, confirmation of the involvement of the GABAAR system in GI 
stress mechanisms is important, since, up till now, GI stress biology and its 
impact on GI health has been dominated by CRH biology (Larauche et al., 
2009, Mayer, 2000). Despite over 30 years of research in the field of CRH, 
there has been a rather poor transfer of basic science to patient benefit, due 
to the ubiquitous nature of the mammalian CRH system and the poor 
specificity of CRH ligands (Zorrilla and Koob, 2010). Thus, the demonstration 
of another role-player in the GI stress system, namely the GABAAR system, 
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provides an opportunity for alternative approaches to modulating what is a 
significant determinant of health and wellbeing.  
 
5.4 The contribution of this work to the field of neurogastroenterology 
 
I believe that I have achieved my stated aims and objectives and my PhD 
research will thus contribute to the body of knowledge within the area of 
science. However, I am cognizant that my work was relatively restricted 
within the field of neurogastroenterology, that is, to the colon of the mouse. 
Nevertheless, the ensuing results appear to have raised more questions than 
answers. I believe this to be advantageous, since the value of data often 
resides in the previously unknown complexity it unveils. The interest in the 
GI-ENS GABAAR field appears to have subsided since the early turn of the 
century primarily due to the lack of GABAAR subtypes specific reagents and 
thus the conclusion by many scientists that this system lacks unique 
functional features. However, over the last ten years, a range of highly 
specific research tools (subunits specific antibodies; KO mice; 
pharmacological ligands) have become available. Therefore, by providing 
evidence for the expression, function and plasticity of GABAARs within a 
region of the GIT, I believed that my PhD research contributes to basic as 
well as clinical neurogastroenterology as elaborated upon below:  
 
Basic neurogastroenterology: 
Firstly, the data presented here provide an explanation for some of the 
inconsistencies between previous research undertaken on the GABA-
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GABAAR system of the ENS and the GIT. For example, some studies show 
that the application of GABA leads to increased level of NANC inhibitory 
transmitters, NO and probably ATP, via activation of GABAARs which leads 
to relaxation of the intestine (Bayer et al., 2002, Bayer et al., 2003). 
However, in chapter 3, I show that positive allosteric modulation of α1/2/3/5-
β-γ2-GABAARs leads to inhibition of colonic contractility via enhancement of 
NO pathways. Furthermore, others have shown that endogenous and 
exogenous GABA acting on GABAARs enhances the cholinergic pathway 
and promotes Ach release (Parkman et al., 1993, Reis et al., 2006). In 
agreement with this, I have also shown that activation of α4-GABAARs leads 
to an increase in colonic contractility via augmentation of cholinergic 
pathways. Therefore, I believe that my data bridges together previous 
incongruent evidence in the field by providing an explanation for these 
putative biphasic effects of GABA on intestinal contractility, by suggesting 
that different populations of GABAARs (α2/3-β-γ2-GABAARs decrease 
contractility; α1/4/5-GABAARs increase contractility) are engage in different 
cellular circuits (NOS and acetylcholine) and thus induce opposing effects.  
 
Hopefully, the questions raised as a consequence of the data obtained in my 
PhD research will provide the scientific justification for basic research 
focusing on the subunit-specific roles of GABAARs in various facets of GI 
functions such as barrier, secretory or immune responses in addition to 
motility function. 
 
 
189 
 
Clinical neurogastroenterology: 
Surprisingly, of the number of therapeutic agents considered for conditions, 
such as IBS or IBD, GABAAR subunit-specific ligands are largely overlooked 
(Hammerle and Surawicz, 2008, Saad and Chey, 2008), although recent 
evidence is promising (Salari and Abdollahi, 2011). Importantly, when CNS 
disorders such as anxiety or depression are treated with GABAAR-
modulating drugs (Chouinard, 2006, Chouinard et al., 1982), the relief of 
secondary, co-existing GI symptoms often occurs. For example, anxiolytic 
drugs, such as chlordiazepoxide, have also been used in the treatment of 
stress-related GI disorders such as IBS. However, these drugs have not 
been very successful due to the unwanted central side-effects such as 
drowsiness, weakness and dizziness. Interestingly, The rich field of GABAAR 
pharmacology (Rudolph and Mohler, 2006, Rudolph and Knoflach, 2011) is 
littered with agents that showed promising pharmacological profiles for 
mental disorders but have translated poorly to the clinic due to either 
unacceptable central side effects or poor CNS penetration. Therefore, the 
data within this thesis provide the scientific rationale for the re-evaluation of 
such agents with a view to reformulating them specifically for delivery to the 
GIT. I therefore predict my PhD research will provide the proof of principal 
that forms the foundation of the next phase of GI-GABAAR research which 
will hopefully spawn novel therapeutic options for a range of GI disorders.  
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